

Historic, Archive Document

Do not assume content reflects current scientific knowledge, policies, or practices.

aTS1975
N38

Star



United States
Department of
Agriculture

Food Safety
and Inspection
Service
Science

COMPOUND EVALUATION and ANALYTICAL CAPABILITY NATIONAL RESIDUE PROGRAM PLAN 1987

**SCIENCE
FOOD SAFETY AND INSPECTION SERVICE**

**COMPOUND EVALUATION AND
ANALYTICAL CAPABILITY
1987 NATIONAL RESIDUE PROGRAM PLAN**

Table of Contents

PREFACE

Section 1 GUIDE

Section 2 INTRODUCTION

Section 3 COMPOUNDS CONSIDERED AND CRITERIA FOR EVALUATION

- A. Criteria for Compound Evaluation and Ranking
- B. List of Compounds Considered
- C. Cross-Referenced Compounds

Section 4 RESIDUE LIMITS

Section 5 FSIS RESIDUE ANALYTICAL CAPABILITY

Section 6 COMPOUNDS INCLUDED IN THE NATIONAL RESIDUE PROGRAM

Historical Chart

Section 7 NATIONAL RESIDUE PROGRAM ANNUAL PLAN

January—December, 1987

Introduction

Background Information on Compounds Included

Tables

PREFACE

Purpose of Document

This document—now in its fourth edition—details the activities of the Food Safety and Inspection Service (FSIS) in its evaluation of compounds that may be present in meat and poultry and its development and implementation of analytical methods for detecting those compounds; it includes the Annual Residue Plan. The document serves as a reference source for those concerned with food safety and with FSIS activities in that area.

Changing Field


The information contained in this document represents the state of FSIS Science affairs as of September 1, 1986. Past revisions and those expected in the future reflect the dynamic nature of a scientific and technological field that is constantly in flux.

Address for Comments

Please send comments regarding this or other aspects of the document to:

Jeffrey Brown, Editor
USDA, FSIS, Science Program
300 12th Street, SW
Washington, DC 20250

Section 1



GUIDE

Section 2

Section 2 is an Introduction to the basic activities of the Residue Program.

Section 3

Section 3 includes in this edition "Criteria for Compound Evaluation," which describes the procedure followed by FSIS in evaluating compounds for inclusion in the National Residue Program, and the "List of Compounds Considered." The list was compiled by reference to the separate entries in the Code of Federal Regulations (CFR) and the New Animal Drug Application (NADA) listing of the Food and Drug Administration. The list provides the compound name and appropriate CFR or NADA references. NADA references are used for approved animal drugs not listed in the CFR. The third column indicates whether the compound was mentioned in the 1979 General Accounting Office (GAO) Report, "Problems in Preventing the Marketing of Raw Meat and Poultry Containing Potentially Harmful Residues" (Publication number HRD-79-10). The fourth column gives the ranking assigned to the compound in the National Residue Program. Also included is a list of cross-referenced compounds.

Section 4

Section 4 is a list of tolerance and action levels for the compounds.

Section 5


Section 5 defines the types of methods used by FSIS to conduct analyses and their suitability for regulatory use; defines key terms used to describe the methods; and lists the analytical methods for compounds in alphabetical order.

Section 6


Section 6 is an historical chart indicating the compounds included in the National Residue Program during a ten-year period and the specific years in which a compound was included. The methods used for some compounds in this section, identified by footnotes, are no longer considered suitable for regulatory use.

Section 7

Section 7 is the National Residue Program Plan for the calendar year 1987, which describes domestic and import program activities. The plan is a guide based on current information, assessment of precedence for testing, and FSIS analytical capability. It is dependent upon our having full staffing and is therefore affected by loss of personnel. The plan will be modified during the year as new information alters the original assessment.



Section 2



INTRODUCTION

The Food Safety and Inspection Service (FSIS) of the U.S. Department of Agriculture (USDA) as part of its National Residue Program collects samples of meat and poultry at slaughtering establishments under its inspection authority and from import shipments at the ports of entry. The samples are analyzed for the presence of unacceptable residue levels of pesticides, animal drugs, and other potentially hazardous chemicals that may contaminate meat and poultry. These activities are carried out as part of the Agency's responsibilities under the Federal Meat Inspection Act and the Poultry Products Inspection Act to ensure that USDA-inspected products in commerce are safe, wholesome, and free of adulterating residues.

Testing

Residue testing of animals slaughtered in the United States is subdivided into three major activities: monitoring, surveillance, and exploratory projects.

Monitoring is designed to provide profile information on the occurrence of residue violations in specified animal populations on an annual, national basis. The current focus of monitoring is on violations; therefore, only compounds with established safe limits—tolerance or action levels—are considered. Compounds are selected for monitoring based on risk profiles and the availability of laboratory methodology that is suitable for regulatory purposes. Monitoring information is obtained through a statistically based selection of random samples from healthy-appearing animals under inspection; area monitoring may be conducted where a localized potential problem appears. The information generated from monitoring is reviewed periodically to assist in the allocation of Agency resources.

In addition to profile information, the monitoring program provides a basis for further action. In particular, the results are used to identify producers marketing animals with violative levels of residues. When such producers subsequently offer animals for slaughter, the animals will be subjected to surveillance sampling and testing until compliance is demonstrated. Other auxiliary uses of the data are to indicate incidences and levels of residue occurrence, to evaluate residue trends, and to identify problems within the industry where educational or other corrective efforts may be needed. Thus monitoring not only gathers information, but also assists in deterring practices that lead to violative residues.

Monitoring samples collected by inspectors at slaughtering plants are sent for analysis either to one of three FSIS field laboratories or, as needed, to a laboratory under contract to FSIS. The results are usually reported within 8 days after arrival at the laboratory. In most cases, the product will have passed into consumer channels and become untraceable.

Because of this pragmatic limitation, some animals containing violative residues inevitably pass into consumer channels, in spite

INTRODUCTION

of the agency's efforts to limit this occurrence as much as possible. The consequences to human health, however, are minimal as long as the violative rate is low. Tolerances and action levels represent the maximum residue concentrations safe for daily consumption over a lifetime. Occasional consumption of products with slightly higher residues is unlikely to result in adverse health effects.

Surveillance is designed to investigate and control the movement of potentially adulterated products. The sampling is biased and is directed at particular carcasses or products in response to information from monitoring or other sources (e.g., industry members or a state agency), or from observations during antemortem or postmortem inspection indicating that adulterating levels of residue may be present.

In-plant testing procedures may be performed by the inspector, or samples may be submitted to an FSIS laboratory for analysis. Depending upon the weight of evidence that led to the testing, product may be retained until test results indicate the appropriate regulatory disposition. Laboratory testing of surveillance samples is completed as rapidly as possible and takes precedence over monitoring samples.

The annual plan estimates the surveillance samples anticipated on the basis of historical data; however, the actual number required depends entirely upon the needs that arise. A major incident, such as the 1979 PCB contamination problem, could drastically alter the expected surveillance requirement and may require an adjustment of the monitoring plan.

Exploratory projects are conducted for a variety of reasons, but these programs, whatever their objective, have in common the fact that test results normally are not used to take regulatory action or to trigger follow-up surveillance testing. The design of an exploratory project is not suitable for this purpose.

Exploratory projects generally fall within the following two types:

Studies of the occurrence of residues for which no safe limits (i.e., tolerances or action levels) have been established

There are many chemicals (e.g., trace metals, industrial chemicals, and mycotoxins) that may be inadvertently present in animals yet have no established safe levels. Their consistent presence in food, and the resulting need for a tolerance or action level to protect public health, has not been established. FSIS may conduct studies to develop information on the frequency and levels at which such residues occur. These studies may be nationwide or limited to specific geographic areas. Sample collection may be random and statistically based, or biased to obtain "worst case" information. The results are given either to the Food and Drug Administration (FDA) or the Environmental

INTRODUCTION

Protection Agency (EPA), which have responsibility for establishing tolerances for contaminants in food under the Federal Food, Drug and Cosmetic Act. Exploratory programs planned on a limited scale may be expanded if preliminary results raise the level of concern and make acquiring comprehensive information more urgent.

Other projects as appropriate

These may be designed for various purposes, such as evaluating new methods and approaches to monitoring, or supplementing the information used in considering a compound for monitoring.

Domestic Quality Assurance

The Agency enters into memoranda-of-understanding with segments of the meat and poultry industry to provide assurance that when the animals are presented for slaughter they do not contain violative concentrations of chemical residues. This assurance is based both on monitoring records of critical control points in pre-slaughter management control programs and residue testing in USDA-accredited laboratories. Because of this control and testing program at critical control points, these animals may be sampled under a Quality Assurance sampling program rather than the Monitoring Program.

Import Program

Residue testing of import products is an assurance check by USDA that the foreign country's residue control program is effective and that its products meet the same standards applied to products produced in the United States. Monitoring, surveillance, and exploratory programs, as defined above, are carried out. When a violation is found in the monitoring program, subsequent shipments from the same establishment are retained at the port of entry under the surveillance program. All shipments of product from that country are placed on an increased monitoring schedule until a history of compliance for the country is re-established. The rationale for the collection of samples for residue analysis is the same in the domestic and foreign programs. The compounds selected for residue testing in imported products were chosen to parallel the domestic residue program as much as possible. The import plan design is discussed more fully in Section 7, the Annual Plan.



Section 3



CRITERIA FOR COMPOUND EVALUATION AND RANKING

Introduction

Livestock and poultry may be exposed to many compounds during their life cycle.

These compounds include primarily:

- Pesticide chemicals approved for direct application to livestock and poultry or for treating crops that become components of animal feed or that are used in some way in the farm environment
- Animal drugs used to treat or prevent disease or otherwise enhance production
- Environmental contaminants

The Environmental Protection Agency (EPA) and the Food and Drug Administration (FDA) establish the acceptable levels of residues (tolerances) for these compounds in their respective areas of responsibility (pesticides, EPA; animal drugs, environmental contaminants, FDA) and the approved methods of use for specific crops or animals that ensure that tolerances will not be exceeded. Where formal tolerances are not established, FDA and EPA, as appropriate, recommend action levels to FSIS upon request for unavoidable contaminants.

Exposure of animals to environmental contaminants, or the use of pesticides or animal drugs in a way that does not conform with approved uses, can result in unacceptable amounts of residues of these chemicals in the edible tissues of animals at slaughter.

CFR References

Tolerances for these chemicals are listed in the Code of Federal Regulations (CFR) in 40 CFR 180 for pesticides, in 21 CFR 556 for animal drugs, and 21 CFR 109 for unavoidable contaminants. The approved use conditions for animal drugs are given in 21 CFR in parts 520, 522, 524, 526, 529 (new animal drugs not subject to certification), 540, 544, 546, 548 (antibiotic drugs for animal use), and 558 (new animal drugs for use in animal feed).

Need for Criteria

It is not feasible to monitor for residues of all of these chemicals in meat and poultry, nor is this necessary to adequately protect public health. It is, however, important to assess the likelihood that animals exposed to these chemicals may contain residues at levels of concern, and to conduct monitoring, where test methods are available, for those chemicals that are most likely to present the greatest potential risk. A hierarchical compound-assessment scheme is used for this purpose.

Ranking System

Each compound is evaluated on a number of factors, to judge the potential for animal exposure and significance for human health, including:

Factors

- Amount of actual or probable use
- Conditions of use as related to residues at slaughter

CRITERIA FOR COMPOUND EVALUATION AND RANKING

- Potential for misuse to result in harmful residues
- Metabolic patterns of the chemical in animals, plants, and the environment, including the bioavailability and persistence of residues
- Toxicity of the residue

The combined assessment of these factors is used to assign the chemical to one of four categories A, B, C, or D, which represent in descending order the potential for harmful residues to occur in animals at slaughter. ("A-B-C" indicates compounds of greater or lesser importance for the commitment of resources; "D" denotes either "insignificant" or "not yet ranked.") However, a new evaluation system has been developed; see the discussion on 3.A.3-3.A.4.

Selection of Compounds for Monitoring

Compounds are selected for monitoring and included in a plan for the calendar year based on several factors, including:

- Compound ranking assigned
- Whether a practical test method is available and is suitable for regulatory use
- Whether the compound is measurable in a multi-residue method where many compounds, even though all may not be assigned a high ranking, can be tested for at a relatively low cost
- Monitoring or other experience that shows whether adulterating residues are present in meat and poultry

Not all of the hundreds of animal drugs and pesticides listed in the CFR are likely to expose animals to harmful residues. FSIS works from a list of about 400 compounds that includes certain environmental contaminants in addition to animal drugs and pesticides (Section 3.B). At present FSIS has suitable regulatory methods of analysis for 145 of these compounds. Some compounds are routinely included in monitoring because experience shows that without active enforcement adulterating residues will occur. Other compounds may be included in monitoring on a cyclical basis to confirm periodically that a potential residue problem does not exist. Cycling of compounds in monitoring allows the agency to include more compounds in the program than would otherwise be possible within its resources. Compounds rotated out of the program for a specific year are not disregarded; if the need arises, they can be added during that year. Over the last ten years, virtually all the residues for which a suitable method was available have been monitored, except when a compound had an especially low ranking.

In 1986 FSIS planned 46,957 sample analyses for 103 compounds; in 1987 FSIS plans to analyze 59,575 sample units for 108 compounds. Table V in the Annual Plan section of this document shows the resource expenditure required by the 1987 sampling plan.

CRITERIA FOR COMPOUND EVALUATION AND RANKING

A Dynamic System

The process of compound evaluation and ranking is a dynamic one. Additional compounds have to be considered in the system, agricultural use practices change, and additional research on a compound's toxicity and its potential for leaving harmful residues may affect previous rankings. The agency uses an advisory board of scientists from EPA, FDA, and USDA (FSIS and the Agricultural Marketing Service) to identify significant new information that may affect a compound or ranking or indicate an urgent need for monitoring. This advisory relationship is defined in the Memorandum of Understanding among the three agencies published in the Federal Register on January 16, 1985.

Compound Evaluation System (CES)

In the 1985 edition of this document, FSIS/Science announced the implementation of a new prototype Compound Evaluation System (CES). The CES was designed to provide the agency with a more systematic approach to the categorization of compounds with respect to their likelihood of occurrence in meat and poultry and their potential impact on public health. The CES has been subjected to extensive external review by the tri-agency advisory board cited above (Surveillance Advisory Team) and is undergoing final revision.

Briefly, the CES addresses the risk of residues in meat and poultry as a function of two major elements: *hazard* (adverse effects that may be produced by a given compound) and *exposure* (residue level; factors affecting level, such as use patterns, withdrawal times, etc.; duration of or frequency of consumption of product containing residues of concern). The proposed system is a two-value, hierarchical compound ranking scheme that classifies a given pesticide, animal drug, or contaminant in any one of 16 categories. Compounds of greatest concern carry a designation of A-1 (high health hazard potential; high likelihood of residue occurrence); those compounds of least concern are designated D-4 (negligible health hazard potential; negligible likelihood of residue occurrence). The letter Z is used to indicate an element of the two-value system lacking the information needed for classification. Care is taken to avoid the use of exact numerical rankings that might suggest a high degree of sophistication possibly not justifiable because of data limitations or the assumptions inherent in the ranking process.

The assignment of a specific ranking is based on a review of information entered in a comprehensive set of CES worksheets prepared for each compound evaluated. These worksheets provide a permanent record and chronology of the nature and extent of the technical and scientific data that were considered. Certain compounds considered within the FSIS National Residue Program have been evaluated using the new CES. These compounds and their rankings are presented in a note at the end of Section 3.B. It should be understood that the rankings are based strictly on data available to FSIS at the time and may well change as additional information becomes available in the open literature, from other agencies, or from

CRITERIA FOR COMPOUND EVALUATION AND RANKING

the private sector. To further advance the CES effort, FSIS is using outside assistance in the preparation of a series of compound evaluation reports that will provide the basic information necessary to prepare the CES worksheets. To this end, a contract was awarded that calls for the preparation of evaluative reports on 50 compounds of potential concern to the agency. This work is now underway.

FSIS believes that the Compound Evaluation System is sufficiently flexible to permit rapid response to new information that may affect previous rankings and to allow for the use of scientific or expert judgement. However, it must be emphasized that the CES was neither designed nor intended for use in the development of formal quantitative estimates of risk from meatborne residues. Rather it provides a rational basis for changes in compound emphasis within the National Residue Program and encourages development of new analytical methods for important compounds for which no methods exist. As such, the CES serves as a useful guide in the planning and allocation of FSIS Program resources for those residues considered to represent the greatest potential effect on public health. The CES is updated as appropriate to provide the FSIS with a constant, informative, and sound approach to dealing with residues in meat and poultry.

The compounds in the List of Compounds Considered that have been assigned values in the new system are marked with an asterisk. The compounds and their rankings are listed in a note at the end of Section 3.B.

FSIS welcomes comments or suggestions regarding the CES; a copy of the CES document is available upon request. Please send comments or requests regarding the CES to:

USDA, FSIS, Science Program
Director, Residue Evaluation and Planning Division
300 12th St., S.W.
Washington, D.C. 20250

LIST OF COMPOUNDS CONSIDERED

System of Compound Listing and Counting

In an eclectic document such as this, a set of rules must be applied for uniformity in listing different forms of the chemical (i.e., salts, esters, isomers, etc.) and significant metabolites. We applied the following criteria for uniformity in our listings.

- CFR reference names, where available, are used for the primary entries; exceptions are footnoted. (Note: In the original edition of this document, some common and trade names were used in the tolerance section. This inconsistency was sometimes confusing; CFR names are now used in both the List of Compounds Considered and the tolerance section. All names thus affected have been included in the cross-reference section.)
- Isomers of a compound—compounds having the same percentage composition and molecular weight but differing in chemical or physical properties—are not listed separately.
- Different salts, esters, etc. are listed separately where the use conditions of these substances appear in different CFR citations. For example, penicillin and penicillin G are listed as two compounds. The various forms of penicillin G—free acid, benzathine, sodium salt, and procaine salts—are shown in the listing under penicillin G but are not counted individually.
- Metabolites are listed separately only when the tolerance citation refers to a specific metabolite, or where a suitable regulatory method is available for the metabolite.
- Complex mixtures such as PCB's are listed as a single entry.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|--------------------------------|---------------------------|---------|
| Acephate | 40 CFR 180.108 | yes | D |
| Acepromazine | 21 CFR 520.23 21 CFR 522.23 | no | D |
| 2-Acetylaminio-5-nitrothiazole | 21 CFR 556.20 | yes | D |
| Aflatoxin | none | no | A-4* |
| Aklomide | 21 CFR 556.30 21 CFR 558.35 | yes | C |
| Alachlor | 40 CFR 180.249 | no | A-2* |
| Albendazole | none | no | A-2* |
| Aldicarb | 40 CFR 180.269 | yes | A-4* |
| Aldrin | 40 CFR 180.135 | yes | A-3* |
| (Alpha RS, 2R)-fluvalinate [(RS)-alpha-cyano-3-phenoxybenzyl (R)-2-[2-chloro-4-(trifluoromethyl)anilino-3-methylbutanoate | 40 CFR 180.427 | no | D |
| Ametryn | 40 CFR 180.258 | no | A |
| 4-Amino-2-chloro-benzamide (metabolite of aklomide) | 21 CFR 556.30 21 CFR 558.35 | no | C |
| 4-Amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one | 40 CFR 180.332 | yes ¹ | D |
| 2-Amino-N-isopropyl benzamide (metabolite of bentazon) | 40 CFR 180.355 | no | D |
| Aminomethyl phosphonic acid (metabolite of glyphosate) | 40 CFR 180.364 | no | D |
| 2-Amino-6-methyl-pyrimidin-4-ol (metabolite of pirimiphos-methyl) | 40 CFR 180.409 | no | D |
| 3-Amino-5-nitro-o-toluamide (metabolite of zoalene) | 21 CFR 556.770 | no | B |

¹ As Sencor.

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|------------------------|--|---------------------------|---------|
| Amitraz | 21 CFR 561.195 40 CFR 180.287 | no | D |
| Amoxicillin trihydrate | 21 CFR 556.38 21 CFR 540.103 | no | B |
| Ampicillin | 21 CFR 556.40 21 CFR 540.105 | yes | B-2* |
| Ampicillin trihydrate | 21 CFR 556.40 21 CFR 540.107 | yes | B-2* |
| Amprolium | 21 CFR 556.50 21 CFR 520.100 21 CFR 558.55 | yes | A |
| Apramycin | 21 CFR 556.52 21 CFR 520.110 | no | D |
| Arsanilate sodium | 21 CFR 556.60 21 CFR 558.60 | no | A |
| Arsanilic acid | 21 CFR 556.60 21 CFR 558.62 | no | C-1* |
| Arsenate, Calcium | 40 CFR 180.192 | no | C |
| Arsenate, Copper | 40 CFR 180.193 | no | D |
| Arsenate, Lead | 40 CFR 180.194 | no | D |
| Arsenate, Magnesium | 40 CFR 180.195 | no | D |
| Arsenate, Sodium | 40 CFR 180.196 | no | D |
| Arsenic | 21 CFR 556.60 | yes | A |
| Arsenite, Potassium | 40 CFR 180.334 | no | D |
| Arsenite, Sodium | 40 CFR 180.335 | no | D |
| Atrazine | 40 CFR 180.220 | yes | C-3* |
| Azaperone | 21 CFR 522.150 | no | B-4* |

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|--|---------------------------|---------|
| Bacitracin methylene disalicylate | 21 CFR 556.70 21 CFR 548.112 21 CFR 558.76 | yes | C |
| Bacitracin zinc | 21 CFR 556.70 21 CFR 548.114 21 CFR 558.78 | yes | C |
| Bambermycins¹ | 21 CFR 558.95 | no | D |
| Bendiocarb | none | yes ² | D |
| Benomyl | 40 CFR 180.294 | yes | B-3* |
| Bentazon | 40 CFR 180.355 | no | D |
| BHC | 40 CFR 180.140 | yes ³ | B-2* |
| 3,6-Bis (2-chlorophenyl)-1,2,4,5-tetrazine | none | no | D |
| Bismuth subsalicylate | NADA 010-158 | no | D |
| Bromoxynil | 40 CFR 180.324 | no | D |
| Buquinolate | 21 CFR 556.90 21 CFR 558.105 | yes | D |
| sec-Butyl amine | 21 CFR 561.60 40 CFR 180.321 | yes | D |
| 3-tert-Butyl-5-chloro-6-hydroxymethyluracil (metabolite of terbacil) | 40 CFR 180.209 | no | D |
| 4-tert-Butyl-2-chlorophenol (metabolite of 4-tert-Butyl-2-chlorophenyl methyl methylphosphoramidate) | 40 CFR 180.295 | no | D |
| 4-tert-Butyl-2-chlorophenyl methyl methylphosphoramidate | 40 CFR 180.295 21 CFR 520.512 ⁴ | yes ⁴ | B |

¹Common name, flavomycin.

²As Ficam.

³As benzene hexachloride.

⁴As crufomate.

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|------------------------------------|---------------------------|---------|
| 2-tert-Butyl-4-(2,4-dichloro-5-hydroxy-phenyl) Δ^2 1,3,4-oxadiazolin-5-one (metabolite of oxadiazon) | 40 CFR 180.346 | no | D |
| Butyl 2[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenoxy] propionate (butyl ester of fluazifop) | 40 CFR 180.411 | no | D |
| Cacodylic acid | 40 CFR 180.311 | no | D |
| Cadmium | none | no | B-4* |
| Calcium | none | no | D |
| Cambendazole | 21 CFR 520.300 | no | B |
| Captan | 40 CFR 180.103 | yes | B-3* |
| Carbadox | 21 CFR 556.100 21 CFR 558.115 | yes | A-3* |
| Carbarsonic acid | 21 CFR 556.60 21 CFR 558.120 | no | C-2* |
| Carbaryl | 40 CFR 180.169 | yes | D |
| Carbofuran | 40 CFR 180.254 | yes | C-3* |
| Carbomycin | 21 CFR 556.110 21 CFR 520.1660a | yes | D |
| Carbophenothion | 40 CFR 180.156 | yes | D |
| Carboxin | 40 CFR 180.301 | no | C-4* |
| 3-Carboxy-5-ethoxy-1,2,4-thiadiazole (metabolite of 5-ethoxy-3-(trichloromethyl) 1,2,4-thiadiazole) | 40 CFR 180.370 | no | D |
| 2-Carboxyisopropyl-4-(4-dichloro)-5-isopropoxyphenyl) Δ^2 1,3,4-oxadiazolin-5-one (metabolite of oxadiazon) | 40 CFR 180.346 | no | D |
| Cephapirin benzathine | 21 CFR 556.115 21 CFR 526.363 | yes | D |

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|--|---------------------------|---------|
| Cephapirin sodium | 21 CFR 556.115 21 CFR 529.365 | yes | D |
| Chloral hydrate | 21 CFR 522.380 | no | D |
| Chloramphenicol | 21 CFR 555 | no | A-2* |
| Chloramphenicol palmitate | 21 CFR 555.111 | no | A-2* |
| Chlorbromuron | 40 CFR 180.279 | no | D |
| Chlordane (technical) ¹ | 40 CFR 180.122 | yes | A-2* |
| Chlordecone | none | no | D |
| Chlordimeform | 40 CFR 180.285 | yes | D |
| Chlorhexidine dihydrochloride | 21 CFR 556.120 21 CFR 524.402 21 CFR 529.400 | yes | C |
| Chlormadinone acetate | none ² | yes | D |
| 4-Chloro-5-amino-2-(a,a,a-trifluoro-m-tolyl)-3(2H)-pyridazinone (metabolite of norflurazon) | 40 CFR 180.356 | no | D |
| Chlorobutanol | 21 CFR 556.140 | no | D |
| 2-Chloro-N,N-diallylacetamide | 40 CFR 180.282 | yes | C |
| 2-Chloro-1-(2,4-dichlorophenyl) vinyl diethyl phosphate | 40 CFR 180.322 | no | D |
| 6-Chloro-2,3-dihydro-7-hydroxymethyl-3,3-dimethyl-5H-oxazolo(3,2-a)pyrimidin-5-one (metabolite of terbacil) | 40 CFR 180.209 | no | D |
| 6-Chloro-2,3-dihydro-3,3,7-trimethyl-5H-oxazolo(3,2-a)pyrimidin-5-one (metabolite of terbacil) | 40 CFR 180.209 | no | D |
| 2-Chloro-N-isopropylacetanilide | 40 CFR 180.211 | yes ³ | D |

¹Residues of metabolized technical chlordane are reported as the sum of the isomers of chlordane, oxychlordane, and nonachlor.

²Tolerances withdrawn in June, 1982.

³As propachlor.

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|--|---------------------------|---------|
| Chloroneb | 40 CFR 180.257 | no | D |
| 1-(4-Chlorophenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)-2-butanone | 40 CFR 180.410 | no | D |
| beta-(4-Chlorophenoxy)-alpha-(1,1-dimethylethyl)-1H-1,2,4-triazole-1-ethanol (metabolite of 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)-2-butanone) | 40 CFR 180.410 | no | D |
| 2-(m-Chlorophenoxy)propionic acid | 40 CFR 180.325 | no | D |
| S-(2-Chloro-1-phthalimidoethyl) O,O-diethyl phosphorothioate (oxygen analog of dialifor) | 40 CFR 180.326 | no | D |
| 6-Chloropicolinic acid (metabolite of nitrapyrin) | 40 CFR 180.350 | no | C |
| Chlorothiazide | 21 CFR 520.420 | no | D |
| 2-Chloro-1-(2,4,5-trichlorophenyl)-vinyl dimethyl phosphate | 40 CFR 180.252 | yes ¹ | A |
| 5-[2-Chloro-4-(trifluoromethyl)-phenoxy]-2-nitrobenzoic acid (metabolite of sodium salt of acifluorfen) | 40 CFR 180.383 | no | D |
| Chlorpyrifos | 40 CFR 180.342 | yes | B-4* |
| Chlorpyrifos-methyl and metabolite | 40 CFR 180.419 | no | D |
| Chlorsulfuron | 40 CFR 180.405 | no | D |
| Chlortetracycline bisulfate | 21 CFR 556.150 21 CFR 558.128 21 CFR 546.113 | yes | A |
| Chlortetracycline hydrochloride | 21 CFR 556.150 21 CFR 558.128 21 CFR 546.110 | yes | A |
| Chorionic gonadotrophin | 21 CFR 522.1081 | no | D |

¹ As Gardona.

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|----------------------------------|---------------------------|---------|
| Clopidol | 21 CFR 556.160 21 CFR 558.175 | yes | C |
| Clorsulon | 21 CFR 556.163 21 CFR 520.462 | no | D |
| Cloxacillin, Benzathine | 21 CFR 556.165 21 CFR 540.814 | yes | B |
| Cloxacillin, Sodium | 21 CFR 556.165 21 CFR 540.815 | yes | B |
| Cobalt | none | no | D |
| Copper | none | no | D |
| Copper glycinate | NADA 031-971 | no | D |
| Copper naphthenate | NADA 012-991 | no | D |
| Corticotropin | NADA 008-760 | no | D |
| Coumaphos and oxygen analog | 40 CFR 180.189 21 CFR 558.185 | yes | A |
| Cresylic acid | none | no | D |
| Cyano(3-phenoxyphenyl)methyl-4-chloro-a-(methylethyl)benzene-acetate | 40 CFR 180.379 | no | D |
| Cypermethrin | 40 CFR 180.418 | no | D |
| Cyromazine ¹ and metabolite | 40 CFR 180.414 | no | D |
| 2,4,D (technical) | 40 CFR 180.142 | yes | B-2* |
| Dalapon | 40 CFR 180.150 | yes | A-3* |
| Daminozide | 40 CFR 180.246 | yes | B-3* |
| DDE (metabolite of DDT) | 40 CFR 180.147 | no | A |
| DDT | 40 CFR 180.147 | yes | A |

¹Trade name Larvadex.

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|----------------------------------|---------------------------|---------|
| Decoquinate | 21 CFR 556.170 21 CFR 558.195 | yes | Z-4* |
| Demeton | 40 CFR 180.105 | yes | D |
| Dexamethasone | 21 CFR 520.540 | no | C |
| Dialifor and oxygen analog | 40 CFR 180.326 | yes | D |
| 1,1-Dichloro-2,2-bis(p-ethylphenyl) ethane | 40 CFR 180.139 | yes ¹ | D |
| Dibromochloropropane | none | no | D |
| Dibutyltin dilaurate | NADA 008-741 | no | D |
| Dicamba | 40 CFR 180.227 | no | C |
| 3,5-Dichloro-N-(1,1-dimethyl-2-propynyl)benzamide | 40 CFR 180.317 | no | C |
| 3-(2,2-Dichloroethyl)-2,2-dimethylcyclopropane carboxylic acid (metabolite of permethrin) | 40 CFR 180.378 | no | D |
| 3,6-Dichloro-5-hydroxy-o-anisic acid (metabolite of dicamba) | 40 CFR 180.227 | no | C |
| 2,5-Dichloro-4-methoxyphenol (metabolite of chloroneb) | 40 CFR 180.257 | no | D |
| 2,4-Dichlorophenol (metabolite of 2,4-D) ² | 40 CFR 180.142 | no | B |
| 2,4-Dichlorophenoxyacetic acid [metabolite of 4-(2,4-dichlorophenoxy)butyric acid] | 40 CFR 180.331 | no | D |
| 4-(2,4-Dichlorophenoxy butyric acid | 40 CFR 180.331 | no | D |
| 1-(2,4-Dichlorophenyl)-2-(1H-imidazole-1-yl)-1-ethanol (metabolite of imazalil) | 40 CFR 180.413 | no | D |

¹As Perthane.

²Common name 2,4-DCP.

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|---|---------------------------|---------|
| 3-(1-(2,4-Dichlorophenyl)-2-(1H-imidazole-1-yl)-ethoxyl)-1,2-propanediol (metabolite of imazalil) | 40 CFR 180.413 | no | D |
| 2,4-Dichlorophenyl p-nitrophenyl ether ¹ | none | no | D |
| 2,2-Dichlorovinyl dimethyl phosphate (metabolite of naled) | 40 CFR 180.215 | no | B |
| Dichlorvos | 21 CFR 556.180 21 CFR 520.600 21 CFR 558.205 40 CFR 180.235 ² | yes | B-4* |
| Dieldrin | 40 CFR 180.137 40 CFR 180.145 | yes | A |
| S-[(Diethoxyphosphinothioyl)thio]-methyl] O,O-diethyl phosphorothioate (oxygen analog of ethion) | 40 CFR 180.173 | no | B |
| 2-Diethylamino-6-methyl-pyrimidin-4-ol (metabolite of pirimiphos-methyl) | 40 CFR 180.409 | no | D |
| O,O-Diethyl O-3-chloro-4-methyl-2-oxo (2H)-1-benzopyran-7-yl phosphate (oxygen analog of coumaphos) | 40 CFR 180.189 | no | A |
| O,O-Diethyl S-[2-(ethylthio)ethyl] phosphorodithioate | 40 CFR 180.183 | yes ³ | D |
| O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate | 40 CFR 180.153 | yes ⁴ | D |
| O,O-Diethyl-O-[p-(methylsulfinyl) phenyl]phosphorothioate | 40 CFR 180.234 | no | B |
| Diethylstilbestrol | none | yes | D |
| Difenoquat | 40 CFR 180.369 | no | D |
| Diflubenzuron | 40 CFR 180.377 | no | D |

¹Common name nitrofen.

* Ranked under CES.

²As 2,2-dichlorovinyl dimethyl phosphate.

³As Disyston, common name disulfoton.

⁴As Diazinon.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|--|---------------------------|---------|
| 5,6-Dihydro-3-carboxanilide-2-methyl-1,4-oxathiin-4-oxide (metabolite of carboxin) | 40 CFR 180.301 | no | D |
| 5,6-Dihydrodihydroxycarbaryl (metabolite of carbaryl) | 40 CFR 180.169 | no | D |
| 5,6-Dihydrodihydroxynaphthol (metabolite of carbaryl) | 40 CFR 180.169 | no | D |
| 2,3-Dihydro-5,6-dimethyl-1,4-dithiin-1,1,4,4-tetraoxide | 40 CFR 180.406 | no | D |
| 2,3-Dihydro-2,2-dimethyl-3,7-benzofurandiol (metabolite of carbofuran) | 40 CFR 180.254 | no | C |
| 2,3-Dihydro-2,2-dimethyl-7-benzofuranol (metabolite of carbofuran) | 40 CFR 180.254 | no | C |
| 2,3-Dihydro-2,2-dimethyl-3-hydroxy-7-benzofuranyl-N-methylcarbamate (metabolite of carbofuran) | 40 CFR 180.254 | no | C |
| 2,3-Dihydro-2,2-dimethyl-3-oxo-7-benzofuranol (metabolite of carbofuran) | 40 CFR 180.254 | no | C |
| 2,3-Dihydro-3,3-dimethyl-2-oxo-5-benzofuranyl methanesulfonate (metabolite of ethofumesate) | 40 CFR 180.345 | no | D |
| Dihydrostreptomycin | 21 CFR 556.200 21 CFR 544.173 21 CFR 544.275 | yes | D |
| Dimethoate and oxygen analog | 40 CFR 180.204 | yes | B-3* |
| (O,O-Dimethyl O-p-(dimethylsulfamoyl) phenyl phosphate) (oxygen analog of O,O-dimethyl O-p-(dimethylsulfamoyl) phenyl phosphorothioate) | 40 CFR 180.233 | no | B |

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|--|---------------------------|---------|
| O,O-Dimethyl O-p-(dimethylsulfamoyl) phenyl phosphorothioate | 21 CFR 524.900 ¹ 21 CFR 558.254 ¹ 40 CFR 180.233 | no | B |
| O,O-Dimethyl S-(N-methylcarbamoyl-methyl) phosphorothioate (oxygen analog of dimethoate) | 40 CFR 180.204 | no | D |
| O,O-Dimethyl S-[(4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl] phosphorodithioate | 40 CFR 180.154 | yes ² | D |
| Dimethyl-4,4'-o-phenylene bis (allophanate) (oxygen analog of thiophanate-methyl) | 40 CFR 180.371 | no | D |
| N,N-Dimethylpiperidinium chloride | 40 CFR 180.384 | no | D |
| Dimethyl phosphate of a-methyl-benzyl 3-hydroxy-cis-crotonate | 40 CFR 180.280 | no | D |
| O,S-Dimethyl phosphoramidothioate (metabolite of acephate) | 40 CFR 180.108 | no | D |
| Dimetridazole | 21 CFR 556.210 21 CFR 558.240 | yes | C |
| 3,5-Dinitrobenzamide | 21 CFR 556.220 21 CFR 558.376 ³ | yes | D |
| Dinoseb | 40 CFR 180.281 | no | C |
| Dioxathion | 40 CFR 180.171 | yes | D |
| Diphenylamine | 40 CFR 180.190 | yes | B-4* |
| Dipropyl isocinchomeronate | 40 CFR 180.143 40 CFR 180.319 | no | A |
| Diquat | 40 CFR 180.226 | no | D |
| Diuron | 40 CFR 180.106 | yes | A |

¹As famphur.

²As azinophosmethyl and as Guthion.

³As nitromide.

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|----------------------------------|---------------------------|---------|
| Dodecachlorooctahydro-1,3,4-metheno-2H-cyclobuta[cd]pentalene | 40 CFR 180.251 | yes ¹ | A |
| Dodine | 40 CFR 180.172 | yes | D |
| Endosulfan | 40 CFR 180.182 | yes | D |
| Endosulfan sulfate (metabolite of endosulfan) | 40 CFR 180.182 | no | D |
| Endrin | 40 CFR 180.131 | yes | A-3* |
| Erythromycin | 21 CFR 556.230 21 CFR 526.820 | yes | A |
| Erythromycin phosphate | 21 CFR 556.230 21 CFR 520.823 | yes | A |
| Erythromycin thiocyanate | 21 CFR 556.230 21 CFR 558.248 | yes | A |
| Estradiol | 21 CFR 522.840 | yes | A |
| Estradiol benzoate | 21 CFR 556.240 21 CFR 522.842 | yes | A |
| Estradiol monopalmitate | 21 CFR 556.250 21 CFR 522.844 | yes | A |
| Estradiol valerate | 21 CFR 522.850 | yes | A |
| Ethion and oxygen analog | 40 CFR 180.173 | yes | B |
| Ethofumesate | 40 CFR 180.345 | no | D |
| Ethopabate | 21 CFR 556.260 21 CFR 558.58 | yes | B |
| 2-(1-(Ethoxyimino)butyl)-5-(2-(ethylthio)propyl)-3-hydroxy-2-cyclohexene-1-one | 40 CFR 180.412 | no | D |
| 5-Ethoxy-3-(trichloromethyl)-1,2,4-thiadiazole | 40 CFR 180.370 | no | D |

¹ As mirex.

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|---|---------------------------|---------|
| 2-Ethylamino-6-methyl-pyrimidin-4-ol (metabolite of pirimiphos-methyl) | 40 CFR 180.409 | no | D |
| O-(2-Ethylamino-6-methyl-pyrimidin-4-yl) O,O-dimethyl phosphorothioate (metabolite of pirimiphos-methyl) | 40 CFR 180.409 | no | D |
| Ethyl 4,4'-dichlorobenzilate (chlorobenzilate) | 40 CFR 180.109 | yes ¹ | D |
| Ethylene dibromide | 40 CFR 180.126 ² 40 CFR 180.397 | no | A-4* |
| Ethyl 3-methyl-4-(methylsulfinyl) phenyl (1-methylethyl) phosphoramidate (metabolite of ethyl 3- methyl-4-(methylthio)phenyl (1-methylethyl) phosphoramidate) | 40 CFR 180.349 | no | D |
| Ethyl 3-methyl-4-(methylsulfonyl) phenyl (1-methylethyl) phosphoramidate (metabolite of ethyl 3- methyl-4-(methylthio)phenyl (1-methylethyl) phosphoramidate) | 40 CFR 180.349 | no | D |
| Ethyl 3-methyl-4-(methylthio) phenyl phosphoramidate (metabolite of ethyl 3-methyl-4- (methylthio)phenyl (1-methylethyl) phosphoramidate) | 40 CFR 180.349 | no | D |
| Ethyl 3-methyl-4-(methylthio) phenyl (1-methylethyl) phosphoramidate | 40 CFR 180.349 | no | D |
| 2-[(2-Ethyl-6-methylphenyl) amino]-1-propanol(metabolite of metolachlor) | 40 CFR 180.368 | no | D |
| 4-(2-Ethyl-6-methylphenyl)- 2-hydroxy-5-methyl-3-morpholinone (metabolite of metolachlor) | 40 CFR 180.368 | no | D |

¹As chlorobenzilate.

²No tolerances have been established for residues in meat and poultry.

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|--|---------------------------|---------|
| Ethyl 4-(methylsulfinyl)phenyl phosphoramidate (metabolite of ethyl 3-methyl-4-(methylthio) phenyl (1-methylethyl) phosphoramidate) | 40 CFR 180.349 | no | D |
| Ethyl 4-(methylsulfonyl)phenyl phosphoramidate (metabolite of ethyl 3-methyl-4-(methylthio) phenyl (1-methylethyl) phosphoramidate) | 40 CFR 180.349 | no | D |
| O-Ethyl-O-[4-(methylthio) phenyl] S-propyl phosphorodithioate | 40 CFR 180.374 | no | D |
| O-Ethyl S-phenyl ethylphosphonodithioate ¹ | 40 CFR 180.221 | no | D |
| S-[2-(Ethylsulfinyl)ethyl] O,O-dimethyl phosphorothioate | 40 CFR 180.330 | no | D |
| Fenbendazole | 21 CFR 556.275 21 CFR 520.905 21 CFR 558.258 | no | B-3* |
| Fenitrothion | none | no | D |
| Fenprostalene | 21 CFR 556.277 21 CFR 522.914 | no | D |
| Fenthion | 40 CFR 180.214 21 CFR 524.920 | yes | C-3* |
| Florogestrone acetate | NADA 034-601 | no | D |
| Fluazifop and butyl ester | 40 CFR 180.411 | no | D |
| Flucythrinate | 40 CFR 180.400 | no | D |
| Flumethasone | 21 CFR 520.960 21 CFR 522.960 21 CFR 524.960 | no | D |
| Fluprednisolone | NADA 012-555 | no | D |

¹Common name fonofos.

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|--|---------------------------|---------|
| Fluprednisolone acetate | NADA 011-789 | no | D |
| Fluridone | 40 CFR 180.420 | no | D |
| Folic acid | NADA 013-029 | no | D |
| Follicle stimulating hormone | NADA 009-505 | no | D |
| Furaltadone | 21 CFR 556.280 21 CFR 526.1014 | no | B |
| Furazolidone | 21 CFR 556.290 21 CFR 524.1005 21 CFR 558.262 | yes | A-1* |
| Furosemide | 21 CFR 522.1010 | no | D |
| Gentamicin sulfate | 21 CFR 556.300 21 CFR 520.1044 21 CFR 522.1044 21 CFR 524.1044 21 CFR 529.1044 | yes | B-2* |
| Gentian violet | none | yes | D |
| Glyphosate | 40 CFR 180.364 | no | D |
| Halofuginone | 21 CFR 556.308 21 CFR 558.265 | no | D |
| Haloxon | 21 CFR 556.310 21 CFR 520.1120 | yes | C |
| HCB | none | no | D |
| Heptachlor and heptachlor epoxide (oxidation product of heptachlor) | 40 CFR 180.104 | yes | A-1* |
| Hetacillin, Potassium | 21 CFR 540.829 | no | B |
| Hexakis(2-methyl-2-phenylpropyl) distannoxane | 40 CFR 180.362 | yes ¹ | C |

¹ As "hexakis."

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|--|---------------------------|---------|
| Hexazinone | 40 CFR 180.396 | no | D-4* |
| Hexetidine | NADA 013-772 | no | D |
| Hydrochlorothiazide | 21 CFR 522.1150 | no | D |
| Hydrocortisone acetate | 21 CFR 556.320 21 CFR 524.1484d,h,i | no | C |
| 2-Hydroxy-2,3-dihydro-3,3-dimethyl-5-benzofuranyl methanesulfonate (metabolite of ethofumesate) | 40 CFR 180.345 | no | D |
| N-(2-Hydroxymethyl-6-methyl)-N-(methoxyacetyl)-alanine methylester (metabolite of metalaxyl) | 40 CFR 180.408 | no | D |
| 5-Hydroxythiabendazole (metabolite of thiabendazole) | 21 CFR 556.730 40 CFR 180.242 21 CFR 558.615 | no | A |
| Hygromycin B | 21 CFR 556.330 21 CFR 558.274 | yes | C |
| Imazalil | 40 CFR 180.413 | no | D |
| Iprodione | 40 CFR 180.399 | no | D |
| Ipronidazole | 21 CFR 556.340 21 CFR 558.305 | yes | Z-4* |
| Ipronidazole hydrochloride | 21 CFR 556.340 21 CFR 520.1162 | no | Z-4* |
| Iron | none | no | D |
| Isopropyl carbanilate (IPC) | 40 CFR 180.319 | no | D |
| Isopropyl m-chlorocarbanilate (CIPC) | 40 CFR 180.319 | no | D |
| Ivermectin | 21 CFR 556.344 21 CFR 520.1192 21 CFR 522.1192 | no | B-1* |

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|--|---------------------------|---------|
| Lasalocid | 21 CFR 556.347 21 CFR 558.311 | no | B |
| Lead | none | no | B-4* |
| Levamisole hydrochloride | 21 CFR 556.350 21 CFR 558.315 21 CFR 520.1242 | yes | C-2* |
| Levamisole phosphate | 21 CFR 556.350 21 CFR 522.1244 | no | C-2* |
| Lidocaine hydrochloride | 21 CFR 522.1258 | no | D |
| Lincomycin hydrochloride | 21 CFR 556.360 21 CFR 520.1263 21 CFR 522.1260 21 CFR 558.325 | yes | B |
| Lindane¹ | 40 CFR 180.133 | yes | A-2* |
| Linuron | 40 CFR 180.184 | yes | C |
| Lysergic acid diethylamide | none | no | D |
| Malathion | 40 CFR 180.111 | yes | B |
| Maneb | 40 CFR 180.110 | yes | D |
| Manganese | 21 CFR 582.5446 | no | D |
| Mebendazole | 21 CFR 520.1320 | no | B-4* |
| Mefluidide | 40 CFR 180.386 | no | D |
| Melamine (metabolite of cyromazine) | 40 CFR 180.414 | no | D |
| Melengestrol acetate | 21 CFR 556.380 21 CFR 558.342 | yes | A |
| N-(Mercaptomethyl)phthalimide S-(O,O-dimethyl phosphorodithioate) | 40 CFR 180.261 21 CFR 524.1742 | no | D |
| N-(Mercaptomethyl) phthalimide S-(O,O-dimethyl phosphorothioate) (oxygen analog of N-(mercaptomethyl) phthalimide S-(O,O-dimethyl phosphorodithioate)) | 40 CFR 180.261 21 CFR 524.1742 | no | D |

¹The gamma isomer of BHC.

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|-----------------------|---------------------------|---------|
| Mercury | none | no | D |
| Metalaxy | 40 CFR 180.408 | no | D |
| Methamidophos¹ | 40 CFR 180.315 | no | D |
| Methanearsonic acid | 40 CFR 180.289 | yes | D |
| Methoprene | 40 CFR 180.359 | yes | D |
| Methoxychlor | 40 CFR 180.120 | yes | D-4* |
| Methyl bromide | none | no | B-4* |
| 2-Methyl-4-chlorophenol (metabolite of 2-methyl-4-chlorophenoxyacetic acid) | 40 CFR 180.339 | no | B |
| 2-Methyl-4-chlorophenoxyacetic acid | 40 CFR 180.339 | no | B |
| Methyl-[2-chloro-4-(trifluoromethyl)-phenoxy]-2-nitrobenzoate (metabolite of sodium salt of acifluorfen) | 40 CFR 180.383 | no | D |
| 6-Methyl-1,3-dithiolo [4,5-b] quinoxalin-2-one | 40 CFR 180.338 | no | D |
| Methylene chloride | 40 CFR 180.1010 | no | A-2* |
| 1-Methylethyl 2-((ethoxy(1-amino) phosphinoyl)oxy)benzoate (metabolite of 1-methylethyl 2-((ethoxy((1-methylethyl)amino) phosphinothioyl)oxy)benzoate) | 40 CFR 180.387 | no | D |
| 1-Methylethyl 2-((ethoxy(1-amino) phosphinothioyl)oxy)benzoate (metabolite of 1-methylethyl 2-((ethoxy((1-methylethyl)amino) phosphinothioyl)oxy)benzoate) | 40 CFR 180.387 | no | D |
| 1-Methylethyl 2-((ethoxy((1-methylethyl)amino)phosphinothioyl)oxy)benzoate | 40 CFR 180.387 | no | D |

¹Also listed as O,S-dimethyl phosphoramidothioate, a metabolite of acephate, q.v.

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|---|---------------------------|---------|
| 1-Methylethyl 2-((ethoxy((1-methylethyl)amino)phosphinoyl)oxy)benzoate (metabolite of 1-methylethyl 2-((ethoxy((1-methylethyl)amino)phosphinothioyl)oxy)benzoate) | 40 CFR 180.387 | no | D |
| 2-Methyl 2-(methylsulfinyl) propionaldehyde O-(methylcarbamoyl) oxime (metabolite of aldicarb) | 40 CFR 180.269 | no | D |
| 2-Methyl-2-(methylsulfonyl) propionaldehyde O-(methylcarbamoyl) oxime (metabolite of aldicarb) | 40 CFR 180.269 | no | D |
| 1-Methyl-5-nitroimidazole-2-isopropanol (metabolite of ipronidazole) | 21 CFR 556.340 21 CFR 558.305 | no | B |
| Methyl parathion | 40 CFR 180.121 | yes | D |
| Metolachlor | 40 CFR 180.368 | no | D |
| Metoserpeate hydrochloride | 21 CFR 556.410 21 CFR 520.1422 | yes | D |
| Metsulfuron methyl | 40 CFR 180.428 | no | D |
| Monensin | 21 CFR 556.420 21 CFR 520.1448 21 CFR 558.355 | yes | B-3* |
| Monuron | none | no | D |
| Monuron-TCA | none | no | D |
| Morantel tartrate | 21 CFR 556.425 21 CFR 520.1450 21 CFR 558.360 | no | D |
| Naled | 40 CFR 180.215 | yes | B-4* |
| Naloxone hydrochloride | 21 CFR 522.1462 | no | D |

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|--|----------------------------------|----------------|
| 1-Naphthol (metabolite of carbaryl) | 40 CFR 180.169 | no | D |
| Narasin | 21 CFR 556.428 21 CFR 558.363 | no | D |
| Neomycin sulfate | 21 CFR 556.430 21 CFR 522.1484 21 CFR 524.1484 | yes | B-3* |
| Neostigmine methyl sulfate | 21 CFR 522.1503 | no | C |
| Nequinate | 21 CFR 556.440 21 CFR 558.365 | yes | D |
| Nicarbazin | 21 CFR 556.445 21 CFR 558.366 | no | C |
| Nickel | none | no | D |
| Nicotine | 40 CFR 180.167a 40 CFR 180.319 | no | D |
| Nifuraldezone | none | no | C |
| Nitrapyrin | 40 CFR 180.350 | no | C |
| Nitrofurazone | 21 CFR 524.1580 21 CFR 558.370 | no | B-1* |
| Nonachlor¹ | none | no | D |
| Norflurazon | 40 CFR 180.356 | no | D |
| Novobiocin | 21 CFR 556.460 21 CFR 558.415 | yes | B |
| Nystatin | 21 CFR 556.470 21 CFR 558.430 | yes | B |
| N-Octyl bicycloheptenedicarboximide | 40 CFR 180.367 | no | C |
| Oleandomycin | 21 CFR 556.480 21 CFR 558.435 | yes | A |
| Ormetoprim | 21 CFR 556.490 21 CFR 558.575 | yes | D |

¹Reported as nonachlor only when it is not included with residues of metabolized chlordane.

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|---|--|---------------------------|---------|
| Oxadiazon | 40 CFR 180.346 | no | D |
| Oxfendazole | 21 CFR 520.1628,29,30 | no | D |
| Oxyfluorfen | 40 CFR 180.381 | no | D |
| Oxytetracycline hydrochloride | 21 CFR 556.500 21 CFR 558.450 21 CFR 520.1662 21 CFR 522.1660 | yes | A |
| Oxytocin | 21 CFR 522.1680 | no | D |
| Paraquat | 40 CFR 180.205 | yes | A-4* |
| Parathion | 40 CFR 180.121 | yes | D |
| PBB (Polybrominated biphenyls) | none | no | D |
| PCB's (Polychlorinated biphenyls) | 21 CFR 109.30 | no | A-4* |
| Pentachlorophenol (PCP) | none | yes | B-1* |
| Penicillin, procaine and procaine G | 21 CFR 556.510 21 CFR 558.460 | yes | A |
| Penicillin G (benzathine, free acid, sodium salt, and procaine salts) | 21 CFR 556.510 21 CFR 540.874 | yes | A |
| Permethrin | 40 CFR 180.378 | no | B-2* |
| Phencyclidine | none | no | D |
| Phenothiazine | 40 CFR 180.319 | no | C |
| 3-Phenoxybenzoic acid (metabolite of permethrin) | 40 CFR 180.378 | no | D |
| (3-Phenoxyphenyl) methanol (metabolite of permethrin) | 40 CFR 180.378 | no | D |
| Phorate | 40 CFR 180.206 | yes | D |
| Phosolone | 40 CFR 180.263 | yes | D |

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|--|---------------------------|---------|
| Picloram | 40 CFR 180.292 | no | B |
| Piperazine | 21 CFR 520.1802 | no | D |
| Piperonyl butoxide | 40 CFR 180.127 | yes | A |
| Pirimiphos-methyl | 40 CFR 180.409 | no | D |
| Pituitary luteinizing hormone | 21 CFR 522.1820 | no | D |
| Poloxalene | 21 CFR 558.464 21 CFR 558.465 | no | D |
| Polymixin | 21 CFR 544.373b | no | C |
| Potassium salt of 1-(4-chlorophenyl)-1,4-dihydro-6-methyl-4-oxo-pyridazine-3-carboxylic acid | 40 CFR 180.423 | no | D |
| Prednisolone | 21 CFR 556.520 21 CFR 522.1880-1890 | no | D |
| Prednisone | 21 CFR 556.530 | no | D |
| Profenofos | 40 CFR 180.404 | no | D |
| Profluralin | 40 CFR 180.348 | no | D |
| Progesterone | 21 CFR 556.540 21 CFR 522.1940 | yes | B |
| Prometryn | 40 CFR 180.222 | no | C-3* |
| Propanil | 40 CFR 180.274 | yes ¹ | D |
| Proparacaine hydrochloride | 21 CFR 524.1982 | no | D |
| Propargite | 40 CFR 180.259 | yes | B |
| Propazine | 40 CFR 180.243 | no | A |
| Propiopromazine | 21 CFR 520.2002 21 CFR 522.2002 | no | D |

¹As Stam.

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|--|---------------------------|---------|
| Prostaglandin | none | no | C |
| Pyrantel tartrate | 21 CFR 556.560 21 CFR 520.2045 21 CFR 558.485 | yes | B |
| Pyrethrins | 40 CFR 180.128 | yes | D |
| Quinoxaline-2-carboxylic acid (metabolite of carbodox) | 21 CFR 556.100 21 CFR 558.115 | no | B |
| Reserpine | none | yes | D |
| Robenidine hydrochloride | 21 CFR 556.580 21 CFR 558.515 | yes | C |
| Ronnel | 40 CFR 180.177 21 CFR 558.526 21 CFR 520.2080 | yes | B |
| Roxarsone | 21 CFR 556.60 21 CFR 558.530 | no | C-1* |
| Salicylic acid | 21 CFR 556.590 21 CFR 529.2090 | no | D |
| Selenium | 21 CFR 522.2100 21 CFR 573.920 | no | D |
| Silvex | 40 CFR 180.340 | yes | A-3* |
| Simazine | 40 CFR 180.213 | yes | A |
| Sodium 5-[2-Chloro-4-(trifluoromethyl)-phenoxy]-2-aminobenzoate (metabolite of sodium salt of acifluorfen) | 40 CFR 180.383 | no | D |
| Sodium salt of acifluorfen | 40 CFR 180.383 | no | D |
| Sodium sulfachloropyrazine monohydrate | 21 CFR 556.625 | yes | D |
| Spectinomycin dihydrochloride | 21 CFR 556.600 21 CFR 520.2122 21 CFR 522.2120 | yes | C |

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|-----------------------------------|--|---------------------------|---------|
| Streptomycin | 21 CFR 556.610 21 CFR 544.110-973b 40 CFR 180.245 | yes | A-3* |
| Styrene | none | no | D |
| Sulfabromomethazine sodium | 21 CFR 556.620 21 CFR 520.2170 | no | C |
| Sulfachloropyridazine | 21 CFR 556.630 21 CFR 520.2200 21 CFR 522.2200 | yes | A |
| Sulfadimethoxine | 21 CFR 556.640 21 CFR 520.2220 21 CFR 522.2220 21 CFR 558.575 | yes | A |
| Sulfaethoxypyridazine | 21 CFR 556.650 21 CFR 520.2240 21 CFR 522.2240 21 CFR 558.579 | yes | A |
| Sulfamethazine | 21 CFR 556.670 21 CFR 520.2260 21 CFR 522.2260 | yes | B-1* |
| Sulfamethoxypyridazine | 21 CFR 520.2300 | no | D |
| Sulfanitran | 21 CFR 556.680 21 CFR 520.2320 | yes | A |
| Sulfapyridine | none | no | D |
| Sulfaquinoxaline | 21 CFR 520.2325 21 CFR 558.586 | no | B-1* |
| Sulfathiazole | 21 CFR 556.690 | yes | B-1* |
| Sulfisoxazole | 21 CFR 520.2330 | no | C |
| Sulfomyxin | 21 CFR 556.700 21 CFR 522.2340 | no | B |
| 2,4,5-T | none | yes | A-3* |

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--------------------------------------|---|---------------------------|---------|
| TDE (metabolite of DDT) | 40 CFR 180.147 | yes | A |
| TDE (or DDD) | 40 CFR 180.187 | yes | A |
| Tebuthiuron | 40 CFR 180.390 | no | D |
| Terbacil | 40 CFR 180.209 | yes | D |
| Terbufos | 40 CFR 180.352 | no | D |
| Terbutylazine | 40 CFR 180.333 | no | A |
| Terbutryn | 40 CFR 180.265 | no | A |
| Terpene polychlorinates | 40 CFR 180.164 | no | A |
| Testosterone propionate | 21 CFR 556.710 | yes | C |
| Tetracycline hydrochloride | 21 CFR 556.720 21 CFR 546.180,a,h,i | yes | B-3* |
| Tetradifon | 40 CFR 180.174 | yes | D |
| Thiabendazole | 21 CFR 556.730 40 CFR 180.242 21 CFR 558.615 21 CFR 520.2380 | yes | B-2* |
| Thiamylal, Sodium | 21 CFR 522.2424 | no | D |
| Thidiazuron | 40 CFR 180.403 | no | D |
| Thiobencarb | 40 CFR 180.401 | no | D |
| Thiophanate-methyl and oxygen analog | 40 CFR 180.371 | no | D |
| Thiram | 40 CFR 180.132 | yes ¹ | D |
| Tiamulin | 21 CFR 556.738 21 CFR 520.2455 | no | ZZ* |
| Toxaphene | 40 CFR 180.138 | yes | A-2* |
| Triamcinolone acetonide | 21 CFR 520.2482 | no | C |

¹Polyram is part of the trade name Polyram Ultra, which is thiram; zineb and maneb, q.v., may also be associated with Polyram.

* Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

| Compound Name | CFR or NADA Reference | Listed in 1979 GAO Report | Ranking |
|--|---|---------------------------|---------|
| S,S,S-Tributyl phosphorotrithioate | 40 CFR 180.272 | yes ¹ | D |
| Trichlorfon | 40 CFR 180.198 ² 21 CFR 520.2520 | yes | B-3* |
| 3,5,6-Trichloro-2-pyridinol (metabolite of chlorpyrifos) | 40 CFR 180.342 | no | B |
| 3,5,6-Trichloro-2-pyridinol (metabolite of chlorpyrifos-methyl) | 40 CFR 180.419 | no | B |
| 3,5,6-Trichloro-2-pyridinol (metabolite of triclopyr) | 40 CFR 180.417 | no | B |
| Triclopyr and metabolite | 40 CFR 180.417 | no | D |
| Tricyclohexyltin hydroxide | 40 CFR 180.144 | yes ³ | D |
| Trifluralin | 40 CFR 180.207 | no | C-4* |
| Triphenyltin hydroxide | 40 CFR 180.236 | no | B-4* |
| Tylosin | 21 CFR 556.740 21 CFR 520.2640 21 CFR 522.2640 21 CFR 524.2640 21 CFR 558.625 | yes | Z-3* |
| Virginiamycin | 21 CFR 556.750 21 CFR 558.635 | yes | B |
| Xylazine | 21 CFR 522.2662 | no | Z-4* |
| Zeranol | 21 CFR 556.760 21 CFR 522.2680 | yes | C-2* |
| Zinc | none | no | D-4* |
| Zinc ion and maneb, coordination product | 40 CFR 180.176 | yes | D |
| Zineb | 40 CFR 180.115 | yes | D |
| Zoalene | 21 CFR 556.770 | yes | B |

¹As DEF.

²As dimethyl (2,2,2-trichloro-1-hydroxyethyl)phosphonate

³As Plictran.

*Ranked under CES.

LIST OF COMPOUNDS CONSIDERED

NOTE

*Compounds Ranked Under Compound Evaluation System (CES)
(See discussion on 3.A.3-4.)*

| <i>Compound</i> | <i>Original Rank</i> | <i>2-Value Ranking</i> |
|-----------------------------------|----------------------|------------------------|
| Aflatoxin | D | A-4 |
| Alachlor | D | A-2 |
| Albendazole | D | A-2 |
| Aldicarb | D | A-4 |
| Aldrin | A | A-3 |
| Ampicillin | A | B-2 |
| Ampicillin trihydrate | A | B-2 |
| Arsanilic acid | A | C-1 |
| Atrazine | A | C-3 |
| Azaperone | D | B-4 |
| Benomyl | D | B-3 |
| BHC | D | B-2 |
| Cadmium | D | B-4 |
| Captan | D | B-3 |
| Carbadox | B | A-3 |
| Carbarsone | A | C-2 |
| Carbofuran | C | C-3 |
| Carboxin | D | C-4 |
| Chloramphenicol | A | A-2 |
| Chloramphenicol palmitate | A | A-2 |
| Chlordane (technical) | A | A-2 |
| Chlorpyrifos | B | B-4 |
| 2,4,D (technical) | B | B-2 |
| Dalapon | A | A-3 |
| Daminozide | D | B-3 |
| Decoquinate | D | Z-4* |
| Dichlorvos | C | B-4 |
| Dimethoate | D | B-3 |
| Diphenylamine | D | B-4 |
| Endrin | A | A-3 |
| Ethylene dibromide | D | A-4 |
| Fenbendazole | B | B-3 |
| Fenthion | B | C-3 |
| Furazolidone | B | A-1 |
| Gentamicin sulfate | A | B-2 |
| Heptachlor and heptachlor epoxide | A | A-1 |
| Hexazinone | D | D-4 |
| Ipronidazole | B | Z-4* |
| Ipronidazole hydrochloride | B | Z-4* |
| Ivermectin | D | B-1 |
| Lead | D | B-4 |
| Levamisole | A | C-2 |
| Levamisole hydrochloride | A | C-2 |
| Lindane | A | A-2 |
| Mebendazole | B | B-4 |

*The letter Z is used to designate an element of the two-value system lacking the information needed for classification.

LIST OF COMPOUNDS CONSIDERED

NOTE

Compounds Ranked Under Compound Evaluation System (CES)

| <i>Compound</i> | <i>Original Rank</i> | <i>2-Value Ranking</i> |
|----------------------------|----------------------|------------------------|
| Methoxychlor | A | D-4 |
| Methyl bromide | D | B-4 |
| Methylene chloride | D | A-2 |
| Monensin | A | B-3 |
| Naled | B | B-4 |
| Nitrofurazone | C | B-1 |
| Neomycin sulfate | A | B-3 |
| Paraquat | A | A-4 |
| PCB's | D | A-4 |
| PCP | D | B-1 |
| Permethrin | D | B-2 |
| Prometryne | C | C-3 |
| Roxarsone | A | C-1 |
| Silvex | D | A-3 |
| Streptomycin | A | A-3 |
| Sulfamethazine | A | B-1 |
| Sulfaquinoxaline | A | B-1 |
| Sulfathiazole | A | B-1 |
| Thiabendazole | A | B-2 |
| 2,4,5-T | D | A-3 |
| Tetracycline hydrochloride | A | B-3 |
| Tiamulin | D | ZZ* |
| Toxaphene | A | A-2 |
| Trichlorfon | C | B-3 |
| Trifluralin | C | C-4 |
| Triphenyltin hydroxide | D | B-4 |
| Tylosin | A | Z-3* |
| Xylazine | D | Z-4* |
| Zeranol | B | C-2 |
| Zinc | D | D-4 |

*The letter Z is used to designate an element of the two-value system lacking the information needed for classification

CROSS-REFERENCED COMPOUNDS

Introduction

CFR names have been used wherever possible in this fourth edition of the Compound Evaluation and Analytical Capability Document. This provides uniformity in nomenclature, but can cause difficulties in locating or identifying certain compounds that have been designated by common or trade names in other places. The cross-reference section is intended to eliminate some of these difficulties. The section includes:

- Names used in the 1979 GAO Report that do not follow CFR usage
- Common and trade names used in the tolerance section of the first edition
- Compounds almost universally known by a common name or trade name
- Compounds identified by different names in different sections of the CFR

CROSS-REFERENCED COMPOUNDS

| | |
|---|--|
| 4-amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)one | metribuzin, Sencor |
| azinphosmethyl | O,O-dimethyl S-[(4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl] phosphorodithioate |
| bambermycins | flavomycin |
| bendiocarb | Ficam |
| benzene hexachloride | BHC |
| BHC | benzene hexachloride |
| 4-tert-butyl-2-chlorophenyl methyl methylphosphoramidate (name used in 40 CFR) | crufomate (name used in 21 CFR), Ruelene |
| carbophenothion | Trithion |
| chlordecone | Kepone |
| chlorfenvinphos | 2-chloro-1-(2,4-dichlorophenyl)vinyl diethyl phosphate |
| chlorobenzilate | ethyl 4,4'-dichlorobenzilate |
| 2-chloro-1-(2,4-dichlorophenyl)vinyl diethyl phosphate | chlorfenvinphos |
| 2-chloro-N-isopropylacetanilide | propachlor |
| 2-chloro-1(2,4,5-trichlorophenyl)vinyl dimethyl phosphate | Gardona, tetrachlorvinphos |
| chlorpyrifos | Dursban |
| crotoxyphos | dimethyl phosphate of alpha-methylbenzyl 3-hydroxy-cis-crotonate |
| crufomate (name used in 21 CFR) | 4-tert-butyl-2-chlorophenyl methyl methylphosphoramidate (name used in 40 CFR), Ruelene |
| cyano(3-phenoxyphenyl) methyl-4-chloro-alpha-methylethyl benzeneacetate | fenvalerate |
| cyromazine | Larvadex |
| 2,4-DB | 4-(2,4-dichlorophenoxy) butyric acid |
| DEF | S,S,S-tributyl phosphorotrithioate |
| Diazinon | O,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate |

CROSS-REFERENCED COMPOUNDS


| | |
|--|---|
| 1,1-dichloro-2,2-bis(p-ethylphenyl) ethane | Perthane |
| 3,5-dichloro-N-(1,1-dimethyl-2-propynyl) benzamide | propyzamide |
| 4-(2,4-dichlorophenoxy) butyric acid | 2,4-DB |
| 2,4-dichlorophenyl p-nitrophenyl ether | nitrofen |
| dichlorvos (name used in 21 CFR) | 2,2-dichlorovinyl dimethyl phosphate (name used in 40 CFR) |
| 2,2-dichlorovinyl dimethyl phosphate (name used in 40 CFR) | dichlorvos (name used in 21 CFR) |
| O,O-diethyl S-[2-(ethylthio)ethyl] phosphorodithioate | disulfoton, Disyston |
| O,O-diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate | Diazinon |
| O,O-diethyl-O-[p-(methylsulfinyl) phenyl] phosphorothioate | fensulfothion |
| O,O-dimethyl O-p-(dimethylsulfamoyl) phenyl phosphorothioate | famphur |
| O,O-dimethyl S-[(4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl] phosphorodithioate | azinophosmethyl, Guthion |
| dimethyl phosphate of alpha-methylbenzyl 3-hydroxy-cis-crotonate | crotoxyphos |
| dimethyl (2,2,2-trichloro-1-hydroxyethyl) phosphonate (name used in 40 CFR) | trichlorfon (name used in 21 CFR) |
| 3,5-dinitrobenzamide | nitromide |
| disulfoton | O,O-diethyl S-[2-(ethylthio)ethyl] phosphorodithioate |
| Disyston | O,O-diethyl S-[2-(ethylthio)ethyl] phosphorodithioate |
| dodecachlorooctahydro-1,3,4-metheno-2H-cyclobuta [cd] pentalene | mirex |
| Dursban | chlorpyrifos |
| ethyl 4,4'-dichlorobenzilate | chlorobenzilate |
| O-ethyl-O-[4-(methylthio)phenyl] S-propyl phosphorodithioate | sulprofos |

CROSS-REFERENCED COMPOUNDS


| | |
|--|--|
| S-[2-(ethylsulfinyl)ethyl] O,O-dimethyl phosphorothioate | oxydemetonmethyl |
| famphur | O,O-dimethyl O-p-(dimethylsulfamoyl) phenyl phosphorothioate |
| fenbutatin oxide | hexakis (2-methyl-2-phenylpropyl) distannoxane |
| fenridazole-potassium | potassium salt of 1-(4-chlorophenyl)-1,4-dihydro-6-methyl-4-oxo-pyridazine-3-carboxylic acid |
| fensulfothion | O,O-diethyl-O-[p-(methylsulfinyl) phenyl] phosphorothioate |
| fenvalerate | cyano(3-phenoxyphenyl) methyl-4-chloro-alpha-(methylethyl) benzeneacetate |
| Ficam | bendiocarb |
| flavomycin | bambermycins |
| Gardona | 2-chloro-1(2,4,5-trichlorophenyl)vinyl dimethyl phosphate, tetrachlorvinphos |
| Guthion | O,O-dimethyl S-[(4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl] phosphorodithioate |
| "hexakis" | hexakis (2-methyl-2-phenylpropyl) distannoxane |
| hexakis (2-methyl-2-phenylpropyl) distannoxane | fenbutatin oxide, "hexakis" |
| isofenphos | 1-methylethyl 2-((ethoxy-((1-methylethyl) amino) phosphinothioyl)oxy)benzoate |
| Kepone | chlordecone |
| Larvadex | cyromazine |
| N-(mercaptomethyl) phthalimide S-(O,O-dimethyl phosphorodithioate | phosmet |
| 6-methyl-1,3-dithiolo[4,5-b]quinoxalin-2-one | oxythioquinox |
| 1-methylethyl 2-((ethoxy-1((methylethyl)amino) phosphinothioyl)oxy)benzoate | isofenphos |
| metribuzin | 4-amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one |
| mirex | dodecachlorooctahydro-1,3,4-metheno-2H-cyclobuta [cd] pentalene |

CROSS-REFERENCED COMPOUNDS

| | |
|---|--|
| nitrofen | 2,4-dichlorophenyl p-nitrophenyl ether |
| nitromide | 3,5-dinitrobenzamide |
| oxydemetonmethyl | S-[2-(ethylsulfinyl)ethyl] O,O-dimethyl phosphorothioate |
| oxythioquinox | 6-methyl-1,3-dithiolo[4,5-b]quinoxalin-2-one |
| Perthane | 1,1-dichloro-2,2-bis(p-ethylphenyl) ethane |
| phosmet | N-(mercaptomethyl) phthalimide S-(O,O-dimethyl phosphorodithioate) |
| Plictran | tricyclohexyltin hydroxide |
| "Polyram" | a partial trade name; possibly refers to thiram, zineb, or maneb |
| potassium salt of 1-(4-chlorophenyl)-1,4-dihydro-6-methyl-4-oxo-pyridazine-3-carboxylic acid | fenridazole-potassium |
| propachlor | 2-chloro-N-isopropylacetanilide |
| propanil | Stam |
| propyzamide | 3,5-dichloro-N-(1,1-dimethyl-2-propynyl) benzamide |
| Ruelene | 4-tert-butyl-2-chlorophenyl methyl methylphosphoramidate (see crufomate) |
| Sencor | 4-amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one |
| Stam | propanil |
| Strobane | terpene polychlorinates |
| sulprofos | O-ethyl-O-[4-(methylthio)phenyl] S-propyl phosphorodithioate |
| terpene polychlorinates | Strobane |
| tetrachlorvinphos | 2-chloro-1-(2,4,5-trichlorophenyl) vinyl dimethyl phosphate, Gardona |
| S,S,S-tributyl phosphorotrithioate | DEF |
| trichlorfon (name used in 21 CFR) | dimethyl (2,2,2-trichloro-1-hydroxyethyl) phosphonate (named used in 40 CFR) |
| tricyclohexyltin hydroxide | Plictran |
| Trithon | carbophenothion |



Section 4



RESIDUE LIMITS

Introduction

This section provides information on residue limits in meat and poultry products applied by FSIS (as of September 1, 1986). These limits include tolerances and action levels developed by the Environmental Protection Agency (EPA) for pesticide chemicals and by the Food and Drug Administration (FDA) for animal drugs and unavoidable contaminants. Formal tolerances are not established in all cases; for some unavoidable contamination situations, FDA and EPA, upon request, recommend action levels to FSIS. FSIS will condemn product as adulterated when the residue level found exceeds a limit listed here or, for pesticide chemical and drug residues, when there is no applicable limit or exemption.

The residue limits for poultry and livestock species are listed alphabetically by compound (which may include a substance's metabolites). The entries include, among other things, Code of Federal Regulations (CFR) citations for tolerances and "AL" notations for action levels. For animal drugs with "zero" or "no residue" tolerances, the entries also include, in parenthesis, the limits of quantification considered by FDA in approving uses of those drugs in food producing animals and for enforcement purposes, and applied by FSIS in determining if product is adulterated.

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses | Units are parts per million |
|--|----------------|----------|-----------------|----------|--------------------|----------|-----------------------------|
| | | | | | | | |
| Acephate and metabolite | 40 CFR 180.108 | 0.1F | 0.1F | 0.1F | 0.1F | 0.1F | 0.1F |
| | | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
| | | 0.1Mb | 0.1Mb | 0.1Mb | 0.1Mb | 0.1Mb | 0.1Mb |
| 2-Acetyl-amino-5-nitrothiazole | 21 CFR 556.20 | — | — | — | 0.1Et ¹ | — | |
| Aklomide and metabolite | 21 CFR 556.30 | — | — | — | 4.5L ² | — | |
| | | — | — | — | 4.5M ² | — | |
| | | — | — | — | 3Sf ² | — | |
| Alachlor and metabolites | 40 CFR 180.249 | 0.02F | 0.02F | 0.02F | 0.02F | 0.02F | 0.02F |
| | | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| | | 0.02Mb | 0.02Mb | 0.02Mb | 0.02Mb | 0.02Mb | 0.02Mb |
| Aldicarb and metabolites | 40 CFR 180.269 | 0.01F | 0.01F | 0.01F | — | 0.01F | |
| | | 0.01M | 0.01M | 0.01M | — | 0.01M | |
| | | 0.01Mb | 0.01Mb | 0.01Mb | — | 0.01Mb | |
| Aldrin | MPI Dir 917.1 | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) |
| (Alpha RS,2R)-fluvalinate [(RS)-alpha-cyano-3-phenoxybenzyl(R)-2-[2-chloro-4-(trifluoromethyl)anilino]-3-methylbutanoate] | 40 CFR 180.427 | 0.01F | 0.01F | 0.01F | 0.01F | 0.01F | 0.01F |
| | | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| | | 0.01Mb | 0.01Mb | 0.01Mb | 0.01Mb | 0.01Mb | 0.01Mb |
| 4-Amino-6-(1,1-dimethylethyl)-3-(methylthio)-1,2,4-triazin-5(4H)-one and metabolites | 40 CFR 180.332 | 0.7F | 0.7F | 0.7F | 0.7F | 0.7F | 0.7F |
| | | 0.7M | 0.7M | 0.7M | 0.7M | 0.7M | 0.7M |
| | | 0.7Mb | 0.7Mb | 0.7Mb | 0.7Mb | 0.7Mb | 0.7Mb |
| Amitraz and metabolites³ | 40 CFR 180.287 | 0.1F | 0.01F | 0.01F | 0.01F | 0.01F | 0.01F |
| | | 0.05M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| | | 0.3Mb | 0.01Mb | 0.01Mb | 0.01Mb | 0.01Mb | 0.01Mb |

¹Turkeys only.²Chickens only.³Tolerances for goats, sheep, swine, poultry, and horses established until April 2, 1987.**KEY**

| | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| EK: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|----------------|--|-----------------------------|--|---|--------------------------|
| | | | Units are parts per million | | | |
| Amoxicillin | 21 CFR 556.38 | 0.01Et | — | — | — | — |
| Ampicillin | 21 CFR 556.40 | 0.01Et | — | 0.01Et | — | — |
| Amprolium | 21 CFR 556.50 | 2.0F ¹ 0.5K ¹ 0.5L ¹ 0.5M ¹ | — | — | 1K ² 1L ² 0.5M ² | — |
| Apramycin | 21 CFR 556.52 | — | — | 0.4F ³ 0.4K ³ 0.3L ³ 0.1M ³ | — | — |
| Arsenic | 21 CFR 556.60 | — | — | 2K 2L 0.5M. 0.5Mb | 0.5M 2Mb | — |
| Atrazine | 40 CFR 180.220 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb |
| Bacitracin | 21 CFR 556.70 | 0.5Et | — | 0.5Et | 0.5Et ⁴ | — |
| Benomyl and metabolites | 40 CFR 180.294 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.2L 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb |
| Bentazon and metabolite | 40 CFR 180.355 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | — |
| BHC | 51 FR 25697 | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) |
| 3,6-Bis(2-chlorophenyl) 1,2,4,5-tetrazine⁵ | none | 0.01F 0.05K 0.1L 0.01M 0.01Mb | — | — | — | — |

¹Calves only.²Chickens and turkeys.³Total residues.⁴Also pheasant and quail.⁵Tolerances established until March 13, 1987.**KEY**

(AL): Action level
 Ek: Excluding kidneys
 Et: Edible tissue
 F: Fat
 K: Kidney
 L: Liver

M: Muscle
 Mb: Meat byproducts
 S: Skin
 Sf: Skin with fat
 Sm: Skeletal muscle
 —: No tolerance

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|---|----------------|---------------------------------------|-----------------------------------|-----------------------------------|---|-----------------------------------|
| | | | Units are parts per million | | | |
| Bromoxynil | 40 CFR 180.324 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | — | 0.1F 0.1M 0.1Mb |
| Buquinolate | 21 CFR 556.90 | — | — | — | 0.4K ¹ 0.4L ¹ 0.1M ¹ 0.4Sf ¹ | — |
| sec-Butyl-amine | 40 CFR 180.321 | 0.75F 3K 0.75M 0.75Mb | — | — | — | — |
| 4-tert-Butyl-2-chlorophenyl methyl methylphosphoramide and metabolite | 40 CFR 180.295 | 1F 1M 1Mb | 1F 1M 1Mb | — | — | — |
| Cacodylic acid (as As ₂ O ₃) | 40 CFR 180.311 | 0.7F 1.4K 1.4L 0.7M 0.7Mb | — | — | — | — |
| Captan | 40 CFR 180.103 | 0.05F 0.05M 0.05Mb | — | 0.05F 0.05M 0.05Mb | — | — |
| Carbadox and metabolite | 21 CFR 556.100 | — | — | 0(0.030)Et | — | — |
| Carbaryl and metabolites | 40 CFR 180.169 | 0.1F 1K 1L 0.1M 0.1Mb | 0.1F 1K 1L 0.1M 0.1Mb | 0.1F 1K 1L 0.1M 0.1Mb | 5F 1K 1L 5M 0.1M 0.1Mb | 0.1F 1K 1L 0.1M 0.1Mb |
| Carbofuran ² and metabolites | 40 CFR 180.254 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | — | 0.05F 0.05M 0.05Mb |

¹Chickens only.²No more than 0.02 can be the carbamate.**KEY**

| | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|---|----------------|--------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|
| | | | Units are parts per million | | | |
| Carbomycin | 21 CFR 556.110 | — | — | — | 0(0.5)Et ¹ | — |
| Carbophenothion | 40 CFR 180.156 | 0.1F | 0.1F | 0.1F | — | — |
| Carboxin and metabolite | 40 CFR 180.301 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb |
| Cephapirin | 21 CFR 556.115 | 0.1Et | — | — | — | — |
| Chlorbromuron and metabolites | 40 CFR 180.279 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb |
| Chlordane | MPI Dir 917.1 | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) |
| Chlormeform and metabolites | 40 CFR 180.285 | 0.25F 0.25M 0.25Mb | 0.25F 0.25M 0.25Mb | 0.25F 0.25M 0.25Mb | 0.25F 0.25M 0.25Mb | 0.25F 0.25M 0.25Mb |
| Chlorhexidine | 21 CFR 556.120 | 0(0.001)Et ² | — | — | — | — |
| 2-Chloro-1-(2,4-dichlorophenyl) vinyl diethyl phosphate | 40 CFR 180.322 | 0.2F | 0.2F ³ | 0.005F | 0.005F | 0.005F |
| 2-Chloro-N-isopropylacetanilide | 40 CFR 180.211 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb |
| Chloroneb and metabolite | 40 CFR 180.257 | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | — | 0.2F 0.2M 0.2Mb |
| 1-(4-Chlorophenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)-2-butanone and metabolites | 40 CFR 180.410 | 1.0F 1.0M 1.0Mb | 1.0F 1.0M 1.0Mb | 0.04F 0.04M 0.04Mb | 0.04F 0.04M 0.04Mb | 1.0F 1.0M 1.0Mb |

¹Chickens only.²Calves only.³Sheep only; goats 0.005F.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|----------------|-------------------|-----------------------------|--------|---------|--------|
| | | | Units are parts per million | | | |
| 2-(m-Chlorophenoxy) propionic acid | 40 CFR 180.325 | 0.05F | 0.05F | 0.05F | 0.05F | 0.05F |
| | | 0.5K | 0.5K | 0.5K | | 0.5K |
| | | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M |
| | | 0.05Mb | 0.05Mb | 0.05Mb | 0.05Mb | 0.05Mb |
| 2-Chloro-1-(2,4,5-trichlorophenyl) vinyl dimethyl phosphate | 40 CFR 180.252 | 1.5F | 0.5F | 1.5F | 0.75F | 0.5F |
| Chlorpyrifos and metabolite | 40 CFR 180.342 | 2.0F | 1.0F | 0.5F | 0.5F | 1.0F |
| | | 2.0M | 1.0M | 0.5M | 0.5M | 1.0M |
| | | 2.0Mb | 1.0Mb | 0.5Mb | 0.5Mb | 1.0Mb |
| Chlorpyrifos-methyl and metabolite | 40 CFR 180.419 | 0.5F | 0.5F | 0.5F | 0.5F | 0.5F |
| | | 0.5M | 0.5M | 0.5M | 0.5M | 0.5M |
| | | 0.5Mb | 0.5Mb | 0.5Mb | 0.5Mb | 0.5Mb |
| Chlorsulfuron | 40 CFR 180.405 | 0.3F | 0.3F | 0.3F | — | 0.3F |
| | | 0.3M | 0.3M | 0.3M | | 0.3M |
| | | 0.3Mb | 0.3Mb | 0.3Mb | | 0.3Mb |
| Chlortetracycline | 21 CFR 556.150 | 0F ¹ | | 0.2F | 1F | — |
| | | 0.1K ¹ | 1K ² | 4K | 4K | |
| | | 0.1L ¹ | 0.5L ² | 2L | 1L | |
| | | 0.1M ¹ | 0.1M ² | 1M | 1M | 1S |
| Clopidol | 21 CFR 556.160 | 3K | 3K | 0.2Et | 15K | — |
| | | 1.5L | 1.5L | | 15L | |
| | | 0.2M | 0.2M | | 5M | |
| Clorsulon | 21 CFR 556.163 | 1.0K ³ | — | — | — | — |
| Cloxacillin | 21 CFR 556.165 | 0.01 Et | — | — | — | — |
| Coumaphos and oxygen analog | 40 CFR 180.189 | 1F | 1F | 1F | 1F | 1F |
| | | 1M | 1M | 1M | 1M | 1M |
| | | 1Mb | 1Mb | 1Mb | 1Mb | 1Mb |

¹Cattle only; calves 1F, 4K, 4L, 1M.²Sheep only.³Tolerance for clorsulon; corresponds to 3.0 total residues in kidney; safe concentrations 4.0F, 3.0K, 2.0L, 1.0M.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|----------------------------------|-----------------------------|-----------------------------|-----------------------------|---|-----------------------------|
| | | | Units are parts per million | | | |
| Cyano(3-phenoxy-phenyl)methyl-4-chloro-a-(methyleneethyl)benzeneacetate | 40 CFR 180.379 | 1.5F 1.5M 1.5Mb | 1.5F 1.5M 1.5Mb | 1.5F 1.5M 1.5Mb | — | 1.5F 1.5M 1.5Mb |
| Cypermethrin¹ | 40 CFR 180.418 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | — | 0.05F 0.05M 0.05Mb |
| Cyromazine | 40 CFR 180.414 | — | — | — | 0.05F ² 0.05M ² 0.05Mb ² | — |
| 2,4-D and metabolite | 40 CFR 180.142 | 0.2F 2K 0.2M 0.2Mb | 0.2F 2K 0.2M 0.2Mb | 0.2F 2K 0.2M 0.2Mb | 0.05F 0.05K 0.05M 0.05Mb | 0.2F 2K 0.2M 0.2Mb |
| Dalapon | 40 CFR 180.150 | 0.2M 0.2Mb | 0.2M 0.2Mb | 0.2M 0.2Mb | 3Ek 9K | — |
| Daminozide | 40 CFR 180.246 | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb 2K | 0.2F 0.2M 0.2Mb |
| DDT and metabolites | 40 CFR 180.147 MPI Dir. 917.1 | 5F | 5F | 5F | 5F(AL) | 5F |
| Decoquinate | 21 CFR 556.170 | 2Et 1Sm | — | — | 2Et ³ 1Sm ³ | — |
| Dialifor and oxygen analog | 40 CFR 180.326 | 0.15F 0.15M 0.15Mb | 0.15F 0.15M 0.15Mb | — | 0.05F 0.05M 0.05Mb | — |

¹Tolerances established until December 31, 1989.²Chicken layer hens only; tolerance for parent cyromazine; an additional tolerance of 0.05F, M, Mb exists for the metabolite, melamine.³Chickens only.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|---|----------------------------------|--|--|--|--|--|
| Units are parts per million | | | | | | |
| Dicamba and metabolite | 40 CFR 180.227 | 0.2F 1.5K 1.5L 0.2M 0.2Mb | 0.2F 1.5K 1.5L 0.2M 0.2Mb | 0.2F 1.5K 1.5L 0.2M 0.2Mb | — | 0.2F 1.5K 1.5L 0.2M 0.2Mb |
| 3,5-Dichloro-N-(1,1-dimethyl-2-propynyl)benzamide and metabolites | 40 CFR 180.317 | 0.02F 0.2K 0.2L 0.02M 0.02Mb | 0.02F 0.2K 0.2L 0.02M 0.02Mb | 0.02F 0.2K 0.2L 0.02M 0.02Mb | 0.02F 0.2K 0.2L 0.02M 0.02Mb | 0.02F 0.2K 0.2L 0.02M 0.02Mb |
| 1,1-Dichloro-2,2-bis(p-ethylphenyl) ethane | 40 CFR 180.139 | 0M | 0M | 0M | 0M | 0M |
| Dichlorvos | 40 CFR 180.235 21 CFR 556.180 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.1F 0.1M 0.1Mb | 0.05F 0.05M 0.05Mb | 0.02F 0.02M 0.02Mb |
| Dieldrin | MPI Dir 917.1 | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) |
| O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate | 40 CFR 180.153 | 0.7F 0.7M 0.7Mb | 0.7F ¹ 0.7M ¹ 0.7Mb ¹ | — | — | — |
| O,O-Diethyl O-(p-(methylsulfinyl) phenyl phosphorothioate and metabolites | 40 CFR 180.234 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | — | 0.02F 0.02M 0.02Mb |
| Difenoquat | 40 CFR 180.369 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |
| Diflubenzuron | 40 CFR 180.377 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |
| 2,3-Dihydro-5,6-dimethyl-1,4-dithiin-1,1,4,4-tetraoxide | 40 CFR 180.406 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | — | 0.02F 0.02M 0.02Mb |

¹Sheep only.**KEY**

| | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|---|--------------------------|-----------------------------|--------------------------|--------------------------|--------------------------|
| | | | Units are parts per million | | | |
| Dihydrostreptomycin | 21 CFR 556.200 | 0(0.5)Et ^{1,2} | — | — | — | — |
| Dimethoate and oxygen analog | 40 CFR 180.204 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb |
| O,O-Dimethyl S-[(4-oxo-1,2,3-benzotriazin-3(4H)-yl) methyl] phosphorodithioate | 40 CFR 180.154 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | — | — | 0.1F 0.1M 0.1Mb |
| O,O-Dimethyl O-p(dimethylsulfamoyl) phenyl phosphorothioate and oxygen analog | 40 CFR 180.233 | 0.1F 0.1M 0.1Mb | — | — | — | — |
| Dimethyl phosphate of a-methylbenzyl 3-hydroxy-cis-crotonate | 40 CFR 180.280 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | — | — |
| N,N-Dimethyl-piperidinium chloride | 40 CFR 180.384 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb |
| Dimetridazole | 21 CFR 556.210 | — | — | — | 0(0.002)Et ³ | — |
| 3,5-Dinitrobenzamide | 21 CFR 556.220 | — | — | — | 0(0.020)Et ⁴ | — |
| Dioxathion | 40 CFR 180.171 | 1F | 1F | 1F | — | 1F |
| Diphenamid | 40 CFR 180.230 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | — | 0.05F 0.05M 0.05Mb |
| Diphenylamine | 40 CFR 180.190 | 0M | 0M | 0M | 0M | 0M |
| Dipropyl isocinchomeronate | 40 CFR 180.143 40 CFR 180.319 ⁵ | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | — | 0.1F 0.1M 0.1Mb |

¹Calves only.²Administrative tolerance in calves and cattle 2.0K.³Turkeys only.⁴Chickens only.⁵Interim tolerance.**KEY**

| | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|----------------|--|--|--------------------------|--------------------------|--------------------------|
| Units are parts per million | | | | | | |
| Diquat | 40 CFR 180.226 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb |
| Diuron | 40 CFR 180.106 | 1F 1M 1Mb | 1F 1M 1Mb | 1F 1M 1Mb | — | 1F 1M 1Mb |
| Dodecachloroocta-hydro-1,3,4-metheno-2H-cyclobuta(cd)pentalene | 40 CFR 180.251 | 0.1F | 0.1F | 0.1F | 0.1F | 0.1F |
| Dodine | 40 CFR 180.172 | 0M | 0M | 0M | 0M | 0M |
| Endosulfan and metabolite | 40 CFR 180.182 | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | — | 0.2F 0.2M 0.2Mb |
| Endrin | MPI Dir 917.1 | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) | 0.3F(AL) |
| Erythromycin | 21 CFR 556.230 | 0(0.3)Et | — | 0.1Et | 0.125Et | — |
| Estradiol benzoate | 21 CFR 556.240 | 480F ¹ 360K ¹ 240L ¹ 120M ¹ | 600F ² 600K ² 600L ² 120M ² | — | — | — |
| Estradiol monopalmitate | 21 CFR 556.250 | — | — | — | 0(0.002)Et ³ | — |
| Ethephon | 40 CFR 180.300 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | — | 0.1F 0.1M 0.1Mb |
| Ethion and oxygen analog | 40 CFR 180.173 | 2.5F 2.5M ⁴ 1.0Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb |

¹Heifers, steers, and calves (ppt); above concentrations naturally present.

²Lambs only (ppt); above concentrations naturally present.

³Chickens only.

⁴Fat basis.

KEY

(AL): Action level
Ek: Excluding kidneys
Et: Edible tissue
F: Fat
K: Kidney
L: Liver

M: Muscle
Mb: Meat byproducts
S: Skin
Sf: Skin with fat
Sm: Skeletal muscle
—: No tolerance

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|---|----------------|--------------------------|--|--------------------------|---|--------------------------|
| | | | Units are parts per million | | | |
| Ethofumesate and metabolites | 40 CFR 180.345 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | — | 0.05F 0.05M 0.05Mb |
| Ethopabate | 21 CFR 556.260 | — | — | — | 1.5K ¹ 1.5L ¹ 0.5M ¹ | — |
| 2-(1-(Ethoxyimino)-butyl)-5-(2-ethylthio)-propyl)-3-hydroxy-2-cyclohexene-1-one and metabolites | 40 CFR 180.412 | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb |
| 5-Ethoxy-3-(trichloromethyl)-1,2,4-thiadiazole and metabolite | 40 CFR 180.370 | 0.10F 0.10M 0.10Mb | 0.10F 0.10M 0.10Mb | 0.10F 0.10M 0.10Mb | 0.10F 0.10M 0.10Mb | 0.10F 0.10M 0.10Mb |
| Ethyl 4,4'-dichlorobenzilate (chlorobenzilate) | 40 CFR 180.109 | 0.5F 0.5M 0.5Mb | 0.5F ² 0.5M ² 0.5Mb ² | — | — | — |
| Ethyl 3-methyl-4-(methylthio) phenyl (1-methylethyl) phosphoramidate | 40 CFR 180.349 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | — | 0.05F 0.05M 0.05Mb |
| O-Ethyl-O-[4-(methylthio)phenyl] S-propyl phosphorodithioate and metabolites | 40 CFR 180.374 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.01F 0.01M 0.01Mb | 0.1F 0.1M 0.1Mb |
| S-[2-(Eethylsulfinyl)-ethyl] O,O-dimethyl phosphorothioate and metabolites | 40 CFR 180.330 | 0.01F 0.01M 0.01Mb | 0.01F 0.01M 0.01Mb | 0.01F 0.01M 0.01Mb | — | 0.01F 0.01M 0.01Mb |
| Fenbendazole | 21 CFR 556.275 | 0.8L ³ | — | — ⁴ | — | — |

¹Chickens only.²Sheep only.³Tolerance for parent fenbendazole; corresponds to 10 ppm total residues in liver; safe concentrations 20F, 15K, 10L, 5M.⁴Tolerance for marker residues not needed. Safe concentrations of total residues 20F, 20K, 15L, 5M, 20S.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses | Units are parts per million |
|----------------------------------|----------------|--|--|--|--|--|--|
| | | | | | | | |
| Fenprostalene | 21 CFR 556.277 | — ¹ | — | — | — | — | — |
| Fenthion and metabolites | 40 CFR 180.214 | 0.1F 0.1M 0.1Mb | — | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | — | — |
| Fluazifop and butyl ester | 40 CFR 180.411 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |
| Flucythrinate | 40 CFR 180.400 | 1.0F 0.1M 0.1Mb | 1.0F 0.1M 0.1Mb | 1.0F 0.1M 0.1Mb | — | — | 1.0F 0.1M 0.1Mb |
| Fluridone | 40 CFR 180.420 | 0.05F 0.1K 0.1L 0.05M 0.05Mb | 0.05F 0.1K 0.1L 0.05M 0.05Mb | 0.05F 0.1K 0.1L 0.05M 0.05Mb | 0.05F 0.1K 0.1L 0.05M 0.05Mb | 0.05F 0.1K 0.1L 0.05M 0.05Mb | 0.05F 0.1K 0.1L 0.05M 0.05Mb |
| Furazolidone | 21 CFR 556.290 | — | — | 0(0.100)Et | — | — | — |
| Gentamicin sulfate | 21 CFR 556.300 | — | — | 0.4F 0.4K 0.3L 0.1M | 0.1Et ² | — | — |
| Glyphosate and metabolite | 40 CFR 180.364 | 0.5K 0.5L | 0.5K 0.5L | 0.5K 0.5L | 0.5K 0.5L | 0.5K 0.5L | 0.5K 0.5L |
| Halofuginone | 21 CFR 556.308 | — | — | — | 0.1L ³ | — | — |
| Haloxon | 21 CFR 556.310 | 0.1Et | — | — | — | — | — |
| HCB | MPI Dir 917.1 | 0.5F(AL) | 0.5F(AL) | 0.5F(AL) | 0.5F(AL) | 0.5F(AL) | 0.5F(AL) |

¹Tolerance for marker residues not needed. Safe concentrations of total residues 40 ppb F, 30 ppb K, 20 ppb L, 10 ppb M, 100 ppb IS (injection site).

²Turkeys only.

³Broiler chickens only; tolerance for parent halofuginone; corresponds to 0.3 ppm total residues in liver; safe concentrations 0.1M, 0.3L, 0.2Sf.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|---------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| | | Units are parts per million | | | | |
| Heptachlor and heptachlor epoxide | 40 CFR 180.104 MPI Dir 917.1 | 0M 0.3F(AL) ¹ |
| Hexakis (2-methyl-2-phenylpropyl) distannoxane | 40 CFR 180.362 | 0.5F 0.5M 0.5Mb | 0.5F 0.5M 0.5Mb | 0.5F 0.5M 0.5Mb | 0.1F 0.1M 0.1Mb | 0.5F 0.5M 0.5Mb |
| Hexazinone and metabolites | 40 CFR 180.396 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb |
| Hygromycin B | 21 CFR 556.330 | — | — | 0Et (0.9M) (1.4K) | 0Et (0.9M) (1.4K) | — |
| Imazalil and metabolites | 40 CFR 180.413 | 0.01F 0.50L 0.01M 0.01Mb | 0.01F 0.50L 0.01M 0.01Mb | 0.01F 0.50L 0.01M 0.01Mb | — | 0.01F 0.50L 0.01M 0.01Mb |
| Iprodione and metabolites | 40 CFR 180.399 | 0.5F 3.0K 3.0L 0.5M 0.5Mb | 0.5F 3.0K 3.0L 0.5M 0.5Mb | 0.5F 3.0K 3.0L 0.5M 0.5Mb | 2.0F 3.0K 3.0L 0.5M 0.5Mb | 0.5F 3.0K 3.0L 0.5M 0.5Mb |
| Ipronidazole and metabolite | 21 CFR 556.340 | — | — | — | 0(0.002)Et ² | — |
| Isopropyl carbanilate (IPC) | 40 CFR 180.319 ³ | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |
| Isopropyl m-chlorocarbanilate (CIPC) | 40 CFR 180.319 ³ | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |
| Ivermectin | 21 CFR 556.344 | 15L ⁴ | — | 20L ⁵ | — | — |

¹In enforcing this action level, the combined concentrations of heptachlor, chlordane, and their metabolites will be used.

²Turkeys only.

³Interim tolerance.

⁴Tolerance in ppb for 22,23-dihydroavermectin B_{1a}; corresponds to 50 ppb total residues in liver; safe concentrations 100 ppb F, 75 ppb K, 50 ppb L, 25 ppb M.

⁵Tolerance in ppb for 22,23-dihydroavermectin B_{1a}; corresponds to 75 ppb total residues in liver; safe concentrations 100 ppb F, K; 75 L; 25 M.

KEY

| | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|----------------------------------|---|---|---|---|--|
| | | | Units are parts per million | | | |
| Lasalocid | 21 CFR 556.347 | 0.7L ¹ | — ² | — | 0.3Sf ³ | — |
| Levamisole hydrochloride | 21 CFR 556.350 | 0.1Et | 0.1Et ⁴ | 0.1Et | — | — |
| Lincomycin | 21 CFR 556.360 | — | — | 0.1Et | 0.1Et ⁵ | — |
| Lindane | 40 CFR 180.133 MPI Dir. 917.1 | 7F | 7F | 4F | 4F(AL) | 7F |
| Linuron | 40 CFR 180.184 | 1F 1M 1Mb | 1F 1M 1Mb | 1F 1M 1Mb | — | 1F 1M 1Mb |
| Malathion | 40 CFR 180.111 | 4F 4M 4Mb | 4F 4M 4Mb | 4F 4M 4Mb | 4F 4M 4Mb | 4F 4M 4Mb |
| Melengestrol acetate | 21 CFR 556.380 | 0(0.025)Et | — | — | — | — |
| N-(Mercaptomethyl) phthalimide S-(O,O-dimethyl phosphoro-dithioate) and oxygen analog | 40 CFR 180.261 | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | 0.2F 0.2M 0.2Mb | — | 0.2F 0.2M 0.2Mb |
| Metalexyl and metabolites | 40 CFR 180.408 | 0.4F 0.4K 0.4L 0.05M 0.05Mb | 0.4F 0.4K 0.4L 0.05M 0.05Mb | 0.4F 0.4K 0.4L 0.05M 0.05Mb | 0.4F 0.4K 0.4L 0.05M 0.05Mb | 0.4F 0.4K 0.4L 0.05M 1.0Mb |
| Methoprene | 40 CFR 180.359 | 0.3F 0.1M 0.1Mb | 0.3F 0.1M 0.1Mb | 0.3F 0.1M 0.1Mb | 0.5F 0.5M 0.05Mb | 0.3F 0.1M 0.1Mb |
| Methoxychlor | 40 CFR 180.120 MPI Dir. 917.1 | 3F | 3F | 3F | 3F(AL) | 3F |

¹Tolerance for parent lasalocid; corresponds to 4.8 total residues in liver; safe concentrations 4.8F, 3.6K, 4.8L, 1.2M

²Tolerance for marker residue not needed. Sheep only; safe concentrations of total residues 6F, 6K, 6L, 1.2M.

³Chickens only; tolerance for parent lasalocid; corresponds to 7.2 total residues in liver; safe concentrations 7.2L, 1.2M, 2.4Sf.

⁴Sheep only.

⁵Chickens only.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|----------------|---|---|---|--|---|
| | | | | | | |
| Units are parts per million | | | | | | |
| 2-Methyl-4-chlorophenoxyacetic acid and metabolite | 40 CFR 180.339 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | — | 0.1F 0.1M 0.1Mb |
| 6-Methyl-1,3-dithiolo(4,5-b) quinoxalin-2-one | 40 CFR 180.338 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | — | 0.05F 0.05M 0.05Mb |
| 1-Methylethyl 2-((ethoxy((1-methyl-ethyl)amino)phosphinothioyl)oxy)benzoate and metabolites | 40 CFR 180.387 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb |
| Metolachlor and metabolites | 40 CFR 180.368 | 0.02F 0.2K 0.05L 0.02M 0.02Mb | 0.02F 0.2K 0.05L 0.02M 0.02Mb | 0.02F 0.2K 0.05L 0.02M 0.02Mb | 0.02F — 0.05L 0.02M 0.02Mb | 0.02F 0.2K 0.05L 0.02M 0.02Mb |
| Metoserpate hydrochloride | 21 CFR 556.410 | — | — | — | 0.02Et ¹ | — |
| Metsulfuron methyl | 40 CFR 180.428 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | — | 0.1F 0.1M 0.1Mb |
| Monensin | 21 CFR 556.420 | 0.05Et | — | — | — ² | — |
| Morantel tartrate | 21 CFR 556.425 | 0.70L ³ | — | — | — | — |
| Naled and metabolite | 40 CFR 180.215 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |
| Narasin | 21 CFR 556.428 | — | — | — | — ⁴ | — |
| Neomycin | 21 CFR 556.430 | 0.25Et ⁵ | — | — | — | — |

¹Chickens only.²Chickens only; tolerance for marker residue not needed; safe concentrations for total residues 1.5M, 3.0Sf, 4.5L.³Tolerance for marker residue N-methyl-1,3-propanediamine (MAPA); corresponds to 2.40 ppm total residues in liver; safe concentrations for total residues 4.80F, 3.60K, 2.40L, 1.20M.⁴Chickens only; tolerance not needed; safe concentrations 1.2F, 1.8L, 0.6M, 1.2Sf.⁵Calves only.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|--|--|--------------------------|--------------------------|--------------------------|--|-----------------------------|
| | | | | | | Units are parts per million |
| Nequinate | 21 CFR 556.440 | — | — | — | 0.1Et ¹ | — |
| Nicarbazin | 21 CFR 556.445 | — | — | — | 4K ¹ 4L ¹ 4M ¹ 4S ¹ | — |
| Nicotine | 40 CFR 180.167a 40 CFR 180.319 ² | — | — | — | 1F 1M 1Mb | — |
| Nitrapyrin and metabolite | 40 CFR 180.350 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |
| Norflurazon | 40 CFR 180.356 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb |
| Novobiocin | 21 CFR 556.460 | 1Et | — | — | 1Et | — |
| Nystatin | 21 CFR 556.470 | — | — | 0(5.6)Et | 0(5.6)Et | — |
| N-Octyl bicycloheptenedicarboximide | 40 CFR 180.367 | 0.3F | 0.3F | 0.3F | — | 0.3F |
| Oleandomycin | 21 CFR 556.480 | — | — | 0.15Et | 0.15Et | — |
| Ormetoprim | 21 CFR 556.490 | — | — | — | 0.1Et | — |
| Oxadiazon and metabolites | 40 CFR 180.346 | 0.01F 0.01M 0.01Mb | 0.01F 0.01M 0.01Mb | 0.01F 0.01M 0.01Mb | — | 0.01F 0.01M 0.01Mb |
| Oxyfluorfen and metabolites | 40 CFR 180.381 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |

¹Chickens only.²Interim tolerance.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|----------------------------|------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|----------------------------|-------------------------------------|
| | | | Units are parts per million | | | |
| Oxytetracycline | 21 CFR 556.500 | 0.1Et | — | 0.1Et | 1F 3K 1L 1M 1S | — |
| Paraquat | 40 CFR 180.205 | 0.01F 0.01M 0.01Mb | 0.01F 0.01M 0.01Mb | 0.01F 0.01M 0.01Mb | 0.01F 0.01M 0.01Mb | 0.01F 0.01M 0.01Mb |
| PCB's ¹ | 21 CFR 109.30 46 FR 39224 | 3F(AL) | 3F(AL) | 3F(AL) | 3F | 3F(AL) |
| Penicillin | 21 CFR 556.510 | 0.05Et | 0(0.04)Et | 0(0.04)Et | 0(0.04)Et ² | — |
| Permethrin and metabolites | 40 CFR 180.378 | 2.0F 0.15M 1.0Mb | 2.0F 0.15M 1.0Mb | 2.0F 0.15M 3.0Mb | 0.05F 0.05M 0.05Mb | 2.0F 0.15M 1.0Mb |
| Phenothiazine | 40 CFR 180.319 ³ | 2F 2M 2Mb | — | — | — | — |
| Phorate and metabolites | 40 CFR 180.206 | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb | 0.05F 0.05M 0.05Mb |
| Phosalone | 40 CFR 180.263 | 0.25F 0.25M 0.25Mb | 0.25F 0.25M 0.25Mb | 0.25F 0.25M 0.25Mb | — | 0.25F 0.25M 0.25Mb |
| Picloram | 40 CFR 180.292 | 0.2F 5K 0.5L 0.2M 0.2Mb | 0.2F 5K 0.5L 0.2M 0.2Mb | 0.2F 5K 0.5L 0.2M 0.2Mb | 0.05F 0.05M 0.05Mb | 0.2F 5K 0.5L 0.2M 0.2Mb |
| Piperonyl butoxide | 40 CFR 180.127 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 3F 3M 3Mb | 0.1F 0.1M 0.1Mb |

¹The processed product tolerance for residues of PCB's in infant and junior foods is 0.2 ppm [21 CFR 109.30(a)(8)]

²Chickens, pheasants, and quail; turkeys 0.01Et; ducks and geese 0.01Et(AL).

³Interim tolerance.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|---|----------------|------------------|-----------------------------|--------|---------|--------|
| | | | Units are parts per million | | | |
| Pirimiphos-methyl and metabolites | 40 CFR 180.409 | 0.2F | 0.2F | 0.2F | 0.2F | 0.2F |
| | | 2.0K | 2.0K | 2.0K | — | 2.0K |
| | | 2.0L | 2.0L | 2.0L | — | 2.0L |
| | | 0.2M | 0.2M | 0.2M | 2.0 | 0.2M |
| | | 0.2Mb | 0.2Mb | 0.2Mb | 2.0Mb | 0.2Mb |
| Potassium arsenite (as As₂O₃) | 40 CFR 180.334 | 0.7F | — | — | — | 0.7F |
| | | 2.7K | | | | 2.7K |
| | | 2.7L | | | | 2.7L |
| | | 0.7M | | | | 0.7M |
| | | 0.7Mb | | | | 0.7Mb |
| Potassium salt of 1-(4-chlorophenyl)-1,4-dihydro-6-methyl-4-oxo-pyridazine-3-carboxylic acid | 40 CFR 180.423 | 0.05F | 0.05F | 0.05F | 0.30F | 0.05F |
| | | 1.0K | 1.0K | 1.0K | — | 1.0K |
| | | 1.0L | 1.0L | 1.0L | — | 1.0L |
| | | 0.05M | 0.05M | 0.05M | 0.30M | 0.05M |
| | | 0.05Mb | 0.05Mb | 0.05Mb | 0.30Mb | 0.05Mb |
| Profenofos and metabolites | 40 CFR 180.404 | 0.05F | 0.05F | 0.05F | 0.05F | 0.05F |
| | | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M |
| | | 0.05Mb | 0.05Mb | 0.05Mb | 0.05Mb | 0.05Mb |
| Profluralin | 40 CFR 180.348 | 0.02F | 0.02F | 0.02F | 0.02F | 0.02F |
| | | 0.02M | 0.02M | 0.02M | 0.02M | 0.02M |
| | | 0.0Mb | 0.02Mb | 0.02Mb | 0.02Mb | 0.02Mb |
| Progesterone | 21 CFR 556.540 | 12F ¹ | 15F ² | — | — | — |
| | | 9K ¹ | 15K ² | | | |
| | | 6L ¹ | 15L ² | | | |
| | | 3M ¹ | 3M ² | | | |
| | | | | | | |
| Propanil and metabolites | 40 CFR 180.274 | 0.1F | 0.1F | 0.1F | 0.1F | 0.1F |
| | | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
| | | 0.1Mb | 0.1Mb | 0.1Mb | 0.1Mb | 0.1Mb |
| Propargite | 40 CFR 180.259 | 0.1F | 0.1F | 0.1F | 0.1F | 0.1F |
| | | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
| | | 0.1Mb | 0.1Mb | 0.1Mb | 0.1Mb | 0.1Mb |

¹Steers and calves (ppb); above concentrations naturally present.

²Lambs (ppb); above concentrations naturally present.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|---|----------------|---------------------------------------|-----------------------------|--------------------------|--|---------------------------------------|
| | | | Units are parts per million | | | |
| Pyrantel tartrate | 21 CFR 556.560 | — | — | 10K 10L 1M | — | — |
| Pyrethrins | 40 CFR 180.128 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.2F 0.2M 0.2Mb | 0.1F 0.1M 0.1Mb |
| Robenidine hydrochloride | 21 CFR 556.580 | — | — | — | 0.2F ¹ 0.2S ¹ 0.1Et ² | — |
| Ronnel and metabolites | 40 CFR 180.177 | 10F 4M 4Mb | 10F 4M 4Mb | 3F 2M 2Mb | 0.01F 0.01M 0.01Mb | — |
| Simazine | 40 CFR 180.213 | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb | 0.02F 0.02M 0.02Mb |
| Sodium arsenite (as As₂O₃) | 40 CFR 180.335 | 0.7F 2.7K 2.7L 0.7M 0.7Mb | — | — | — | 0.7F 2.7K 2.7L 0.7M 0.7Mb |
| Sodium salt of aclfluorfen and metabolites | 40 CFR 180.383 | 0.02K 0.02L | 0.02K 0.02L | 0.02K 0.02L | 0.02F 0.02M 0.02Mb | 0.02K 0.02L |
| Sodium sulfachloropyrazine monohydrate | 21 CFR 556.625 | — | — | — | 0(0.1)Et ¹ | — |
| Spectinomycin | 21 CFR 556.600 | — | — | — | 0.1Et ¹ | — |
| Streptomycin | 21 CFR 556.610 | — ³ | — | 0(0.5)Et ³ | 0(0.5) ³ | — |

¹Chickens only.²Other than fat or skin (chickens only).³Administrative tolerance 2.0K.

| KEY | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses | Units are parts per million |
|------------------------------|----------------------------------|--------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|--------------------------------|
| | | | | | | | |
| Sulfabromomethazine sodium | 21 CFR 556.620 | 0.1Et | — | — | — | — | — |
| Sulfachlorpyridazine | 21 CFR 556.630 | 0.1Et ¹ | — | 0.1Et | — | — | — |
| Sulfadimethoxine | 21 CFR 556.640 | 0.1Et | — | — | 0.1Et | — | — |
| Sulfaethoxypyridazine | 21 CFR 556.650 | 0.1Et | — | 0(0.1)Et | — | — | — |
| Sulfamethazine | 21 CFR 556.670 | 0.1Et | — | 0.1Et | 0.1Et | — | — |
| Sulfanitran and metabolites | 21 CFR 556.680 | — | — | — | 0(0.1)Et ² | — | — |
| Sulfathiazole | 21 CFR 556.690 | — | — | 0.1Et | — | — | — |
| Sulfomyxin | 21 CFR 556.700 | — | — | — | 0(0.1)Et | — | — |
| Tebuthiuron and metabolites | 40 CFR 180.390 | 2F 2M 2Mb | 2F 2M 2Mb | — | — | — | 2F 2M 2Mb |
| Terbacil and metabolites | 40 CFR 180.209 | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | 0.1F 0.1M 0.1Mb | — | — | 0.1F 0.1M 0.1Mb |
| Testosterone propionate | 21 CFR 556.710 | 0(0.200)Et ³ | — | — | — | — | — |
| Tetracycline | 21 CFR 556.720 | 0.25Et ¹ | 0.25Et | 0.25Et | 0.25Et | — | — |
| Tetradifon | 40 CFR 180.174 | 0M | 0M | 0M | 0M | 0M | 0M |
| Thiabendazole and metabolite | 21 CFR 556.730 40 CFR 180.242 | 0.1Et 0.1F 0.1M 0.1Mb | 0.1Et 0.1F 0.1M 0.1Mb | 0.1Et 0.1F 0.1M 0.1Mb | — 0.1F 0.1M 0.1Mb | — 0.1F 0.1M 0.1Mb | 0.1Et 0.1F 0.1M 0.1Mb |

¹Calves only.²Chickens only.³Heifers only.

| KEY | | | |
|--------------------|---------------------|-----------------------|---------------------|
| (AL): Action level | M: Muscle | Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin | F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle | L: Liver | —: No tolerance |

RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|---|----------------------------------|-----------------------------|-----------------|-------------------|---------|--------|
| | | Units are parts per million | | | | |
| Thidiazuron and metabolites | 40 CFR 180.403 | 0.2F | 0.2F | 0.2F | 0.2F | 0.2F |
| | | 0.2M | 0.2M | 0.2M | 0.2M | 0.2M |
| | | 0.2Mb | 0.2Mb | 0.2Mb | 0.2Mb | 0.2Mb |
| Thiobencarb and metabolites | 40 CFR 180.401 | 0.2F | 0.2F | 0.2F | 0.2F | 0.2F |
| | | 0.2M | 0.2M | 0.2M | 0.2M | 0.2M |
| | | 0.2Mb | 0.2Mb | 0.2Mb | 0.2Mb | 0.2Mb |
| Thiophanate-methyl and metabolites | 40 CFR 180.371 | 0.1F | 0.1F | 0.1F | 0.1F | 0.1F |
| | | 0.2K | 0.2K | 1.0L | 0.2L | 1.0L |
| | | 2.5L | 2.5L | 0.1M | 0.1M | 0.1M |
| | | 0.1M | 0.1M | 0.1Mb | 0.1Mb | 0.1Mb |
| | | 0.1Mb | 0.1Mb | | | |
| Tiamulin | 21 CFR 556.738 | — | — | 0.4L ¹ | — | — |
| Toxaphene | 40 CFR 180.138 MPI Dir. 917.1 | 7F | 7F | 7F | 7F(AL) | 7F |
| S,S,S-Tributyl phosphorotrithioate | 40 CFR 180.272 | 0.02F | 0.02F | — | — | — |
| | | 0.02M | 0.02M | | | |
| | | 0.02Mb | 0.02Mb | | | |
| Trichlorfon | 40 CFR 180.198 | 0.1F | 0.1F | — | — | 0.1F |
| | | 0.1M | 0.1M | | | 0.1M |
| | | 0.1Mb | 0.1Mb | | | 0.1Mb |
| Triclopyr and metabolite | 40 CFR 180.417 | 0.05F | 0.05F | 0.05F | — | 0.05F |
| | | 0.5K | 0.5K | 0.5K | | 0.5K |
| | | 0.5L | 0.5L | 0.5L | | 0.5L |
| | | 0.05M | 0.05M | 0.05M | | 0.05M |
| | | 0.05Mb | 0.05Mb | 0.05Mb | | 0.05Mb |
| Tricyclohexyltin hydroxide and metabolites | 40 CFR 180.144 | 0.2F | 0.2F | 0.2F | — | 0.2F |
| | | 0.5K | 0.5K | 0.5K | | 0.5K |
| | | 0.5L | 0.5L | 0.5L | | 0.5L |
| | | 0.2M | 0.2M | 0.2M | | 0.2M |
| | | 0.2Mb | 0.2Mb | 0.2Mb | | 0.2Mb |

¹Tolerance for 8-a-hydroxymutilin; corresponds to 10.8 total residues in liver; safe concentrations 14.4F, 14.4K, 10.8L, 3.6M.

| KEY | |
|------------------------------------|----------------------------------|
| (AL): Action level | M: Muscle |
| E _k : Excluding kidneys | M _b : Meat byproducts |
| E _t : Edible tissue | S: Skin |
| F: Fat | S _f : Skin with fat |
| K: Kidney | S _m : Skeletal muscle |
| L: Liver | —: No tolerance |


RESIDUE LIMITS

| Compound | CFR Reference | Cattle | Goats/ Sheep | Swine | Poultry | Horses |
|---|----------------|------------------------------|-------------------------|--------------------------------------|---|----------------|
| Units are parts per million | | | | | | |
| Triphenyltin hydroxide | 40 CFR 180.236 | 0.05K 0.05L | 0.05K 0.05L | 0.05K 0.05L | — | 0.05K 0.05L |
| Tylosin | 21 CFR 556.740 | 0.2F 0.2K 0.2L 0.2M | — | 0.2F 0.2K 0.2L 0.2M | 0.2F 0.2K 0.2L 0.2M | — |
| Virginiamycin | 21 CFR 556.750 | — | — | 0.4F 0.4K 0.3L 0.1M 0.4S | 0.2F ¹ 0.5K ¹ 0.3L ¹ 0.1M ¹ 0.2S ¹ | — |
| Zeranol | 21 CFR 556.760 | 0(0.020)Et | 0(0.020)Et ² | — | — | — |
| Zinc ion & maneb, coordination product | 40 CFR 180.176 | 0.5K 0.5L | 0.5K 0.5L | 0.5K 0.5L | 0.5K 0.5L | 0.5K 0.5L |
| Zoalene and metabolite | 21 CFR 556.770 | — | — | — | 2F ³ 6K ³ 6L ³ 3M ³ | — |

¹Broiler chickens only.²Sheep only.³Chickens only; turkeys: 3L, 3M.**KEY**

| | |
|-----------------------|---------------------|
| (AL): Action level | M: Muscle |
| Ek: Excluding kidneys | Mb: Meat byproducts |
| Et: Edible tissue | S: Skin |
| F: Fat | Sf: Skin with fat |
| K: Kidney | Sm: Skeletal muscle |
| L: Liver | —: No tolerance |

Section 5



FSIS RESIDUE ANALYTICAL CAPABILITY

Introduction

The Food Safety and Inspection Service (FSIS) requires practical analytical methods for detecting, quantifying, and identifying all residues that may be present in meat, poultry, and their processed products at levels above established safe residue limits. These methods can be used by the Agency for monitoring and surveillance activities to determine whether product is adulterated.

The Agency uses available methodology to take appropriate regulatory action against adulterated products, consistent with the reliability of the analytical data. However, because of the large number of potential residues that may occur in the food chain, practical methods are not available for many compounds of interest.

This section describes the types of methods used by FSIS to conduct analyses (as of September 1, 1986) and their suitability for regulatory use. A list of key terms precedes the method descriptions.

Method Levels

Methods are described in terms of levels of use:

Level I—These are assays with the highest level of credibility. They are unequivocal at the level of interest. They may be single procedures that determine both the concentration and the identity of the analyte, or combinations of determinative methods for concentration and confirmatory methods for definitive identification.

Level II—These are assays that are not unequivocal but are used to determine the concentration of an analyte at the level of interest and to provide some structural information. These methods are reliable enough to be used as reference methods.

Level III—These are screening methods that may generate limited though useful information. These tests detect the presence or absence of a compound or a class of compounds at some concentration level of interest. They are used because of a greater throughput, portability, or convenience than the Level I or Level II methods. The level of reliability has been determined and documented. The hallmark of Level III tests is that *action based on individual positive results requires substantiation based on Level I or Level II methods*, as required by the uncertainty of any individual results.

Methods are further classified according to their status. Within each classification, subgroups are defined according to the extent to which a method was subjected to study. Therefore, whether (or how well) a specific analytical method meets a defined suitability criterion determines its classification and subgroup.

Criteria for Practical Methods

The following criteria have been identified as guidelines for methods suitable for regulatory use.

FSIS RESIDUE ANALYTICAL CAPABILITY

1. The method requires no more than 2-4 hours of analytical time per sample.
2. The method requires no instrumentation not customarily available in a laboratory devoted to trace drug or environmental analysis.
3. Chemical methods have a Minimum Proficiency Level (MPL) at or below the established residue limit and antimicrobial methods have a Minimum Inhibitory Concentration (MIC) at or below the established residue limit.
4. A quality assurance plan (QAP) has been developed for the method.
5. The method has been subjected successfully to an interlaboratory study at 0, $\frac{1}{2}X$, X, and 2X, where X is the analyte concentration at the residue limit.

FSIS considers the methods described for "zero tolerance" compounds to be suitable for regulatory use if they meet the suitability criteria listed above and have an MPL or MIC at the operational definition of zero defined by FDA or EPA. Methods determined to be suitable for regulatory use except for criterion 3 or 5 will be marked with an asterisk (*). In an emergency situation, exceptions to a method's suitability may be necessary.

The method classifications are:

A. AOAC Official Methods. Such a method has been subjected to an interlaboratory study in which five or more laboratories participated. If this collaborative process provides results that establish the acceptability of the method, it is accepted as an official method by the AOAC. Some AOAC official methods have been subsequently studied for extension as follows:

1. Extension to other analytes, tissues, species, and products by a three-analyst (two or three laboratory) study—a validation study.
2. Extension by a one or two analyst intralaboratory or inter-laboratory study as follows:
 - a. Extended to other tissues, species, and products for the initial analyte(s) studied.
 - b. Extended to other similar analytes in the same matrices as initially studied.

B. Validated Methods. Such a method is subjected to an interlaboratory study in two or three laboratories with a minimum of three independent analysts. The resulting data are reviewed by a peer group of

FSIS RESIDUE ANALYTICAL CAPABILITY

government scientists. The data that result from the study are made available for review upon request. Included in this category would be post-1973 New Animal Drug Application (NADA) methods developed by sponsors that have been successfully studied by FSIS and FDA laboratories. Some validated methods have been subsequently studied for extension by a single or two analyst intralaboratory or interlaboratory study as follows:

1. Extended to other tissues, species, and products for the initial analyte(s) studied.
2. Extended to other similar analytes for the initial tissues/species and products studied.

C. Federal Register Methods. Methods of analysis published in the Federal Register and later incorporated into the Code of Federal Regulations.

D. Historical Official Methods. Methods that were considered to be the best available at the time of initial acceptance and have continued in use over an extended period in the absence of a more effective method. Included in this category would be pre-1974 NADA methods that were submitted by sponsors and accepted by FDA and FSIS without a multilaboratory study.

E. Nonvalidated Methods (NVM). Methods for quantification and/or confirmation that have not been subjected to a multilaboratory study of at least three independent analysts; or, analytical methods that have been subjected to a multilaboratory study but do not meet either criterion 3 or 5 of the criteria for methods suitable for routine use.

F. Published Methods. These methods have been subjected to a study by a single analyst or laboratory where the data for evaluation are limited. However, a quality control plan will be in place. The results are reviewed by a peer group of government scientists.

G. Correlated Methods. These methods have not been validated by traditional interlaboratory study, but data obtained from use of the method have been correlated and/or compared with data obtained from use of a method for regulatory enforcement. The same samples must be used for this comparison, and the data must be reviewed by a peer group of government scientists.

FSIS RESIDUE ANALYTICAL CAPABILITY

KEY TERMS

| | |
|---------------|---|
| AAS | Atomic absorption spectrometry |
| AOAC | Association of Official Analytical Chemists |
| CELIA CA | Competitive Enzyme Labeled Immunoassay for Chloramphenicol: a laboratory test that detects and identifies chloramphenicol residues in cattle and pork muscle |
| EI | Electron impact |
| E-Z Screen | A proprietary immunoassay system for rapidly detecting and identifying various antibiotics and other residues in tissue extracts |
| GC | Gas chromatography |
| GLC | Gas liquid chromatography |
| HPLC | High pressure liquid chromatography |
| JAOAC | Journal of the Association of Official Analytical Chemists |
| J. Food Prot. | Journal of Food Protection |
| LDL | Lowest detectable limit: the smallest amount of individual residue or sample component that can be reliably observed or found in the sample matrix by the current appropriate methodology |
| Method Status | See discussion, Section 5.2-5.3. |
| MIC | Minimum inhibitory concentration: the minimum level of antimicrobial compound present in a buffer extract of tissue that will inhibit bacterial growth. |
| MPL | Minimum proficiency level: the minimum amount of analyte expected to be identified and quantified by a laboratory and upon which ongoing capability will be evaluated. It is the smallest concentration for which the predicted coefficient for reproducibility (CV) is less than or equal to 20 percent and the upper 90 percent confidence for the predicted CV is less than 30 percent |
| MS | Mass spectrometry |
| NADA | New Animal Drug Application, issued by the Food and Drug Administration (FDA) |
| NE | Level not established |

FSIS RESIDUE ANALYTICAL CAPABILITY

| | |
|------------------------------------|---|
| Quantification (Quant.) | The determination of the amount of residue present in a sample |
| Reference Method | Analytical procedures by which other methods may be evaluated and for which performance standards are established. These methods are considered suitable for regulatory use in the National Residue Monitoring Program. |
| Residue | The presence of remnants of a drug, agricultural or industrial chemical, or trace metal in a food animal |
| SOS | Sulfa-on-Site: a rapid in-plant chemical screening test for detecting sulfonamide residues in food animal urine or serum that provides same-day results |
| STOP | Swab Test on Premises: an overnight in-plant microbiological screen test for detecting antibiotic residues in edible tissues |
| SWAB | STOP precursor: an overnight laboratory microbiological screen test for detecting antibiotic residues in edible tissues |
| UV | Ultraviolet spectroscopic technique for detection and quantification |

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|-------------------------------|--|-------------|----------|-------|-----------------------------|--|--|
| | | LDL/ MIC | MPL | Level | Status | | |
| Albendazole | The marker residue is detected and quantified by HPLC-fluorescence detection | 20 ppb | 50 ppb | II | B | Cattle/liver | Sec. 5.034 FSIS Chemistry Lab Guidebook |
| | Extracts from HPLC method are confirmed by GC-MS | 20 ppb | 50 ppb | I | B | Cattle/liver | Sec. 5.034 FSIS Chemistry Lab Guidebook |
| Aldrin | Micro alumina assay: column chromatography plus GLC | 0.02 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook |
| | Gel permeation chromatography (GPC) plus GLC | 0.02 ppm | 0.10 ppm | II | A | All/fat | Sec. 5.003 FSIS Chemistry Lab Guidebook |
| Mills | Mills method: Florisil column chromatography plus GLC | 0.02 ppm | 0.10 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.02 ppm | NE | I | E | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook |
| Amoxicillin trihydrate | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.02 ppm | 0.02 ppm | II | (GPC/MS) F (Mills/MS) | Cattle, swine/ kidney liver muscle | NADA 55-080 & 55-089 Beecham |
| | Tissue extracts quantified by HPLC using fluorometer | 0.01 ppm | 0.01 ppm | II | B | Cattle, swine/ kidney liver muscle | NADA 55-080 & 55-089 Beecham |
| Ampicillin | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth. | 0.01 ppm | 0.01 ppm | II | B | Cattle, swine/ all | NADA 55-030 Squibb |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|-----------------------------------|--|-------------|----------|-------|--------|-------------------------|---|-----------|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Apramycin | Sample extraction TLC/bioautographed using <i>Bacillus subtilis</i> as a test organism | 0.05 ppm | 0.1 ppm | II | B | Swine/kidney muscle | NADA 106-964 | |
| Arsanilate sodium | Dry ashed tissue is dissolved and reacted to produce arsine gas, which is quantified by AAS | 0.05 ppm | NE | I | E | All/kidney liver muscle | Sec. 5.009 FSIS Chemistry Lab Guidebook | |
| Arsanilic acid | Dry ashed tissue is dissolved and reacted to produce arsine gas, which reacts to form blue complex for colorimetric quantification | 0.05 ppm | 0.20 ppm | II | A | All/kidney liver muscle | AOAC Book of Methods 14th Ed., 25.050 | |
| Arsenate, Calcium | | | | | | | | |
| Arsenate, Copper | | | | | | | | |
| Arsenate, Lead | | | | | | | | |
| Arsenate, Magnesium | | | | | | | | |
| Arsenate, Sodium | | | | | | | | |
| Arsenic | | | | | | | | |
| Arsenite, Potassium | | | | | | | | |
| Arsenite, Sodium | | | | | | | | |
| Atrazine | Fat extracts are quantified by capillary GLC with nitrogen/phosphorous detector | 5 ppb | NE | II | E | All/fat | Section 5.032 FSIS Chemistry Lab Guidebook | |
| | Tissue extracts are confirmed by GC/MS | 5 ppb | NE | II | E | All/fat | Copy available upon request | |
| Bacitracin methylene disalicylate | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.05 ppm | NE | II | D | All/kidney liver muscle | Kramer et. al. FDA 1974 | |
| Bacitracin, zinc | | | | | | | | |

FSIS RESIDUE ANALYTICAL CAPABILITY

| TEST METHOD | | | | | | |
|--------------------|--|---------------------|------------|--------------|-----------------------------|-----------------------------|
| Compound | Description | LDL/ MIC | MPL | Level | Status | Species/ Tissues |
| Bambermycins | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 25 ppb | NE | II | D | All/kidney liver muscle |
| BHC | Micro alumina assay: column chromatography plus GLC | 0.01 ppm | NE | II | E | All/fat pp ¹ |
| | Gel permeation chromatography (GPC) plus GLC | 0.02 ppm | 0.10 ppm | II | A | All/fat |
| | Mills method: Florisil column chromatography plus GLC | 0.02 ppm | 0.10 ppm | II | B | All/fat pp ¹ |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.02 ppm | NE | I | (GPC/MS) F (Mills/MS) | |
| Buquinolate | Tissue extracts are screened by fluorescence detection | 0.13 ppm | NE | III | E | Cattle/kidney liver muscle |
| Cacodylic acid | Dry ashed tissue is dissolved and reacted to produce arsine gas, which is quantified by AAS | 0.05 ppm | NE | I | E | All/kidney liver muscle |
| | Dry ashed tissue is dissolved and reacted to produce arsine gas, which reacts to form blue complex for colorimetric quantification | 0.05 ppm | 0.20 ppm | II | A | All/kidney liver muscle |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|------------------|--|-------------|----------|-------|------------|--|--|--|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Cadmium | Dry ashed tissue is dissolved and quantified by AAS | 0.10 ppm | 0.30 ppm | I | B | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook | JAOAC, 60 ⁴ , 826-832 (1977) |
| | Dry ashed tissue is quantified by anodic stripping voltammetry | 1.0 ppb | NE | I | F | Poultry/kidney liver | | |
| | Tissue is wet ashed and titrated with specific indicator | 0.03% 0.03% | II | A | All/muscle | AOAC Book of Methods, 14th Edit., 24.062 | Sec. 6.008 FSIS Chemistry Lab Guidebook | |
| Calcium | Wet ashed tissue is quantified by AAS | NE | NE | I | E | All | | |
| | Tissue extract is hydrolyzed and a derivative is prepared and separated by preparative TLC, quantified by GLC | 15 ppb | 30 ppb | II | B | Swine/liver muscle | Sec. 5.014 FSIS Chemistry Lab Guidebook | Pfizer |
| | Extraction followed by ion exchange chromatography, quantified by GLC | 15 ppb | NE | II | F | Swine/liver muscle | | |
| Carbarson | Dry ashed tissue is dissolved and reacted to produce arsine gas, which is quantified by AAS | 0.05 ppm | NE | I | E | All/kidney liver muscle | Sec. 5.009 FSIS Chemistry Lab Guidebook | AOAC Book of Methods, 14th Edit., 25.050 |
| | Dry ashed tissue is dissolved and reacted to produce arsine gas, which reacts to form blue complex for colorimetric quantification | 0.05 ppm | 0.20 ppm | II | A | All/kidney liver muscle | | |
| | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.10 ppm | NE | II | B | All/liver muscle | | |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|---|--|-------------|----------|-------|----------------------------------|-----------------------------|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Chloramphenicol | Tissue extracts are screened by E-Z screen | 5 ppb | NE | III | E | Cattle, swine/muscle kidney | Environmental Diagnostics | |
| Chloramphenicol palmitate | Tissue extract screened for chloramphenicol by CELIA CA | 5 ppb | NE | II | E | Cattle, swine/muscle | Antimic. Ag. Chemo., 25, 2, 205-211 (1984) | |
| | Tissue extract is derivatized and quantified by GLC with an electron capture detector | 10.0 ppb | 10.0 ppb | II | B | Cattle/muscle | Sec. 5.022 FSIS Chemistry Lab Guidebook | |
| | Tissue extracts are confirmed by mass spectrometry using negative ion chemical ionization | 10.0 ppb | NE | I | B | Cattle/muscle | Sec. 5.023 FSIS Chemistry Lab Guidebook | |
| Chlordane (technical) | Micro alumina assay: column chromatography plus GLC | 0.15 ppm | NE ppm | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.15 ppm | 0.30 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 | |
| | Mills method: Florisil column chromatography plus GLC | 0.15 ppm | 0.30 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.15 ppm | NE | I | E (GPC/MS) F (Mills/MS) | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook | |
| Chlordecone | Organic solvent extraction; Florisil column cleanup with GC quantitation | 0.05 ppm | NE | II | E | All/fat liver | JAOAC, 61, 1, 8-14 (1978) | |
| 2-Chloro-1,(2,4,5-trichlorophenyl)-vinyl dimethyl phosphate | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | E | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook | |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | TEST METHOD | | | | | Species/ Tissues | Reference |
|---------------------------------|---|----------|-------|--------|---|-------------------------|---|
| | LDL/ MIC | MPL | Level | Status | | | |
| Chlorpyrifos | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| Chlortetracycline bisulfate | Antibiotic screen test (SWAB); the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 0.01 ppm | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 |
| Chlortetracycline hydrochloride | Microbiological assay procedure; the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.01 ppm | NE | II | D | All/kidney liver muscle | Sec. 6.312 FSIS Microbiology Lab Guidebook |
| | Tissue extraction of parent drug is converted to anhydro derivative and quantified and identified by HPLC | 0.01 ppm | NE | II | E | All/kidney liver muscle | Sec. 5.031 FSIS Chemistry Lab Guidebook |
| | Tissue extraction of parent drug is converted to anhydro derivative for identification by TLC | 0.1 ppm | NE | II | E | All/kidney liver muscle | Copy available upon request |
| Chromium | Dry ashed tissue is extracted with organic reagent and quantified using AAS | NE | NE | I | E | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook |
| Clopidol | Organic solvent extraction with HPLC-UV detection | 0.1 ppm | NE | II | E | Poultry/liver | JAOC, 67, 2, 334-336 (1984) |
| | Organic solvent extraction with GC-EC detection | 0.1 ppm | NE | II | A | Poultry/liver | AOAC Book of Methods, 14th Edit., 41.013. |

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|--------------------------------|---|-------------|----------|-------|--------|--|---|
| | | LDL/ MIC | MPL | Level | Status | | |
| Clostrulon | Tissue extracts are quantified by HPLC-UV detection | 0.25 ppm | 0.50 ppm | II | B | Red meat/kidney muscle liver pp ¹ | NADA 136-762 Merck, Sharp, and Dohme |
| | Tissue extracts for HPLC are derivatized and confirmed by GC/MS | 0.5 ppm | NE | I | B | Red meat/kidney muscle liver pp | NADA 136-762 Merck, Sharp, and Dohme |
| Cloxacillin, Benzathine | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 0.16 ppm | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 |
| Cloxacillin, Sodium | Microbiological assay combined with HPLC separation and quantified by microbial inhibition | 0.02 ppm | NE | II | F | Dairy cows/ kidney liver muscle | NADA 55-069 Beecham-Masengill |
| Cobalt | Dry ashed tissue is dissolved and quantified using AAS | 0.20 ppm | NE | I | B | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook |
| Copper | Dry ashed tissue is dissolved and quantified using AAS | 0.50 ppm | NE | I | B | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook |
| Coumaphos | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.10 ppm | NE | II | E | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| Coumaphos, oxygen analog of | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | E | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| Cresylic acid | Tissue extracts are derivatized and determined by GC-EC | NE | NE | III | E | Poultry/fat | Sec. 5.036 FSIS Chemistry Lab Guidebook |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|--|--|-------------|-------------|-------|----------------------------------|-------------------------|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Crufomate | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.10 ppm | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook | |
| Cyromazine | Tissue extracts are quantified by HPLC-UV detection | 0.05 ppm | 0.25 ppm | II | B | All/muscle | ClBA Geigy AG 417A | |
| DDE (metabolites of DDT collectively reported as DDT) | Micro alumina assay: column chromatography plus GLC | 0.02 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.02 ppm | 0.10 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 | |
| | Mills method: Florisil column chromatography plus GLC | 0.02 ppm | 0.10 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.02 ppm | NE | I | E (GPC/MS) F (Mills/MS) | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook | |
| DDT (isomers of DDT collectively reported as DDT) | Micro alumina assay: column chromatography plus GLC | 0.04 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.04 ppm | 0.15 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 | |
| | Mills method: Florisil column chromatography plus GLC | 0.04 ppm | 0.15 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|---|--|-------------|-------------|-------|------------------------|--|--|
| | | LDL/ MIC | MPL | Level | Status | | |
| Decoquinate | Tissue extracts are screened by fluorescence detection and identified and quantified by GLC | 0.13 ppm | 0.2 ppm | II | B | Cattle, poultry/ kidney liver muscle | Sec. 5.030 FSIS Chemistry Lab Guidebook |
| Dibutyltin dilaurate | Tissue extraction followed by acid digestion, quantified by spectrophotometry | 0.05 ppm | NE | II | E | Turkey/liver muscle | Anal. Chem. 45, 534-537 (1973) |
| Dichlorvos | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | A | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| Dieldrin | Micro alumina assay: column chromatography plus GLC | 0.01 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook |
| | Gel permeation chromatography (GPC) plus GLC | 0.01 ppm | 0.10 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 |
| | Mills method: Florisil column chromatography plus GLC | 0.01 ppm | 0.10 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.01 ppm | NE | I | (GPC/MS) (Mills/MS) | | Sec. 5.004 FSIS Chemistry Lab Guidebook |
| O,O-Diethyl S-[2-(ethylothio)ethyl] phosphorodithioate | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | F | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.1 ppm | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |

¹ Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|----------------------------|--|-------------|---------|-------|--------|-----------------------------------|---|
| | | LDL/ MIC | MPL | Level | Status | | |
| Diethylstilbestrol | Modified Donoho Method: extract is hydrolyzed and derivatized and quantified by GLC | 0.50 ppb | 2.0 ppb | II | B | Cattle, sheep/liver muscle | Copy available upon request |
| | Tissue extract is hydrolyzed, derivative is quantified by GLC, positives are confirmed by mass spectrometry | 0.1 ppb | NE | I | E | Cattle, sheep/kidney liver muscle | Copy available upon request |
| | Solid state extraction technique followed by HFB derivitization and GLC determination | 0.25 ppb | NE | III | E | Cattle/kidney liver muscle | Copy available upon request |
| | Solid state extraction technique using an internal standard followed by methylsilation for GC/MS quantification and confirmation | 0.1 ppb | NE | I | F | Cattle/kidney liver muscle | Copy available upon request |
| Dihydrostreptomycin | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 0.25 ppm | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 |
| | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.25 ppm | NE | II | D | All/kidney liver muscle | Sec. 6.315 FSIS Microbiology Lab Guidebook |
| Dioxathion | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.10 ppm | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | TEST METHOD | | | | | | Species/ Tissues | Reference |
|---|---|----------|----------|--------------------------|----------------------------|---|--|-----------|
| | LDL/ MIC | MPL | Level | Status | All/fat pp ¹ | | | |
| Dodecachloro-octahydro-1,3,4-metheno-2H-cyclobuta(cd)-pentalene | Micro alumina assay: column chromatography plus GLC | 0.04 ppm | NE II | E | All/fat pp ¹ | | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.04 ppm | 0.10 ppm | II A | All/fat | | AOAC Book of Methods, 14th Edit., 29.037 | |
| Endrin | Mills method: Florisil column chromatography plus GLC | 0.04 ppm | 0.10 ppm | II B | All/fat pp ¹ | | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Micro alumina assay: column chromatography plus GLC | 0.03 ppm | NE II | E | All/fat pp ¹ | | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.03 ppm | 0.10 ppm | II A | All/fat | | AOAC Book of Methods, 14th Edit., 29.037 | |
| | Mills method: Florisil column chromatography plus GLC | 0.03 ppm | 0.10 ppm | II B | All/fat pp ¹ | | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.04 ppm | NE I | E (GPC/MS) (Mills/MS) | All/fat pp ¹ | | Sec. 5.004 FSIS Chemistry Lab Guidebook | |
| Erythromycin | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 25 ppb | NE III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 | | |
| Erythromycin phosphate | Microbiological assay procedure; the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 25 ppb | NE II | D | All/kidney liver muscle | Sec. 6.316 FSIS Microbiology Lab Guidebook | | |
| Erythromycin thiocyanate | | | | | | | | |

¹ Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|-----------------------------|--|-------------|------------|-------|--------|------------------------|---|
| | | LDL/ MIC | MPL | Level | Status | | |
| Ethion | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.10 ppm | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| Ethion, oxygen analog of | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | E | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| Ethylene dibromide | Residue is co-distilled from aqueous suspension and quantified by GLC | 0.5 ppb | 1.0 ppb | II | B | All/fat | Sec. 5.005 FSIS Chemistry Lab Guidebook |
| Fenbendazole | Mass spectrometry by NICI to determine bromine | 1 ppb | NE | I | E | All/fat | Sec. 5.005 FSIS Chemistry Lab Guidebook |
| | Liquid-liquid extraction followed by HPLC-UV quant. | 0.05 ppm | NE | II | A | Cattle/liver muscle | Hazelton Labs No. 6128-100 |
| | Tissue extracts are quantified by HPLC | 200 ppb | 200 ppb | II | B | Cattle, calf/ liver | NADA 128-620 American Hoechst |
| | Quantification extract purified by TLC, derivatized and identified by HPLC fluorescence | 200 ppb | NE | II | B | Cattle, calf/ liver | NADA 128-620 American Hoechst |
| Fenitrothion | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.10 ppm | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | TEST METHOD | | | | | Species/ Tissues | Reference |
|---------------------------|---|----------|----------|--------|---|-------------------------|--|
| | LDL/ MIC | MPL | Level | Status | | | |
| Fenthion | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | E | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| | Tissue extracts are quantified by GLC with KCl thermionic detector | 0.10 ppm | NE | II | E | All/liver muscle | Sec. 5.016 FSIS Chemistry Lab Guidebook |
| Gentamicin sulfate | Tissue extracts are screened by E-Z Screen | 5 ppb | NE | III | E | All/muscle liver kidney | Environmental Diagnostics |
| | Microbiological assay procedure; the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | NE | NE | II | B | Swine/kidney | NADA 103-037 & 91-191 Schering |
| | Extraction followed by detection by HPLC with fluorescence detector | 0.2 ppm | 0.4 ppm | I | B | Swine/kidney | NADA 103-037 & 91-191 Schering |
| Halofuginone | Tissue extracts are quantified by HPLC-UV | 0.05 ppm | 0.05 ppm | II | B | Chicken/liver muscle | NADA 130-951 American Hoechst Corp. |
| | Tissue extracts are confirmed by GC/MS/MS | 0.05 ppm | NE | I | B | Chicken/liver muscle | NADA 130-951 American Hoechst Corp. |

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|-----------------------------------|---|-------------|----------|-------|-----------------------------|-------------------------|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | All/fat pp ¹ | | |
| HCB | Micro alumina assay: column chromatography plus GLC | 0.01 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.01 ppm | 0.10 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 | |
| | Mills method: Florisil column chromatography plus GLC | 0.01 ppm | 0.10 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.01 ppm | NE | I | (GPC/MS) F (Mills/MS) | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook | |
| Heptachlor and heptachlor epoxide | Micro alumina assay: column chromatography plus GLC | 0.01 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.01 ppm | 0.10 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 | |
| | Mills method: Florisil column chromatography plus GLC | 0.01 ppm | 0.10 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.01 ppm | NE | I | (GPC/MS) F (Mills/MS) | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook | |
| Heptacillin, Potassium | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | NE | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 | |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|-----------------------------|---|-------------|-------|-------|---------------------|--|--|
| | | LDL/ MIC | MPL | Level | Status | | |
| 5-Hydroxy thiabendazole | Tissue extracts are quantified by HPLC/UV | 0.05 NE | II | E | Cattle/liver muscle | Hazelton Labs No. 6128-100 | |
| Hygromycin B | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 5.00 ppm | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 |
| Ipronidazole and metabolite | Tissue extracts are quantitated by capillary GLC | 0.4 ppb | NE | II | E | Turkey, swine/ muscle pp ¹ | Sec. 5.012 FSIS Chemistry Lab Guidebook |
| | Tissue extracts for GLC are confirmed by GC/MS | 0.4 ppb | NE | I | E | Turkey, swine/ muscle pp ¹ | Sec. 5.013 FSIS Chemistry Lab Guidebook |
| Iron | Dry ashed tissue is dissolved and quantified by AAS | 0.50 ppm | NE | I | B | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook |
| | Dry ashed tissue is dissolved and reacted to produce a red complex which is quantified by colorimetry | NE | NE | II | E | All/all | Sec. 6.009 FSIS Chemistry Lab Guidebook |
| | Wet ashed tissue is quantified by AAS | NE | NE | III | E | All/kidney liver muscle | Sec. 6.008 FSIS Chemistry Lab Guidebook |
| Ivermectin | Tissue extracts are quantified by HPLC fluorescence | 2 ppb | 5 ppb | II | B | Red meat/liver muscle ² | Sec. 5.035 FSIS Chemistry Lab Guidebook |
| | Derivatization to form 3 components with detection by HPLC fluorescence | 2 ppb | NE | I | B | Red meat/liver muscle ² | Sec. 5.035 FSIS Chemistry Lab Guidebook |

¹Processed product.

²To be evaluated for surveillance samples.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|--------------------------|---|------------------------|----------------|----------------|--------|-------------------------------------|---|
| | | LDL/ MIC | MPL | Level | Status | | |
| Lasalocid | Tissue extracts are quantified by HPLC fluorescence detector | 0.025 ppm 0.025 ppm | 0.35 ppm NE | II | B | Cattle/liver Poultry/fat skin | Sec. 5.029 FSIS Chemistry Lab Guidebook |
| | Tissue extraction followed by bioautography | 0.005 ppm | 0.01 ppm | II | B | Poultry/fat skin | Hoffman-LaRoche |
| | GC pyrolysis of the HPLC extract with MS identification of the fragments | 0.2 ppm | NE | I | B | Cattle/liver Poultry/fat skin | NADA 96-298V Hoffman-LaRoche |
| Lead | Dry ashed tissue is dissolved and quantified by AAS | 0.03 ppm | 0.05 ppm | I | B | All/kidney liver muscle | Sec. 5.022 FSIS Chemistry Lab Guidebook |
| | Dry ashed tissue is quantified by anodic stripping voltammetry | 1.0 ppb | NE | I | E | Poultry/ kidney liver | JAOAC, 60, 4, 826-832 (1977) |
| Levamisole | Tissue extracts are quantified by GLC | 0.05 ppm | 0.05 ppm | II | B | Cattle, sheep/ liver | American Cyanamid NADA 126-23 |
| | Tissue extracts are quantified by GLC flame photometric detection | 0.05 ppm | NE | II | E | Red meat/ liver muscle | Sec. 5.033 FSIS Chemistry Lab Guidebook |
| | Tissue extracts are subjected to GC/MS | 0.05 ppm | NE | I ¹ | E | Red meat/ liver muscle | Copy available upon request |
| Lincomycin hydrochloride | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.10 ppm | 0.10 ppm | II | C | Poultry, swine/all | NADA 97-505 Upjohn |

¹ Applies only when used in combination with FSIS Chemistry Lab Guidebook Section 5.033 method.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|----------------------------|--|-------------|----------|----------------|-----------------------------|---|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | All/fat pp ¹ | | |
| Lindane | Micro alumina assay: column chromatography plus GLC | 0.01 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.01 ppm | 0.10 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 | |
| | Mills method: Florisil column chromatography plus GLC | 0.01 ppm | 0.10 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.01 ppm | NE | I | E | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook | |
| | | | | | (GPC/MS) F (Mills/MS) | | | |
| Lysergic acid diethylamide | Tissue extracts are spotted for TLC and detected with specific chromogenic reagent | NE | NE | I ² | E | All/kidney liver muscle pp ¹ | Sec. 5.028 FSIS Chemistry Lab Guidebook | |
| Malathion | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.10 ppm | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook | |
| Manganese | Dry ashed tissue is dissolved and quantified by AAS | 0.05 ppm | NE | I | E | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook | |
| Mebendazole | Tissue extracts are quantified by HPLC with UV detector | 0.05 ppm | NE | II | E | Cattle/liver muscle | Hazelton Labs No. 6128-100 | |
| Melengestrol acetate | Tissue extract is column chromatographed on Florisil and quantified by GLC | 5.0 ppb | 10.0 ppb | II | A | Cattle/muscle kidney liver fat | AOAC Book of Methods, 14th Edit., 41.029 | |

¹ Processed product.

² Applies only to compound identification.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|----------------------------|---|-------------|-------------|-------|----------------------------------|----------------------------|--|
| | | LDL/ MIC | MPL | Level | Status | | |
| Mercury | Tissue is digested in acid. Mercury is reduced to its vapor and quantified by flameless AAS | 0.01 ppm | 0.02 ppm | I | B | All/kidney liver muscle | Sec. 5.007 FSIS Chemistry Lab Guidebook |
| Methanearsonic acid | Dry ashed tissue is dissolved and reacted to produce arsine gas which is quantified by AAS | 0.05 ppm | NE | I | E | All/kidney liver muscle | Sec. 5.090 FSIS Chemistry Lab Guidebook |
| | Dry ashed tissue is dissolved and reacted to produce arsine gas which reacts to form blue complex for colorimetric quantification | 0.05 ppm | 0.20 ppm | II | A | All/kidney liver muscle | AOAC Book of Methods, 14th Edit., 25.050 |
| Methoxychlor | Micro alumina assay: column chromatography plus GLC | 0.15 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook |
| | Gel permeation chromatography (GPC) plus GLC | 0.15 ppm | 0.50 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 |
| | Mills method: Florisil column chromatography plus GLC | 0.15 ppm | 0.50 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.15 ppm | NE | I | E (GPC/MS) F (Mills/MS) | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook |
| Methyl parathion | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | 0.10 ppm | NE | II | B | All/liver muscle | Sec 5.006 FSIS Chemistry Lab Guidebook |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|-------------------|---|-------------|----------|-------|--------|--------------------------------------|--|
| | | LDL/ MIC | MPL | Level | Status | | |
| Monensin | Tissue extract is partitioned by TLC and semi-quantified by inhibition of microorganism growth | 0.05 ppm | 0.10 ppm | II | B | Cattle, poultry/ liver fat | NADA 38-878V Eli Lilly |
| Morantel tartrate | Tissue extract is hydrolyzed and a derivative is quantified by GLC | 0.25 ppm | 0.50 ppm | II | B | Cattle/liver | NADA 92-444 NADA 93-903 Pfizer |
| | Identification of a structurally significant hydrolyzed fragment by GC/MS | 0.50 ppm | NE | II | E | Cattle/muscle | |
| Narasin | Tissue extracts are spotted on TLC and quantified with a bioautographic overlay | 0.25 ppm | NE | I | B | Cattle/liver muscle | NADA 92-444 NADA 93-903 Pfizer |
| Neomycin sulfate | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth. | 5 ppb | NE | II | B | Cattle, poultry/ liver kidney fat | NADA 118-980 Elanco |
| | Tissue extracts are screened by E-Z Screen | 0.25 ppm | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 |
| | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 10 ppb | NE | III | E | All/muscle liver kidney | Environmental Diagnostics |
| | Tissue extracts are screened by fluorescence detection | 0.13 ppm | NE | II | E | Cattle/kidney liver muscle | Sec. 6.317 FSIS Microbiology Lab Guidebook |
| Nequinone | | | | | | | Sec. 5.030 FSIS Chemistry Lab Guidebook |

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|--------------|---|-------------|----------|-------|--------|-------------------------|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Nickel | Dry ashed tissue is dissolved and quantified by AAS | 0.20 ppm | NE | I | B | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook | |
| Nonachlor | Micro alumina assay: column chromatography plus GLC | 0.05 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.05 ppm | 0.15 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29.037 | |
| | Mills method: Florisil column chromatography plus GLC | 0.05 ppm | 0.15 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.05 ppm | NE | I | E | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook | |
| Novobiocin | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.125 ppm | NE | II | D | All/kidney liver muscle | Kramer et. al. FDA 1974 | |
| Oleandomycin | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth. | 0.25 ppm | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 | |
| Oxfendazole | Tissue extracts are quantified by HPLC with UV detector | 0.05 ppm | NE | II | E | Cattle/liver muscle | Hazelton Labs No. 6128-100 | |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|---|--|-------------|----------|-------|--------|----------------------------------|---|-----------|
| | | LDL/ MIC | MPL | Level | Status | D | | |
| Oxytetracycline hydrochloride | Antibiotic screen test (SWAB); the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth. | 0.08 ppm | NE | III | E | All/kidney liver muscle | J. Food Prot., 1981, 44, 828-831 | |
| | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth. | 0.08 ppm | 0.08 ppm | II | E | All/kidney liver muscle | Sec. 6.312 FSIS Microbiology Lab Guidebook | |
| | Tissue extraction of parent drug is converted to anhydro derivative and identified and quantified by HPLC | 0.01 ppm | NE | II | E | All/kidney liver muscle | Sec. 5.031 FSIS Chemistry Lab Guidebook | |
| | Tissue extraction of parent drug is converted to anhydro derivative for identification by TLC | 0.1 ppm | NE | II | E | All/kidney liver muscle | Copy available upon request | |
| Parathion | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook | |
| PBB | Micro alumina assay: column chromatography plus GLC detection by electron capture. UV degradation of PBB's is used as confirmation | 0.05 ppm | NE | II | E | All/fat | Ralston-Purina Method MP-PBB-36 9/12/79 | |
| PCB's (reported as Arachlor 1242, 1248, 1254, 1260, etc.) | Micro alumina assay: column chromatography plus GLC | 0.30 ppm | NE | II | E | All/fat/pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) | 0.30 ppm | 0.50 ppm | II | A-2-b | All/fat | Sec. 5.003 FSIS Chemistry Lab Guidebook | |
| | AOAC Method: solvent extraction combined with column chromatography plus GLC with electron capture detection | 0.30 ppm | 0.50 ppm | I | A | Poultry/fat | AOAC Book of Methods, 14th Edit., 29.001 | |
| | | | | | A-1 | All other/fat pp ₁ | | |

¹ Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|---|---|-------------|----------|-------|--------|----------------------------|---|
| | | LDL/ MIC | MPL | Level | Status | | |
| Penicillin, procaine and procaine G | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 12.5 ppb | NE | III | E | All/kidney liver muscle | J. Food Prot., 1981, 44, 828-831 |
| Penicillin G (benzathine, free acid, sodium salt, and procaine salts) | Microbiological assay procedure: the ability of tissue extracts containing microbial growth | 12.5 ppb | NE | II | D | All/kidney liver muscle | Sec. 6.311 FSIS Microbiology Lab Guidebook |
| Pentachlorophenol | Tissue digestate is extracted with cyclohexane and quantified by GLC | 0.03 ppm | 0.05 ppm | II | B | All/liver muscle | Sec. 5.024 FSIS Chemistry Lab Guidebook |
| | Tissue extracts for GLC are confirmed by GC/MS | 0.03 ppm | NE | I | E | All/liver muscle | Sec. 5.025 FSIS Chemistry Lab Guidebook |
| Phencyclidine | Tissue extracts are spotted for TLC with specific chromagenic reagent | NE | NE | III | E | All/liver muscle | Sec. 5.028 FSIS Chemistry Lab Guidebook |
| Propazine | Fat extracts are quantified by capillary GLC with nitrogen-phosphorous detector | 5 ppb | 10 ppb | II | E | All/fat | Sec. 5.032 FSIS Chemistry Lab Guidebook |
| | Tissue extracts are confirmed by GC/MS | 5 ppb | NE | II | E | All/fat | Copy available upon request. |
| Pyrantel tartrate | Tissue extract is hydrolyzed and a derivative is quantified by GLC | 0.25 ppm | 0.50 ppm | II | B | Swine/liver muscle | NADA 43-290 |
| | Identification by a structurally significant hydrolyzed fragment by GC/MS | 0.25 ppm | NE | I | E | Swine/liver muscle | JAOAC, 65, 3 640-646 (1982) |

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | Species/ Tissues | Reference |
|-----------------------------|--|-------------|----------|-------|--------|-------------------------------|--|
| | | LDL/ MIC | MPL | Level | Status | | |
| Robenidine hydrochloride | Tissue extracts are quantified by differential pulse polarography | 0.1 ppm | NE | II | B | Chicken/fat muscle liver skin | Sec. 5.017 FSIS Chemistry Lab Guidebook |
| Ronnel | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | B | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook |
| Roxarsone | Dry ashed tissue is dissolved and reacted to produce arsine gas, which is quantified by AAS | 0.05 ppm | NE | I | E | All/kidney liver muscle | Sec. 5.009 FSIS Chemistry Lab Guidebook |
| | Dry ashed tissue is dissolved and reacted to produce arsine gas, which reacts to form blue complex for colorimetric quantification | 0.05 ppm | 0.20 ppm | II | A | All/kidney liver muscle | AOAC Book of Methods, 14th Edit., 25.050 |
| Selenium | Tissue is digested in acid and quantified by graphite furnace AAs | 0.02 ppm | NE | I | E | All/kidney liver muscle | Copy available upon request |
| Simazine | Fat extracts are quantified by capillary GLC with nitrogen-phosphorous detector | 5 ppb | NE | II | E | All/fat | Sec. 5.032 FSIS Chemistry Lab Guidebook |
| | Tissue extracts are confirmed by GC/MS | 5 ppb | NE | II | E | All/fat | Copy available upon request |
| Spectinomycin hydrochloride | Microbiological assay: tissue extracts are quantified using a turbidimetric assay | 2.8 ppm | NE | III | E | All/kidney liver muscle | NADA 47-244 Upjohn |

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|-------------------------------|---|-------------|----------|----------------|--------|---|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Streptomycin | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 0.25 ppm | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 | |
| | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.25 ppm | NE | II | D | All/kidney liver muscle | Sec. 6.315 FSIS Microbiology Lab Guidebook | |
| Styrene | Tissues are subjected to GC/MS headspace analysis | 1 ppb | NE | I ¹ | F | All/kidney liver muscle fat pp ² | Sec. 5.026 FSIS Chemistry Lab Guidebook | |
| Sulfabromo-methazine | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A-2-b | Red meat/ liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| Sulfachloropyridazine | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A-2-b | Red meat/ liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| Sulfadimethoxine | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry Extraction followed by GC/EI mass spectrometry | 0.02 ppm | 0.05 ppm | II | A | All/liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| Sultaethoxy-pyridazine | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A-2-b | Red meat/ liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |

¹Method is semi-quantitative.

²Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|-------------------------|---|-------------|----------|-------|--------|-----------------------|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Sulfamethazine | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A | All/liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| | Tissue extracts are confirmed by GC/EI mass spectrometry | 0.05 ppm | NE | I | B | All/liver muscle | Sec. 5.013 FSIS Chemistry Lab Guidebook | |
| | Tissue extracts are detected by TLC fluorescence (SOS-urine) | NE | NE | III | G | Swine/urine | Copy available upon request | |
| Sulfamethoxy-pyridazine | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A-2-b | Red meat/liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A-2-b | All/liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| Sulfapyridine | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A | Poultry/liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| | Tissue extracts are confirmed by GC/EI mass spectrometry | 0.05 ppm | NE | I | B | Poultry/liver muscle | Sec. 5.013 FSIS Chemistry Lab Guidebook | |
| Sulfaquinoxaline | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A-1 | Red meat/liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| | Tissue extracts are confirmed by GC/EI mass spectrometry | 0.05 ppm | NE | I | B | Red meat/liver muscle | Sec. 5.013 FSIS Chemistry Lab Guidebook | |
| Sulfathiazole | TLC fluorescence: tissue extracts are partitioned by TLC and quantified by densitometry | 0.02 ppm | 0.05 ppm | II | A-1 | Red meat/liver muscle | Sec. 5.018 FSIS Chemistry Lab Guidebook | |
| | Tissue extracts are confirmed by GC/EI mass spectrometry | 0.05 ppm | NE | I | B | Red meat/liver muscle | Sec. 5.013 FSIS Chemistry Lab Guidebook | |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|---|---|-------------|-------------|-------|----------------------------------|-------------------------|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | All/fat pp ¹ | | |
| TDE (metabolite of DDT reported collectively as DDT) | Micro alumina assay: column chromatography plus GLC | 0.04 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.02 ppm | 0.05 ppm | II | A | All/fat | AOAC Book of Methods, 14th Edit., 29-029 | |
| | Mills method: Florisil column chromatography plus GLC | 0.04 ppm | 0.15 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| | Extracts from GPC or Mills are confirmed by GC/MS | 0.02 ppm | NE | I | E (GPC/MS) F (Mills/MS) | All/fat pp ¹ | Sec. 5.004 FSIS Chemistry Lab Guidebook | |
| Terbutylazine | Fat extracts are quantified by capillary GLC with nitrogen-phosphorous detector | 5 ppb | NE | II | E | All/fat | Sec. 5.032 FSIS Chemistry Lab Guidebook | |
| | Tissue extracts are confirmed by GC/MS | 5 ppb | NE | II | E | All/fat | Copy available upon request | |
| Terpene polychlorinates | Micro alumina assay: column chromatography plus GLC | 0.50 ppm | NE | II | E | All/fat | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Mills method: Florisil column chromatography plus GLC | 0.50 ppm | NE | II | E | All/fat | Sec. 5.001 FSIS Chemistry Lab Guidebook | |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|----------------------------|---|-------------|---------|-------|--------|----------------------------|---|-----------|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Tetracycline hydrochloride | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 0.08 ppm | NE | III | E | All/kidney | J. Food Prot., 1981, 44, 828-831 | |
| | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.08 ppm | NE | II | D | All/kidney liver muscle | Sec. 6.312 FSIS Microbiology Lab Guidebook | |
| | Tissue extraction of parent drug is converted to anhydro derivative for identification and quantification by HPLC | 0.01 ppm | NE | II | E | All/kidney liver muscle | Sec. 5.031 FSIS Chemistry Lab Guidebook | |
| | Tissue extraction of parent drug is converted to anhydro derivative for identification by TLC | 0.1 ppm | NE | II | E | All/kidney liver muscle | Copy available upon request | |
| Thiabendazole | Tissue extracts are quantified by HPLC with UV detector | 0.05 ppm | NE | II | E | Cattle/liver muscle | Copy available upon request | |
| Thiram | Tissue extracts are quantified by HPLC with UV detector | 0.1 ppm | NE | II | E | Cattle, swine/ muscle | Copy available upon request | |
| Tiamulin | Organic solvent extraction followed by GC of the 8 hydroxymutilin metabolite | 0.2 ppm | 0.4 ppm | II | B | Swine/liver | INAD 1776 Diamond-Shamrock Corp | |
| | Extracts confirmed by GC/MS | NE | 0.4 ppm | I | B | Swine/liver | INAD 1776 Diamond-Shamrock Corp | |
| Tin | Tissue is dry ashed and dissolved and quantified by AAS | NE | NE | I | E | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook | |

FSIS RESIDUE ANALYTICAL CAPABILITY


| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|---------------|---|-------------|----------|-------|--------|---------------------------|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | All/fat pp ¹ | | |
| Toxaphene | Micro alumina assay: column chromatography plus GLC | 0.50 ppm | NE | II | E | All/fat pp ¹ | Sec. 5.002 FSIS Chemistry Lab Guidebook | |
| | Gel permeation chromatography (GPC) plus GLC | 0.50 ppm | NE | II | E | All/fat | Sec. 5.003 FSIS Chemistry Lab Guidebook | |
| | Mills method: Florisil column chromatography plus GLC | 0.50 ppm | 1.00 ppm | II | B | All/fat pp ¹ | Sec. 5.001 FSIS Chemistry Lab Guidebook | |
| Trichlorfon | Tissue extracts are quantified by GLC with flame photometric or nitrogen-phosphorous flame ionization detector | NE | NE | II | E | All/liver muscle | Sec. 5.006 FSIS Chemistry Lab Guidebook | |
| Tylosin | Antibiotic screen test (SWAB): the ability of tissue fluids containing antimicrobial activity to inhibit microbial growth | 0.20 ppm | NE | III | E | All/kidney | J. Food Prot. 1981, 44, 828-831 | |
| | Tissue extracts are screened by E-Z screen | 5 ppb | NE | III | E | All/muscle liver kidney | Environmental Diagnostics | |
| | Liquid-liquid extraction followed by HPLC-UV detection | 0.1 ppm | NE | II | E | Cattle/muscle | Copy available upon request | |
| Virginiamycin | Microbiological assay procedure: the ability of tissue extracts containing antimicrobial activity to inhibit microbial growth | 0.64 ppm | NE | II | E | Swine/kidney liver muscle | NADA 91-467 & 91-513 Smith Kline & French | |

¹Processed product.

FSIS RESIDUE ANALYTICAL CAPABILITY

| Compound | Description | TEST METHOD | | | | | Species/ Tissues | Reference |
|----------|--|-------------|-----|-------|--------|-------------------------|--|-----------|
| | | LDL/ MIC | MPL | Level | Status | | | |
| Zeranol | Extraction followed by radioimmunoassay | 1.0 ppb | NE | III | E | All/liver muscle | Copy available upon request | |
| | Solid state extraction using an internal standard followed by polymethylsilylation for GC/MS quantification and confirmation | 0.25 ppb | NE | I | F | All/liver muscle | Copy available upon request | |
| Zinc | Tissue is dry ashed and dissolved and quantified by AAS | NE | NE | I | B | All/kidney liver muscle | Sec. 5.010 FSIS Chemistry Lab Guidebook | |

Section 6



**NATIONAL RESIDUE PROGRAM—
COMPOUNDS INCLUDED**

| Compounds/Years | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 |
|------------------------|------|------|------|------|------|------|------|------|------|------|
| Aflatoxin ¹ | | | | | X | X | | X | | X |
| Albendazole | | | | | | | X | | | |
| Aldrin | X | X | X | X | X | X | X | X | X | X |
| Amoxicillin trihydrate | X | X | X | X | X | X | X | X | X | X |
| Ampicillin | X | X | X | X | X | X | X | X | X | X |
| Ampicillin trihydrate | X | X | X | X | X | X | X | X | X | X |
| Apramycin | | | | | | X | X | X | X | X |
| Arsanilate sodium | X | X | X | X | X | X | X | X | X | X |
| Arsanilic acid | X | X | X | X | X | X | X | X | X | X |
| Arsenate, Calcium | X | X | X | X | X | X | X | X | X | X |
| Arsenate, Copper | X | X | X | X | X | X | X | X | X | X |
| Arsenate, Lead | X | X | X | X | X | X | X | X | X | X |
| Arsenate, Magnesium | X | X | X | X | X | X | X | X | X | X |
| Arsenate, Sodium | X | X | X | X | X | X | X | X | X | X |
| Arsenic | X | X | X | X | X | X | X | X | X | X |
| Atrazine | | | | | | | X | X | X | X |
| BHC | X | X | X | X | X | X | X | X | X | X |
| Cacodylic Acid | X | X | X | X | X | X | X | X | X | X |
| Cadmium | X | X | X | X | X | X | X | X | X | X |

¹Analysis done by contractor.

**NATIONAL RESIDUE PROGRAM—
COMPOUNDS INCLUDED**

| Compounds/Years | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 |
|--|------|------|------|------|------|------|------|------|------|------|
| Carbadox | X | X | X | X | X | X | X | X | X | X |
| Carbarsone | X | X | X | X | X | X | X | X | X | X |
| Chloramphenicol | | | | | X | X | X | X | X | X |
| Chloramphenicol palmitate | | | | | X | X | X | X | X | X |
| Chlordane (technical) | X | X | X | X | X | X | X | X | X | X |
| 2-Chloro-1-(2,4,5-trichlorophenyl)vinyl dimethyl phosphate | X | X | X | | | | X | X | X | X |
| Chloryrifos | X | | | | X | X | X | X | X | X |
| Chlortetracycline bisulfate | X | X | X | X | X | X | X | X | X | X |
| Chlortetracycline hydrochloride | X | X | X | X | X | X | X | X | X | X |
| Clopidol | X | X | X | | | | | | X | X |
| Clorsulon | | | | | | | | | | X |
| Cloxacillin, Benzathine | X | X | X | X | X | X | X | X | X | X |
| Cloxacillin, Sodium | X | X | X | X | X | X | X | X | X | X |
| Cobalt | X | | | | X | X | X | X | X | X |
| Copper | X | X | | | | X | X | X | X | X |
| Coumpahos and oxygen analog | X | X | X | X | X | X | X | X | X | X |

**NATIONAL RESIDUE PROGRAM—
COMPOUNDS INCLUDED**

| Compounds/Years | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 |
|---|------|------|------|------|------|------|------|------|------|------|
| Crufomate | X | | X | X | X | X | X | X | X | X |
| Cyromazine | | | | | | | X | X | X | X |
| DDE (metabolite of DDT) | X | X | X | X | X | X | X | X | X | X |
| DDT | X | X | X | X | X | X | X | X | X | X |
| Decoquinate | | | | | | X | X | X | X | X |
| Dibutyltin dilaurate | | | | | X | | | | | |
| Dichlorvos | X | X | X | X | X | X | X | X | X | X |
| Dieldrin | X | | | | X | X | X | X | X | X |
| O,O-Diethyl S-(2-(ethylthio)-ethyl) phosphorodithioate | X | | X | X | X | X | X | X | X | X |
| O,O-Diethyl O-(2-isopropyl-6-methyl-4-pyrimidinyl) phosphorothioate | X | | X | X | X | X | X | X | X | X |
| Diethylstilbestrol | X | X | X | X | X | X | X | X | X | X |
| Dihydrostreptomycin | X | X | X | X | X | X | X | X | X | X |
| Dimefridazole ¹ | X | | X | | X | | | X | X | X |
| Dioxathion | X | | | | | | | | | |
| Dodecachlorooctahydro-1,3,4-metheno-2H-cyclobuta(cd)pentalene | X | X | X | X | X | X | X | X | X | X |

¹Method used was best available at the time; since made obsolete by scientific advancement.

**NATIONAL RESIDUE PROGRAM—
COMPOUNDS INCLUDED**

| Compounds/Years | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 |
|-----------------------------------|----------------|----------------|------|------|------|------|------|------|------|------|
| Endrin | X | X | X | X | X | X | X | X | X | X |
| Erythromycin | X | X | X | X | X | X | X | X | X | X |
| Erythromycin phosphate | X | X | X | X | X | X | X | X | X | X |
| Erythromycin thiocyanate | X | X | X | X | X | X | X | X | X | X |
| Ethion and oxygen analog | X | | | X | X | X | X | X | X | X |
| Ethylene dibromide | | | | | X | X | X | X | X | X |
| Fenbendazole | | | | | | X | X | X | X | X |
| Fenitrothion | X | | X | | X | X | X | X | X | X |
| Fenthion | X | | X | | X | X | X | X | X | X |
| Gentamicin sulfate | | | | | | X | X | X | X | X |
| Halofuginone | | | | | | | X | X | X | X |
| HCB | X | X | X | X | X | X | X | X | X | X |
| Heptachlor and heptachlor epoxide | X | X | X | X | X | X | X | X | X | X |
| Hetacillin, Potassium | X | X | X | X | X | X | X | X | X | X |
| Iproniazole | X ¹ | X ¹ | | | | | X | X | X | X |
| Ipronidazole hydrochloride | X ¹ | X ¹ | | | | | X | X | X | X |
| Iron | | | | | | | X | X | X | X |
| Ivermectin | | | | | | | X | X | X | X |

¹Method used was best available at the time; since made obsolete by scientific advancement.

**NATIONAL RESIDUE PROGRAM—
COMPOUNDS INCLUDED**

| Compounds/Years | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 |
|---------------------------------|----------------|----------------|----------------|------|------|------|------|------|------|------|
| Lasalocid | | | | X | | | X | X | X | X |
| Lead | X | X | | | X | | X | X | X | X |
| Levamisole hydrochloride | | X ¹ | X ¹ | | | | X | X | X | X |
| Levamisole phosphate | X ¹ | X ¹ | | | | | X | X | X | X |
| Lindane | X | X | X | X | X | X | X | X | X | X |
| Malathion | X | | X | X | X | X | X | X | X | X |
| Manganese | X | | X | | X | X | X | X | X | X |
| Mebendazole | | | | | X | X | X | | | X |
| Melengestrol acetate | X | X | X | X | X | X | X | | | X |
| Mercury | X | | X | X | | | X | X | X | X |
| Methaneearsonic acid | X | X | X | X | X | | X | X | X | X |
| Methoxychlor | X | X | X | X | X | X | X | X | X | X |
| Methyl parathion | X | | X | X | X | X | X | X | X | X |
| Monensin | X | X | | X | X | X | X | X | X | X |
| Morantel tartrate | | | | | | X | X | X | X | X |
| Neomycin sulfate | X | X | X | X | X | X | X | X | X | X |
| Nickel | X | | | X | X | X | X | X | X | X |
| Nonachlor | X | X | X | X | X | X | X | X | X | X |

¹Method used was best available at the time; since made obsolete by scientific advancement.

**NATIONAL RESIDUE PROGRAM—
COMPOUNDS INCLUDED**

| Compounds/Years | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 |
|--|------|------|------|------|------|------|------|------|------|------|
| Novobiocin | | | | | | | | | X | X |
| Oxfendazole | X | X | X | X | X | X | X | X | | X |
| Oxytetracycline hydrochloride | | | | | | | | X | X | X |
| Parathion | X | | X | X | X | X | X | X | X | X |
| PBB | | | | | | X | X | X | X | X |
| PCB | X | X | X | X | X | X | X | X | X | X |
| Penicillin, procaine and procaine G | X | X | X | X | X | X | X | X | X | X |
| Penicillin G (benzathine, free acid, sodium salt and procaine salts) | X | X | X | X | X | X | X | X | X | X |
| Pentachlorophenol | X | X | X | X | X | X | X | X | X | X |
| Potassium arsenite | X | X | X | X | X | X | X | X | X | X |
| Propazine | | | | | | | X | X | X | X |
| Pyrantel tartrate | | | | | | | X | X | X | X |
| Robenidine hydrochloride | X | X | | | X | X | X | X | X | X |
| Ronnel | X | X | X | X | X | X | X | X | X | X |
| Roxarsone | X | X | X | X | X | X | X | X | X | X |
| Simazine | | | | | | | X | X | X | X |

**NATIONAL RESIDUE PROGRAM—
COMPOUNDS INCLUDED**


| Compounds/Years | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 |
|----------------------------|------|------|------|------|------|------|------|------|------|------|
| Selenium | X | | | | | | | | X | |
| Sodium arsenite | X | X | X | X | X | X | X | X | X | X |
| Streptomycin | X | X | X | X | X | X | X | X | X | X |
| Sulfabromomethazine sodium | X | X | X | X | X | X | X | X | X | X |
| Sulfachloropyridazine | | | | | | | X | X | X | X |
| Sulfadimethoxine | X | X | X | X | X | X | X | X | X | X |
| Sulfathoxypyridazine | | | | | X | X | X | X | X | X |
| Sulfamethazine | X | X | X | X | X | X | X | X | X | X |
| Sulfamethoxypyridazine | | | | | | | X | X | X | X |
| Sulfapyridine | X | X | X | X | X | X | X | X | X | X |
| Sulfiquinoxaline | X | X | X | X | X | X | X | X | X | X |
| Sulfathiazole | X | X | X | X | X | X | X | X | X | X |
| TDE (metabolite of DDT) | X | X | X | X | X | X | X | X | X | X |
| TDE (or DDD) | X | X | X | X | X | X | X | X | X | X |
| Terbutylazine | | | | | | | X | X | X | X |
| Terpene polychlorinates | X | X | X | X | X | X | X | X | X | X |
| Tetracycline hydrochloride | X | X | X | X | X | X | X | X | X | X |

**NATIONAL RESIDUE PROGRAM—
COMPOUNDS INCLUDED**

| Compounds/Years | 1977 | 1978 | 1979 | 1980 | 1981 | 1982 | 1983 | 1984 | 1985 | 1986 |
|--------------------------------|----------------|----------------|------|------|------|------|------|------|------|------|
| Thiabendazole | X ¹ | X ¹ | | | | | | | X | X |
| Tin | | | | | X | X | X | X | | |
| Toxaphene | X | X | X | X | X | X | X | X | X | X |
| Trichlorfon | X | | X | | | X | X | X | X | X |
| Tylosin | | | | | | | X | X | X | X |
| Virginiamycin | | | | | | | | X | X | X |
| Zearalenone¹ | | | X | | | | | | X | X |
| Zeranol | | X | X | | X | | | | | |
| Zinc | | | | | | X | X | X | X | |

¹Method used was best available at the time; since made obsolete by scientific advancement.

Section 7



NATIONAL RESIDUE PROGRAM PLAN—INTRODUCTION

The development of the National Residue Program Annual Plan begins in February of the preceding year and progresses by means of discussions, both formal and informal, among the Residue Evaluation and Planning Division of the Science Program (FSIS), other Science divisions, and involved Federal agencies; it culminates in formal reviews by FSIS and an interagency working group during the late summer and fall.

In 1983 FSIS asked the Food and Nutrition Board of the National Research Council (NRC) to evaluate the scientific basis of the present system for inspecting meat and poultry and meat and poultry products; an assessment of the National Residue Program was included in the request. The NRC report, "Meat and Poultry Inspection: The Scientific Basis of the Nation's Program," was published on July 16, 1985. It contained a number of recommendations and described the characteristics of an ideal program. During fiscal year 1986, FSIS considered the mission and design of the residue program in terms of the NRC report. This review influenced portions of the 1986 plan and has had an additional impact on the 1987 plan.

Although the projections upon which the plan is based are as exact as possible, they may not match budgetary or facility resources or specific sampling and analytical capabilities or requirements during 1987. Residue control is a dynamic field, with continual change; the plan will be modified during the year as additional information alters the original assessment.

The Introduction describes the tables in which the details of the plan are presented. Preceding the tables is an alphabetical list (with explanatory material) of the compounds included in the 1987 plan.

Table I

Table I lists the compounds included in the 1987 plan, the ranking assigned, and the residue designation used in the plan. The residue designation identifies the class of compounds detected by the initial analytical procedure. For example, "arsenic" includes several arsenical compounds.

The Analytical Capability section of this document lists the analytical methods used, the minimal levels of measurement that can be achieved, and references to full descriptions of the methods. FSIS maintains a laboratory development and quality-assurance program to ensure progress in residue testing and the integrity of its test results. Before an analyst is allowed to conduct a test on a monitoring or surveillance sample, he or she must demonstrate adequate proficiency and meet specified standards in analyzing quality-assurance samples. (Additional information on the quality-assurance program can be obtained from the FSIS Quality Assurance Handbook.)

Whenever possible, multiple-residue methods are used to detect the presence of more than one residue in a sample; such procedures are

NATIONAL RESIDUE PROGRAM PLAN—INTRODUCTION

used for chlorinated hydrocarbons, antibiotics, sulfonamides, and other classes of compounds. Some of the multiple-residue methods detect the presence of additional compounds not included in this listing; however, the confirmation of identity of precise quantification of these additional residues may or may not be possible. Some compounds that are not significant public health concerns may be included because they are detected in multi-residue testing procedures. The multi-residue methods and the number of compounds that may be identified by each method are expanded when new or modified technology is available.

Table II

The plan is based on a “residue/species pair” design concept. The species or production-class groups used in residue/species couplings are determined by commonalities in rearing, as these factors affect the animal’s exposure and the probability that residues may be present at slaughter. For example, market hogs have an exposure-potential profile different from that of boars and sows.

Table II lists the species or production-class groups normally used for a residue/species pair in a statistical design, the apportionment of samples between production classes, and the minimal number of samples usually planned for evaluating the data set. Exceptions to the groupings for particular compounds are made when appropriate.

Table III

Although the monitoring program is not designed to provide statistical estimates of the percentage of violations in large populations, such estimates are available as auxiliary information provided a high, or otherwise specified, degree of precision is not necessary. Table III depicts the relationship between the sample size and the precision of the estimates of the percentage of violations in large populations. For example, if no violations are found in a set of 300 analyses, there is 95 percent confidence that the frequency of violations in the population is not larger than 1.0 percent. If one violation is found, there is a 5 percent chance that the percentage of violations in the population is more than 1.8 percent or less than 0.01 percent. Providing assurance that the frequency of violations was not more than 0.1 percent, with 95 percent confidence, would require 3,000 samples. Such enormous data sets would cost a great deal and would provide little additional information or public health protection. A much more effective procedure is to control the exposure of the animals to contamination.

When it is known or anticipated that a residue presents a significant problem, sampling may be increased. The increased sampling permits study of trends and geographic or seasonal variation in violation rates, and may aid in preparing effective control actions.

Collection requests for samples are generated using a computerized system in Washington, D.C. Sample and plant selection is random and statistically (probability) based, with a minimal bias. Normally, residues are monitored for the entire year, but some may be introduced during

NATIONAL RESIDUE PROGRAM PLAN—INTRODUCTION

the year and may continue into the following year. Others may be included only during a particular period of the year. Variables such as production volume, geography, and season are addressed statistically within resource constraints. In some cases where method development is incomplete, samples will be collected on a monthly basis but analytical work may be delayed until the methods are implemented.

Table IV

Table IV lists the tissues to be collected for domestic sample analysis.

Table V

Table V presents a summary of the combined domestic and import plans. The plans specify the minimum sample units planned for analysis. In the domestic program a sample unit refers to a set of one or more tissues collected for analysis from either one head of livestock or six head of poultry where samples of a tissue type (e.g., liver) from the birds are composited and a representative sample is analyzed. The number of tissues composing a sample unit depends upon the residue, as shown in Table IV.

Table VI

In themselves, sample numbers are not good indicators of the actual commitment of resources, or of the effectiveness of these commitments. Table VI illustrates the wide divergence among test procedures in amount of analyst time required per sample.

Table VII

Table VII presents the domestic program sample units planned for 1987, including monitoring, surveillance, and exploratory activities.

Tables VIII-IX

Tables VIII and IX show the monitoring and exploratory sample units planned for domestic livestock and poultry, respectively. The sample unit numbers for each residue designation are dispersed according to species.

Table X

Table X presents the sample plan for imported products.

The design of the import plan differs from the domestic plan because it involves the reinspection of product that has already been inspected under an approved foreign system with a residue program equal to that of the U.S. Thus port-of-entry residue sampling is intended to provide further information on the operation of the foreign system's residue controls.

The import inspection program uses an Automated Import Information System (AIIS) to direct the selection of samples from any port where product may arrive. Data stored in the AIIS are used for monthly updates of the sampling requirements for each country, product, and residue class, to assure that the commitments of the annual plan are met. Appropriate changes can be made in the AIIS if, during the course of the year, there are unexpected changes in the volume or type of imported product from any country or countries.

NATIONAL RESIDUE PROGRAM PLAN—INTRODUCTION

Tables XI-XII

Table XI shows the planned import samples by species and Table XII shows estimated analyses per country.

Table XIII

Table XIII shows how the sampling rates are determined. Volume of products exported to the U.S. is factored into a formula to yield a "starting point" number. This number is modified according to a compound's evaluation and ranking, and FSIS laboratory capabilities.

Tables XIV-XXII

Table XIV shows the estimated annual volume of imported beef, divided into fresh (including frozen) and processed products, and the estimated sampling rates for each class of product. Table XV lists the monitoring and exploratory sample unit analyses planned for fresh and processed beef products. Tables XVI and XVII follow the same procedure for imported pork; Tables XVIII and XIX for fresh veal, mutton, and lamb; and Tables XX, XXI, and XXII for ducks/geese, turkeys, and chickens.

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

Albendazole

Albendazole is a broad-spectrum anthelminitic temporarily authorized by FDA for emergency use against liver flukes (*fascioliasis*) in cattle and sheep in 18 states and Guam; this authorization was withdrawn in 1985. Albendazole is a teratogen and immunosuppressant in some species.

Albendazole is effective not only against flukes but also against lung and intestinal helminths; for this reason, albendazole analysis will be performed in 1987 on samples from cattle, sheep, and goats, to provide assurance that albendazole is not being used. Sample collection will be nationwide, as major lung and intestinal helminthic disease occurs in areas that are not necessarily afflicted with *fascioliasis*.

Albendazole is available in foreign countries. Since the analytical method for albendazole has been validated for beef liver and is being extended to beef muscle and to sheep and lamb muscle, analysis of beef and sheep muscle tissue for albendazole is included in the import sampling program for 1987. (Note asterisks in pertinent tables.)

Antibiotics

Agricultural use of antibiotics to control disease processes is ubiquitous. During the last decade antibiotic use in food animals, as in human medicine, has been increasingly directed against specific conditions and less toward general therapy or disease prevention. However, antibiotics are still fed at subtherapeutic levels to enhance feed efficiency and promote growth.

The antibiotics vary widely in their toxicity, safe residue levels, and withdrawal periods required. Toxic effects include, for example, life-threatening hypersensitivity responses (penicillin) and hearing impairment (streptomycins). In addition, there is concern about the development and transmission of pathogenic organisms resistant to antibiotic therapy.

The screening test for antibiotics used in the 1987 National Residue Monitoring program will identify penicillins, streptomycins, tetracyclines, bacitracin, neomycin, erythromycin, gentamicin, and tylosin. Another screening test, for lincomycin, novobiocin, and virginiamycin, was used during 1986 and indicated that there was no apparent problem with these antibiotics.

The 1987 domestic plan contains sampling for antibiotics in all species/production groups. Included in the domestic activities are area monitoring samples in Puerto Rico, in fulfillment of a commitment to Puerto Rican authorities to increase monitoring (50 bulls and cows, 25 market hogs, 25 boars and sows, and 50 young chickens).

Calves have presented the highest percentage of violative antibiotic residues (principally streptomycin and neomycin). Previously, all classes of calves have been grouped together for monitoring. In 1987

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

calves will be divided into three groups: bob veal (up to 3 weeks of age or 150 pounds in weight), fancy veal (formula- and non-formula-fed calves between 150 and 400 pounds), and other calves (above 400 pounds). For national monitoring, each class of calves will be sampled separately (300 analyses per class). The existing data base does not allow for this division but is being upgraded so that it will be possible.

Bob veal calves present an especially acute problem, as they are slaughtered before any administered drugs can deplete to safe levels. In response to this problem, FSIS conducts an intensive in-plant testing program—the Calf Antibiotic and Sulfonamide Test (CAST) program—for the occurrence of violative antibiotic and sulfonamide residues in bob calves.

Violative residues could also occur in calves that have been treated with aminoglycosides for respiratory disease common at 3-4 weeks of age, as these drugs are retained in the kidney well after treatment. Thus special surveillance programs of three months duration will be conducted to determine if there is misuse of antibiotics in fancy veal calves.

Cows also tend to have violative residues. Cows presented for slaughter are usually culled from beef or dairy herds for substandard performance and may have been treated before slaughter. FSIS has an active in-plant testing program—the Swab Test on Premises (STOP) program—for cows suspected of containing violative residues, that has been effective over the years in reducing the previously very high violation rate in this vulnerable group of animals. Since cows are often presented for slaughter singly or in small lots, it has proved difficult to trace violative carcasses found in monitoring to their place of origin for follow-up surveillance testing. In 1987, all cows sampled under the national monitoring program will be concurrently screened by the STOP test. Carcasses that are STOP-positive will be retained pending confirmation of adulteration by laboratory analysis. Also, the use of STOP procedures at establishments slaughtering significant numbers of cows will be reviewed. Data from this review may be used to develop special surveillance projects in 1987.

The problem of antibiotic contamination may occur in culled mature animals of other species as well. Special surveillance projects will also be conducted in 1987 for mature sows, ewes, chickens, and turkeys. Three hundred samples will be collected for each of these classes from plants with a moderate slaughter volume (1,000 to 30,000 head annually) and a high condemnation rate.

During 1987 the rate of monitoring for horses will be increased from 100 to 300 samples per year. In addition, all sampled horses are to be screened in-plant by the STOP test; if the horse is STOP-positive, the carcass will be retained pending confirmation of adulteration by laboratory analysis. This new approach to monitoring samples collected from horses will provide the first economic incentive to

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

assure that horses presented for slaughter are not adulterated with antibiotic residues. Additional surveillance sampling may be added to a particular plant that has a greater incidence of adulterated animals.

While the 1987 plan shows increased testing for antibiotics through projects directed toward known or suspected problem areas, the number of monitoring samples to be collected from broilers (young chickens) and ducks will be reduced from 300 to 100 per year because there have been no antibiotic violations in these slaughter classes for at least two years.

Imported beef, pork, veal, mutton, and lamb will be sampled and tested for antibiotics in 1987.

Arsenic

Compounds containing arsenic are monitored by a method that measures total arsenic (Table I). Arsenic is an element and thus occurs naturally in several molecular forms and in various concentrations in the earth's crust.

Organic arsenical compounds, either alone or combined with other compounds, have been widely used both in humans and in food-producing animals as tonics, restoratives, nutrients, herbicides, pesticides, antiprotozoal and anthelmintic agents, antimicrobials, and growth promoters. They are approved for use in chickens as coccidiostats and growth promoters and in swine as growth promoters and for bacterial enteritis. Arsenical preparations are widely used by horsemen for a variety of conditions. Both in chickens and swine (and in humans), arsenical compounds have generally been replaced by compounds that are less expensive and more efficient and specific. When arsenicals are used as approved in chicken and swine, the animals and birds must not be treated with or exposed to the arsenical compounds within five days of slaughter. This five-day withdrawal period is sufficient to ensure that concentrations of arsenic in the tissues are lower than the tolerance concentrations.

There is information linking inorganic arsenicals to skin, lung, and liver cancer. However, information on the classes of organic arsenical compounds being used in food animal production indicates that these compounds do not have carcinogenic or irritant effects.

Arsenic is included in the domestic monitoring plan for horses, market hogs, and young chickens and turkeys. In imports it will be monitored in pork, fresh turkeys and cooked turkey products, and fresh chickens and processed chicken products.

Benzimidazoles

The benzimidazoles detected by FSIS's current laboratory procedures are mebendazole, fenbendazole, oxfendazole, and thiabendazole and its 5-hydroxy metabolite. These anthelmintics have various approvals for use in cattle, horses, swine, poultry, goats, or sheep, for treatment of gastrointestinal or lung worms.

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

Undesirable side effects frequently encountered in human beings treated with benzimidazoles are anorexia, nausea, vomiting, and dizziness. Less frequently noted are diarrhea, epigastric distress, drowsiness, and headache.

During 1986, a method became available for screening samples from cattle for the group of benzimidazoles noted above. During 1987 the method will be extended to sheep, lambs, and market hogs (note asterisks in pertinent tables). Imported beef, pork, mutton, and lamb will also be sampled and tested for benzimidazoles. In all, the benzimidazole screening analysis will be conducted on 2,100 samples.

Carbadox

Carbadox is approved for use in swine weighing less than 75 pounds to prevent or treat enteritis and for increased feed efficiency and weight gain. The last exposure of swine to carbadox must be at least 10 weeks before slaughter (withdrawal period). The parent compound is a liver carcinogen. Domestic market hogs, boars, and sows will be monitored for carbadox.

As carbadox is approved in other countries for use with swine, it is included in the import plan for fresh pork. Confirmation depends upon an evaluation of the mass spectrometry (MS) confirmatory procedure (based upon a determinative extract for the carbadox metabolite), expected to be completed in early 1987. (Note the asterisks in pertinent tables.)

Carbamates

Carbamates are primarily systemic insecticides and acaricides but are also used extensively as soil treatments and as topical and knockdown agents for ectoparasites and other pests. Carbamates are generally neurotoxic, since they are cholinesterase inhibitors. Symptoms of toxicity include nausea, vomiting, diarrhea, and dyspnea.

Analysis for carbamates is a new procedure for the National Residue Monitoring Program in 1987. Technology is available to analyze samples for aldicarb, carbaryl, and carbofuran. The carbamates method is scheduled for completion in January 1987, and final method performance data will be determined at that time (note asterisks in pertinent tables). When established, this technology may be extended to include other carbamates.

During 1987, 900 domestic samples from bulls and cows, swine, and ducks will be analyzed for these carbamates.

Chloramphenicol

Chloramphenicol is a potent, rapidly metabolized, and toxic antibiotic with a wide spectrum of effectiveness. Chloramphenicol is not approved for use in food-producing animals and in humans because of its idiosyncratic production of fatal aplastic anemia in people. Current analytical methodology is effective in finding chloramphenicol concentrations of 10 ppb, but is not effective in finding metabolites of the compound. New methodology is being evaluated and adopted.

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

that may be more sensitive in identifying chloramphenicol. By 1988 it may be possible to screen urine in the plant for chloramphenicol and then confirm the presence of these compounds by laboratory analysis. Such a system may be considerably more sensitive and efficient than current methodology.

During 1987 samples from imported product will be monitored. Domestically, special and regular surveillance and exploratory projects will be conducted to develop and evaluate the new methodology and to examine carefully selected animal populations that may have a risk of contamination with chloramphenicol.

Chlorinated Hydrocarbons (CHC)

FSIS laboratories use multi-residue screening and confirmatory analytical procedures to identify aldrin, endrin, dieldrin, BHC, chlordane, heptachlor and heptachlor epoxide, DDE, DDT, TDE, HCB, lindane, methoxychlor, nonachlor, PCB's, mirex, terpene polychlorinates, and toxaphene. Most of these compounds are potent and persistent pesticides whose use has been discontinued or severely restricted because of their suspected carcinogenicity in some species, their effect on egg shell production (especially in predatory fowl), and their characteristic propensity to accumulate in the food chain. These compounds generally induce microsomal epoxidation systems that are among the avian and mammalian defense mechanisms against several classes of toxicants. Accumulation of these compounds in body fat may result in concentrations 10 to 30 times as great as in the food supply. Metabolism and excretion are slow, and the biological half-life of these compounds may be several months in mammals and several years in arid soils. Their persistence and potency contributed greatly to their effectiveness as long-term insecticides, especially in the control of arthropod-borne disease, and also cause their continuing though diminishing occurrence as residues in meat and poultry products.

During 1987, analysis for residues of chlorinated hydrocarbons is planned for all domestic and imported species and production classes. Domestic activities include 150 area monitoring samples in Puerto Rico, in fulfillment of a commitment to Puerto Rican authorities to increase monitoring.

Clorsulon

Clorsulon, approved in 1985, is the only drug approved for the treatment of fascioliasis in cattle. Unlike albendazole, whose temporary use was withdrawn in 1985, clorsulon is not an effective treatment for helminths (intestinal or pulmonary). It is administered orally, and the last dose must be at least eight days before slaughter (withdrawal period). As there currently are no residue data for clorsulon in milk, it is not approved for use in dairy cows. As with albendazole, there is some concern about the health effects of clorsulon (blood dyscrasias have been observed in experimental animals).

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

During 1986, domestic samples from bulls and cows, heifers and steers, sheep, lambs, and goats will be analyzed for residues of clorsulon. As practical, analysis for clorsulon will be directed to samples collected from areas with endemic fascioliasis.

Clorsulon may be used in other countries where fascioliasis is endemic. Thus clorsulon will be included in the import plan.

Cyromazine

Cyromazine (Larvadex) is an insect growth regulator that is highly effective in preventing the development of *diptera* larvae in livestock and poultry manure; it is recommended for use in poultry feed to control flies in the droppings of laying hens. In the U.S., cyromazine is approved for use in laying hens only, but it is used in livestock in some countries. High doses of a metabolic breakdown product of cyromazine, melamine, resulted in bladder tumors in rats. However, these tumors are thought to result from mechanical irritation caused by bladder stones formed at high levels of exposure, and not from the intrinsic carcinogenicity of melamine.

In 1985, current analytical methodology was reevaluated at a considerably lower limit of sensitivity and installed in the Field Services Laboratories. During 1986 testing with the new technology was started in cattle and chickens at the lower detection limit and in 1987 will be expanded to include sheep and goats. Samples in 1987 will be collected only during the fly season, from February through November in the Southeastern and Southwestern regions, from March through September in the Western region, and from May through September in the Northeastern and North Central regions.

Cyromazine is included in the import plan for fresh-frozen beef, mutton, and lamb, as the compound may be used in some countries.

Decoquinate

Decoquinate is a coccidiostat approved for use in cattle and chickens. It is often used with an antibiotic or arsenical compound. Decoquinate is prohibited from use in laying hens, dairy cows, and breeding animals, and its use in broilers (young chickens) is minimal because of the availability of alternate compounds. During 1986 the monitoring plan included analysis of samples collected from domestic cattle and broilers for decoquinate. The 1987 plan for decoquinate analysis will continue the 1986 activities and further includes sampling in imported beef. This sampling activity is part of a cyclic check program.

DES, Zeranol, and Other Estrogenic Compounds

DES and zeranol are estrogenic compounds. Estrogenic compounds are used to increase feed efficiency and the rate of weight gain. DES was banned from use in 1979 when it was linked to cancer in humans. Some illegal use was detected in fancy veal calves in 1981. Zeranol is approved for use in cattle 65 or more days before slaughter.

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

All externally administered estrogenic compounds (including DES and zeranol) will cause characteristic histopathologic changes in the prostate in immature males that may be identified by histopathologic examination.

Before 1986, FSIS analyzed samples collected from mature cattle and calves for DES or zeranol by separate analytical procedures. During 1986 these procedures were combined and the screening program for estrogenic effects in the prostate of calves was approved; sampling procedures were changed accordingly. In 1987 the current procedure will be as follows:

1. Tissues from domestic heifers and steers will be analyzed for DES and zeranol by the combined analytic method currently in use.
2. Screening for estrogenic effects in the prostate will be increased in calves and will be initiated in lambs. When the prostate is collected, the liver will be collected from the same animal, frozen, and held in reserve.
3. When a prostate contains histopathologic evidence of estrogenic effects, the reserved liver tissue from that animal will be analyzed for DES and zeranol.

Domestic calves, sheep, and lambs will be monitored for estrogenic compounds in 1987 (including 50 area monitoring samples in Puerto Rico, in fulfillment of a commitment to Puerto Rican authorities to increase monitoring). Domestic heifers and steers will be monitored for DES/zeranol; in addition, 50 area monitoring samples from young chickens in Puerto Rico will be tested. Imported beef, veal, mutton, and lamb will be sampled for DES/zeranol.

Halofuginone

Halofuginone is a coccidiostat for broilers (young chickens). In higher doses halofuginone is a growth depressant, impairs feed utilization, and reduces feed intake. In rats it causes alopecia. The compound is prohibited from use during the last four days before slaughter (withdrawal period). During 1986 samples were analyzed for halofuginone for the first time. This sampling program will be continued through 1987.

Ipronidazole

Ipronidazole is approved for use domestically to control blackhead in turkeys and in other countries to treat or prevent enteritis in swine. Although ipronidazole is not approved for use in swine in the United States, some misuse in swine may occur in the U.S. and thus could result in unacceptable residues. Ipronidazole is prohibited from use during the last four days before slaughter (withdrawal period). It is a suspect carcinogen in experimental animals.

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

In 1987, samples from ipronidazole will be collected from imported fresh-frozen swine and turkeys. Ipronidazole will be monitored in domestic market hogs and young turkeys.

Ivermectin

Ivermectin is a macrocyclic lactose compound active at extremely low dosage against a wide variety of nematode and arthropod parasites. It is used for treatment of internal parasites. Ivermectin is teratogenic in the rat, rabbit, and mouse. FSIS plans to monitor domestically for residues of this drug in livestock.

Melengestrol acetate

Melengestrol acetate (MGA) is a progestational agent added to the feed of heifers to suppress estrus and thereby achieve an increase in feed efficiency and the rate of weight gain. It is regulated as a suspect carcinogen in feedlot heifers. Because of its suspected carcinogenicity, samples will be collected from heifers during 1987 and analyzed for MGA. Imported beef samples will be monitored for MGA. Confirmation depends upon the evaluation of the mass spectrometry (MS) confirmatory procedure plus additional clean-up for MGA, to be completed in early 1987 (note asterisks in pertinent tables).

Organophosphates

Organophosphate insecticides are widely used in crop production to combat a diversified group of insects. They are also used in topical treatments of animals to control grubs and flies and are approved for use as animal drugs to control gastrointestinal roundworms.

The organophosphates generally are far less persistent than the chlorinated hydrocarbon insecticides, although withdrawal periods are required after direct treatment of animals. The primary toxic effect of concern is the inhibition of cholinesterase, a key enzyme in regulating the nervous system.

Previous domestic monitoring, which has involved analysis of liver tissue from all species, has not shown any problems. In 1987 the chlorinated hydrocarbon method will be modified slightly to allow for the detection of a group of chlorinated organophosphates in fat as well as chlorinated hydrocarbons. With no additional sample collection, the domestic samples tested for chlorinated hydrocarbons will yield an equal number of results for certain chlorinated organophosphates. (Note asterisks in pertinent tables.) The chlorinated organophosphates determined will include carbophenothion, chlorpyrifos, coumaphos, crufomate, dichlorvos, and ronnel. This change in testing procedure will allow FSIS to determine for the first time whether some of these commonly used organophosphates are present in fat. The chlorinated organophosphate procedure will begin in July.

Included in the domestic organophosphate plan will be 75 area monitoring samples in Puerto Rico, in fulfillment of a commitment to Puerto Rican authorities to increase monitoring.

The traditional organophosphate procedure will be performed for import muscle tissue samples, as the chlorinated organophosphate procedure does not work with low-fat samples.

COMPOUNDS INCLUDED IN THE 1987 RESIDUE PLAN

Sulfonamides

Sulfonamides are bacterial and protozoal suppressant agents that have been widely used in animals and humans since the early 1940's. They continue to enjoy widespread popularity because of considerable clinical experience with them and their economic advantages and wide spectrum of activity. Toxic effects include renal damage, thyroid degeneration, and allergy. FSIS uses a multi-residue method of analysis for sulfonamides that can determine residues of sulfabromomethazine, sulfachloropyridazine, sulfadimethoxine, sulfaethoxypyridazine, sulfamethazine, sulfamethoxypyridazine, sulfapyridine, sulfaquinoxaline, and sulfathiazole.

In addition to national domestic monitoring samples planned for 1987 in all relevant species/production groups, additional area monitoring samples will be collected from market hogs in selected states on a rotational basis to gain additional information on the extent of the problem in those states. This special program, initiated in 1986 and continuing through 1987, will focus on states with a high volume of hog slaughter.

During 1987 major efforts will be made to complete development of an intensive in-plant testing program to reduce the level of violative residues of sulfonamides in swine carcasses; these efforts will include field trials of methods planned for use by inspectors at slaughtering establishments. The exploratory sample units listed for domestic swine in the respective tables are estimates of the sample units required to complete these field trials.

Also, in fulfillment of a commitment to Puerto Rican authorities to increase monitoring, additional samples are planned for heifers and steers (50), market hogs (25), boars and sows (25), and young chickens (200).

In the import plan, all commodities will be sampled for sulfonamide testing.

Trace Elements

The trace elements included in the multi-residue method used for monitoring are listed in Table I. The presence of these elements in animal tissues could result from either the natural background levels found in the environment or food chain, or from industrial contamination.

The trace elements show diverse toxicity. Due to the infrequent occurrence of high levels in normal animals, regulatory action levels or tolerances have not been found necessary for red meat and poultry. Exploratory sampling for trace elements is conducted periodically in order to verify that their presence in animal-derived food does not endanger human health.

In 1987 imported pork will be sampled in an exploratory project for trace elements. This project is part of a cyclic check program.

Table I
**COMPOUNDS INCLUDED IN THE
1987 RESIDUE PLAN**

| Compound(s) | Ranking | Residue Designation Used in Plan¹ |
|-----------------------------------|----------------|---|
| Albendazole | A-2 | Albendazole |
| Aldicarb | A-4 | Carbamates |
| Aldrin | A-3 | Chlorinated Hydrocarbons (CHC's) |
| Amoxicillin trihydrate | B | Antibiotics |
| Ampicillin | B-2 | Antibiotics |
| Apramycin | D | Apramycin |
| Arsanilate sodium | A | Arsenic |
| Arsanilic acid | C-1 | Arsenic |
| Arsenate, calcium | C | Arsenic |
| Arsenate, copper | D | Arsenic |
| Arsenate, lead | D | Arsenic |
| Arsenate, magnesium | D | Arsenic |
| Arsenate, sodium | D | Arsenic |
| Arsenic | A | Arsenic |
| Bacitracin methylene disalicylate | C | Antibiotics |
| Bacitracin zinc | C | Antibiotics |
| BHC | B-2 | Chlorinated Hydrocarbons (CHC's) |
| Cadmium | B-4 | Trace Elements |
| Carbadox | A-3 | Carbadox |
| Carbarsone | C-2 | Arsenic |
| Carbaryl | D | Carbamates |
| Carbofuran | C-3 | Carbamates |
| Carbophenothion | D | Organophosphates |

¹For planning, FSIS uses a residue term signifying the compound or group detected by the method used for a planned sample set.

Table I
**COMPOUNDS INCLUDED IN THE
1987 RESIDUE PLAN**

| Compound(s) | Ranking | Residue Designation Used in Plan¹ |
|---|----------------|---|
| Chloramphenicol | A-2 | Chloramphenicol |
| Chloramphenicol palmitate | A-2 | Chloramphenicol |
| Chlordane (technical) | A-2 | Chlorinated Hydrocarbons (CHC's) |
| 2-Chloro-1,(2,4,5-trichlorophenyl)- vinyl dimethyl phosphate (Gardona) | A | Organophosphates |
| Chlorpyrifos | B-4 | Organophosphates |
| Chlortetracycline bisulfate | A | Antibiotics |
| Chlortetracycline hydrochloride | A | Antibiotics |
| Clorsulon | D | Clorsulon |
| Cloxacillin, benzathine | B | Antibiotics |
| Cloxacillin, sodium | B | Antibiotics |
| Cobalt | D | Trace Elements |
| Copper | D | Trace Elements |
| Coumaphos and oxygen analog | A | Organophosphates |
| Crufomate | B | Organophosphates |
| Cyromazine | D | Cyromazine |
| DDE (metabolite of DDT) | A | Chlorinated Hydrocarbons (CHC's) |
| DDT | A | Chlorinated Hydrocarbons (CHC's) |
| Decoquinate | Z-4 | Decoquinate |
| Dichlorvos | B-4 | Organophosphates |
| Dieldrin | A | Chlorinated Hydrocarbons (CHC's) |
| O,O-Diethyl S-[2-(ethylthio)ethyl] phosphorodithioate | D | Organophosphates |
| O,O-Diethyl O-(2-isopropyl-6-methyl- 4-pyrimidinyl) phosphorothioate | D | Organophosphates |

¹For planning, FSIS uses a residue term signifying the compound or group detected by the method used for a planned sample set.

Table I

**COMPOUNDS INCLUDED IN THE
1987 RESIDUE PLAN**

| Compound(s) | Ranking | Residue Designation Used in Plan¹ |
|---|----------------|---|
| Diethylstilbestrol | D | DES/Zeranol |
| Dihydrostreptomycin | D | Antibiotics |
| Dioxathion | D | Organophosphates |
| Dodecachloro-octahydro-1, 3,4,-metheno-2H-cyclobuta [cd]pentalene (mirex) | A | Chlorinated Hydrocarbons (CHC's) |
| Endrin | A-3 | Chlorinated Hydrocarbons (CHC's) |
| Erythromycin | A | Antibiotics |
| Erythromycin phosphate | A | Antibiotics |
| Erythromycin thiocyanate | A | Antibiotics |
| Estradiol benzoate | A | Estrogenic Compounds |
| Estradiol monopalmitate | A | Estrogenic Compounds |
| Ethion and oxygen analog | B | Organophosphates |
| Fenbendazole | B-3 | Benzimidazoles |
| Fenitrothion | D | Organophosphates |
| Fenthion | C-3 | Organophosphates |
| Gentamicin sulfate | B-2 | Antibiotics |
| Halofuginone | D | Halofuginone |
| HCB | D | Chlorinated Hydrocarbons (CHC's) |
| Heptachlor and heptachlor epoxide | A-1 | Chlorinated Hydrocarbons (CHC's) |
| Hetacillin, potassium | B | Antibiotics |
| Ipronidazole | Z-4 | Ipronidazole |
| Ipronidazole hydrochloride | Z-4 | Ipronidazole |
| Iron | D | Trace Elements |

¹For planning, FSIS uses a residue term signifying the compound or group detected by the method used for a planned sample set.

Table I
**COMPOUNDS INCLUDED IN THE
1987 RESIDUE PLAN**

| Compound(s) | Ranking | Residue Designation Used in Plan¹ |
|---|----------------|---|
| Ivermectin | B-1 | Ivermectin |
| Lead | B-4 | Trace Elements |
| Lindane | A-2 | Chlorinated Hydrocarbons (CHC's) |
| Malathion | B | Organophosphates |
| Manganese | D | Trace Elements |
| Mebendazole | B-4 | Benzimidazoles |
| Melengestrol acetate | A | Melengestrol acetate |
| Methanearsonic acid | D | Arsenic |
| Methoxychlor | D-4 | Chlorinated Hydrocarbons (CHC's) |
| Methyl parathion | D | Organophosphates |
| Neomycin sulfate | B-3 | Antibiotics |
| Nequinone | D | Decoquinone |
| Nickel | D | Trace Elements |
| Nonachlor | D | Chlorinated Hydrocarbons (CHC's) |
| Oxfendazole | D | Benzimidazoles |
| Oxytetracycline hydrochloride | A | Antibiotics |
| Parathion | D | Organophosphates |
| PCB's | A-4 | Chlorinated Hydrocarbons (CHC's) |
| Penicillin, procaine and procaine G | A | Antibiotics |
| Penicillin G (benzathine, free acid, sodium salt, and procaine salts) | A | Antibiotics |

¹For planning, FSIS uses a residue term signifying the compound or group detected by the method used for a planned sample set.

Table I
**COMPOUNDS INCLUDED IN THE
1987 RESIDUE PLAN**

| Compound(s) | Ranking | Residue Designation Used in Plan¹ |
|----------------------------|----------------|---|
| Ronnel | B | Organophosphates |
| Roxarsone | C-1 | Arsenic |
| Streptomycin | A-3 | Antibiotics |
| Sulfabromomethazine sodium | C | Sulfonamides |
| Sulfachloropyridazine | A | Sulfonamides |
| Sulfadimethoxine | A | Sulfonamides |
| Sulfaethoxypyridazine | A | Sulfonamides |
| Sulfamethazine | B-1 | Sulfonamides |
| Sulfamethoxypyridazine | D | Sulfonamides |
| Sulfapyridine | D | Sulfonamides |
| Sulfaquinoxaline | B-1 | Sulfonamides |
| Sulfathiazole | B-1 | Sulfonamides |
| TDE (metabolite of DDT) | A | Chlorinated Hydrocarbons (CHC's) |
| Terpene polychlorinates | A | Chlorinated hydrocarbons (CHC's) |
| Tetracycline hydrochloride | B-3 | Antibiotics |
| Thiabendazole | B-2 | Benzimidazoles |
| Toxaphene | A-2 | Chlorinated Hydrocarbons (CHC's) |
| Trichlorfon | B-3 | Organophosphates |
| Tylosin | Z-3 | Antibiotics |
| Zeranol | C-2 | DES/Zeranol |
| Zinc | D-4 | Trace Elements |

¹For planning, FSIS uses a residue term signifying the compound or group detected by the method used for a planned sample set.

Table II
SPECIES GROUPS FOR RESIDUE EVALUATION

| <u>Species/Production Classes</u> | <u>Apportionment</u> | <u>Minimum Sample Units Analyzed Per Year</u> |
|---|----------------------|---|
| Horses | | 300 |
| Bulls/Cows | (10%/90%) | 300 |
| Heifers/Steers | (40%/60%) | 300 |
| Calves | | |
| Bob Veal | | 300 |
| Fancy Veal | | 300 |
| Other | | 300 |
| Sheep/Lamb (Seasonal) | (10%/90%) | 200 |
| Goats | | 100 |
| Hog, market | | 300 |
| Sows/Boars | (80%/20%) | 300 |
| Chickens, young | | 300 |
| Chickens, mature | | 300 |
| Turkeys, young ¹ (Seasonal) | | 300 |
| Turkeys, mature ² (Seasonal) | | 300 |
| Ducks | | 300 |
| Geese (Seasonal) | | 100 |
| Rabbits | | 100 |

¹Normally 16 weeks old.

²Breeding stock.

Table III
95 PERCENT CONFIDENCE INTERVALS FOR THE
PERCENTAGE OF VIOLATIONS IN THE POPULATION

| Sample Size | NUMBER OF VIOLATIONS | | | | | | |
|-------------|----------------------|-----------|-----------|-----------|-----------|----------|-----------|
| | 0 | 1 | 2 | 3 | 4 | 5 | 7 |
| 50 | 0.0-5.82 | | | | | | |
| 100 | 0.0-2.95 | | | | | | |
| 150 | 0.0-1.98 | | | | | | |
| 300 | 0.0-0.99 | 0.01-1.84 | 0.08-2.39 | 0.21-2.89 | 0.36-3.38 | .53-3.88 | .93-4.77 |
| 500 | 0.0-0.60 | 0.01-1.11 | | | | | |
| 600 | 0.0-0.50 | 0.4-1.20 | | | | | |
| 800 | 0.0-0.37 | | 0.08-1.09 | | | | |
| 900 | 0.0-0.33 | | | 0.12-1.13 | .18-1.30 | .31-1.60 | .53-2.04 |
| | | | | | | | .93-2.74 |
| | | | | | | | 1.36-3.42 |
| | | | | | | | 2.26-4.73 |
| | | | | | | | 3.19-6.01 |
| | | | | | | | 4.15-7.26 |

Table IV

**TARGET SAMPLE TISSUES
TO BE COLLECTED FOR ANALYSIS**

| Residue Designation | Species Sampled | Tissue Analyzed¹ |
|----------------------------|---|---|
| Albendazole | Cattle Goats Sheep | Liver, muscle |
| Antibiotics | Cattle Chickens Ducks Geese Goats Horses Rabbits Sheep Swine Turkeys | Kidney, liver, muscle |
| Arsenic | Chickens Horses Swine Turkeys | Liver, muscle |
| Benzimidazoles | Cattle Sheep Swine | Liver, muscle |
| Carbadox | Swine | Liver, muscle |
| Carbamates | Cattle Ducks Swine | Liver, muscle |
| Chloramphenicol | Cattle Sheep Swine | Kidney, muscle (domestic) Muscle (imports) |
| Chlorinated Hydrocarbons | Cattle Chickens Ducks Geese Goats Horses Rabbits Sheep Swine Turkeys | Fat |
| Clorsulon | Cattle Goats Sheep | Kidney, muscle |

¹Tissues in bold-face type submitted for monitoring samples; if more than one target tissue, all tissues submitted for surveillance samples.

Table IV
**TARGET SAMPLE TISSUES
TO BE COLLECTED FOR ANALYSIS**

| Residue Designation | Species Sampled | Tissue Analyzed¹ |
|--|---|-------------------------------------|
| Cyromazine | Cattle Chickens Goats Sheep | Muscle |
| Decoquinate | Cattle Chickens | Liver, muscle |
| DES/Zeranol | Cattle Chickens Sheep | Liver, muscle |
| Estrogenic Compounds/ Histopathologic Screening | Cattle (Male) Sheep (Male) | Prostate gland ² , liver |
| Halofuginone | Chickens | Liver, muscle |
| Ipronidazole (Hydroxy) | Swine Turkeys | Muscle |
| Ivermectin | Cattle Goats Horses Sheep Swine | Liver, muscle |
| Melengestrol acetate | Cattle | Fat, muscle |
| Organophosphates (imports) | Cattle Sheep | Muscle |
| Organophosphates (domestic) | Cattle Chickens Ducks Geese Goats Horses Rabbits Sheep Swine Turkeys | Fat |
| Sulfonamides | Cattle Chickens Ducks Geese Goats Horses Rabbits Sheep Swine Turkeys | Liver, muscle |

¹Tissues in bold-face type submitted for monitoring samples; if more than one target tissue, all tissues submitted for surveillance samples.

²Companion liver will be analyzed if positive.

Table IV

**TARGET SAMPLE TISSUES
TO BE COLLECTED FOR ANALYSIS**

| Residue Designation | Species Sampled | Tissue Analyzed¹ |
|----------------------------|------------------------|------------------------------------|
| Trace Elements (imports) | Swine | Muscle |

¹Tissues in bold-face type submitted for monitoring samples; if more than one target tissue, all tissues submitted for surveillance samples.

Table V
**DOMESTIC AND IMPORT RESIDUE SAMPLES
TO BE ANALYZED IN 1987**

| Residue Designation | Domestic Samples | Import Samples | Totals |
|---|-------------------------|-----------------------|---------------|
| Albendazole | 700 | 400 | 1,100 |
| Antibiotics | 18,050 | 2,000 | 20,050 |
| Arsenic | 1,200 | 300 | 1,500 |
| Benzimidazoles | 1,500 | 600 | 2,100 |
| Carbadox | 600 | 300 | 900 |
| Carbamates | 900 | — | 900 |
| Chloramphenicol | 500 | 1,000 | 1,500 |
| Chlorinated Hydrocarbons | 4,950 | 3,600 | 8,550 |
| Clorsulon | 900 | 300 | 1,200 |
| Cyromazine | 900 | 300 | 1,200 |
| Decoquinate | 600 | 300 | 900 |
| DES/Zeranol | 700 | 200 | 900 |
| Estrogenic Compounds (Histopathologic Screening) | 950 | — | 950 |
| Halofuginone | 300 | — | 300 |
| Ipronidazole | 400 | 600 | 1,000 |
| Ivermectin | 1,800 | — | 1,800 |
| Melengestrol Acetate | 300 | 200 | 500 |
| Organophosphates | 2,725 | 500 | 3,225 |
| Sulfonamides | 8,400 | 2,500 | 10,900 |
| Trace Elements | — | 100 | 100 |
| TOTALS | 46,375 | 13,200 | 59,575 |

Table VI
**DOMESTIC AND IMPORT
SAMPLE UNIT ANALYSES**

| Residue Designation | Total Sample Unit Analyses | Estimated Lab Time Per Sample Unit (Hours)¹ | Estimated Total Lab Time (x 100 Hours) |
|--|-----------------------------------|---|---|
| Albendazole | 1,100 | 1.20 | 13.20 |
| Antibiotics | 20,050 | 0.55 | 110.28 |
| Arsenic | 1,500 | 0.51 | 7.65 |
| Benzimidazoles | 2,100 | 4.30 | 90.30 |
| Carbadox | 900 | 3.00 | 27.00 |
| Carbamates | 900 | 2.00 | 18.00 |
| Chloramphenicol | 1,500 | 0.55 | 8.25 |
| Chlorinated Hydrocarbons | 8,550 | 0.92 | 78.66 |
| Clorsulon | 1,200 | 1.50 | 18.00 |
| Cyromazine (Seasonal/Area) | 1,200 | 2.00 | 24.00 |
| Decoquinate | 900 | 1.26 | 11.34 |
| DES/Zeranol | 900 | 1.00 | 9.00 |
| Estrogenic Compounds (Histopathologic Screening) | 950 | 1.00 | 9.50 |
| Halofuginone | 300 | 6.01 | 18.03 |
| Ipronidazole | 1,000 | 2.00 | 20.00 |
| Ivermectin | 1,800 | 2.00 | 36.00 |
| Melengestrol Acetate | 500 | 3.00 | 15.00 |
| Organophosphates | 500 | 3.89 | 19.45 |
| Organophosphates (Chlorinated) | 2,725 | 0.10 | 2.73 |
| Sulfonamides | 10,900 | 0.95 | 103.55 |
| Trace Elements | 100 | 1.04 | 1.04 |
| TOTALS | 59,575 | | 640.98 |

¹ Estimate of analyst time; does not include administrative, inspector, or other nonanalytical staff hours required.

Table VII
**DOMESTIC RESIDUE PLAN 1987
SAMPLE UNIT ANALYSES**

| Residue Designation | Monitoring | Surveillance | Exploratory | Total |
|---|-------------------|---------------------|--------------------|---------------|
| Albendazole | 700 | — | — | 700 |
| Antibiotics | 8,150 | 2,900 | — | 11,050 |
| STOP | — | 3,000* | — | 3,000 |
| CAST | — | 4,000* | — | 4,000 |
| Arsenics | 1,200 | — | — | 1,200 |
| Benzimidazoles | 1,500 | — | — | 1,500 |
| Carbadox | 600 | — | — | 600 |
| Carbamates | 900 | — | — | 900 |
| Chloramphenicol | — | 500 | — | 500 |
| Chlorinated Hydrocarbons | 4,450 | 500 | — | 4,950 |
| Clorsulon | 900 | — | — | 900 |
| Cyromazine | 900 | — | — | 900 |
| Decoquinate | 600 | — | — | 600 |
| DES/Zeranol | 700 | — | — | 700 |
| Estrogenic Compounds (Histopathologic Screening) | 950 | — | — | 950 |
| Halofuginone | 300 | — | — | 300 |
| Ipronidazole | 400 | — | — | 400 |
| Ivermectin | 1,800 | — | — | 1,800 |
| Melengestrol Acetate | 300 | — | — | 300 |
| Organophosphates | 2,225 | 500 | — | 2,725 |
| Sulfonamides | 7,400 | 500* | 500* | 8,400 |
| TOTALS | 33,975 | 11,900 | 500 | 46,375 |

*See discussion under pertinent compound in "Compounds Included in the 1987 Residue Plan."

Table VIII
DOMESTIC MONITORING AND EXPLORATORY
SAMPLE UNIT ANALYSES: LIVESTOCK

| Residue Designation | Horses | Bulls/ Cows | Heifers/ Steers | Calves | Sheep/ Lamb | Market Hogs | Boars/ Sows | Total |
|--|--------------|----------------|--------------------|--------------|----------------|----------------|----------------|---------------|
| | | | | Bob | Fancy | Other | Seasonal | Goats |
| Albendazole | — | — | 300 | — | — | — | 300* | 100* |
| Antibiotics | 300 | 300 | 300 | 300 | 1,800* | 300 | 1,000 | 300 |
| Aged Animals Area | — | 300 | — | — | — | 300 | — | 5,000 |
| Arsenic | 300 | — | — | — | — | — | — | 300 |
| Benzimidazoles | — | 300 | 300 | — | — | — | — | 25 |
| Carbadox | — | — | — | — | — | — | — | 25 |
| Carbamates | — | 300* | — | — | — | — | — | 300* |
| Chlorinated Hydrocarbons Area | 300 | 300 | 400 | 300 | 300 | 300 | 300 | 300 |
| Clorsulon | — | 50 | — | — | — | — | — | 300 |
| Cyromazine* | — | 300 | 300 | — | — | 200 | 100 | — |
| Decoquinate | — | — | 300 | — | — | — | — | — |
| DES/Zeranol Area | — | — | 600 | — | — | — | — | — |
| Estrogenic Compounds (Histopathologic Screen) Area | — | — | 50 | — | — | — | — | — |
| Ipronidazole | — | — | — | 50* | — | — | — | — |
| Ivermectin | 100 | 300 | 300 | — | — | 100 | 100 | 300 |
| Melengestrol Acetate | — | — | 300* | — | — | — | — | — |
| Organophosphates Area | 150 | 150 | 200 | 150 | 150 | 150 | 150 | 150 |
| Sulfonamides Area Exploratory | 100 | 300 | 100 | 300 | 300 | 100 | 100 | 100 |
| Totals | 1,250 | 2,675 | 3,800 | 1,050 | 3,800 | 1,050 | 2,550 | 1,050 |
| | | | | | | | | 5,525 |
| | | | | | | | | 3,100 |
| | | | | | | | | 26,850 |

* See discussion under pertinent compound in "Compounds Included in the 1987 Residue Plan."

Table IX
DOMESTIC MONITORING AND EXPLORATORY
SAMPLE UNIT ANALYSES: POULTRY AND RABBITS

| Residue Designation | Chickens | | Turkeys | | Ducks | | Geese | | Rabbits | Total |
|-------------------------------------|----------------|-----------------|---------------|-----------------|---------------|-------------|---------------|-------------|---------------|--------------------|
| | Young | Mature | Young | Seasonal | Seasonal | — | Seasonal | — | | |
| Antibiotics Aged Animals Area | 100 — 50 | 300 300 — | 300 — — | 300 300 — | 100 — — | — — — | 100 — — | — — — | 300 — — | 1,500 600 50 |
| Arsenic | 300 | — | 300 | — | — | — | — | — | — | 600 |
| Carbamates | — | — | — | — | 300 | — | — | — | — | 300 |
| Chlorinated Hydrocarbons Area | 100 50 | 100 — | 100 — | 100 — | 100 — | — — | 100 — | — — | 300 — | 900 50 |
| Cyromazine* | — | 300 | — | — | — | — | — | — | — | 300 |
| Decoquinate | 300 | — | — | — | — | — | — | — | — | 300 |
| DES/Zeranol Area | — 50 | — — | — — | — — | — — | — — | — — | — — | — — | 0 50 |
| Halofuginone | 300 | — | — | — | — | — | — | — | — | 300 |
| Ipronidazole | — | — | 100 | — | — | — | — | — | — | 100 |
| Organophosphates Area | 50 25 | 50 — | 50 — | 50 — | 50 — | — — | 50 — | — — | 150 — | 450 25 |
| Sulfonamides Area | 1,000 200 | — — | 300 — | 300 — | 100 — | — — | 100 — | 100 — | 100 — | 1,900 200 |
| Totals | 2,525 | 1,050 | 1,150 | 1,050 | 650 | 350 | 950 | 950 | 7,625 | |

*See discussion under pertinent compound in "Compounds Included in the 1987 Residue Plan."

Table X**ESTIMATED IMPORT SAMPLE
UNIT ANALYSES—1987**

| Residue Designation | Monitoring | Surveillance | Exploratory | Total |
|----------------------------|-------------------|---------------------|--------------------|--------------|
| Albendazole | 400 | — | — | 400 |
| Antibiotics | 2000 | — | — | 2000 |
| Arsenic | 300 | — | — | 300 |
| Benzimidazoles | 600 | — | — | 600 |
| Carbadox | 300 | — | — | 300 |
| Chloramphenicol | 1000 | — | — | 1000 |
| Chlorinated Hydrocarbons | 3600 | — | — | 3600 |
| Clorsulon | 300 | — | — | 300 |
| Cyromazine | 300 | — | — | 300 |
| Decoquinate | 300 | — | — | 300 |
| DES/Zeranol | 200 | — | — | 200 |
| Ipronidazole | 600 | — | — | 600 |
| Melengestrol Acetate | 200 | — | — | 200 |
| Organophosphates | 500 | — | — | 500 |
| Sulfonamides | 2500 | — | — | 2500 |
| Trace Elements | — | — | 100 | 100 |
| TOTAL | 13100 | — | 100 | 13200 |

Table XI
ESTIMATED IMPORT SAMPLE UNIT ANALYSES—1987

| Residue Designation | Beef | Pork | Veal | Mutton/Lamb | Poultry | Totals |
|---------------------------------|-------|-------|-------|-------------|---------|--------|
| Albendazole | 300* | — | — | 100* | — | 400 |
| Antibiotics | 1,000 | 600 | 300 | 100 | — | 2,000 |
| Arsenic | — | 150 | — | — | 150 | 300 |
| Benzimidazoles | 200 | 200* | — | 200* | — | 600 |
| Carbadox | — | 300 | — | — | — | 300 |
| Chloramphenicol | 300 | 300 | 300 | 100 | — | 1,000 |
| Chlorinated Hydrocarbons | 2,200 | 1,000 | 150 | 100 | 150 | 3,600 |
| Clorsulon | 300 | — | — | — | — | 300 |
| Cyromazine | 150 | — | — | 150 | — | 300 |
| Decoquinate | 300 | — | — | — | — | 300 |
| DES/Zeranol | 60 | — | 70 | 70 | — | 200 |
| Ipronidazole | — | 540 | — | — | 60 | 600 |
| Melengestrol Acetate | 200 | — | — | — | — | 200 |
| Organophosphates | 300 | — | — | 200 | — | 500 |
| Sulfonamides | 700 | 1,200 | 300 | 100 | 200 | 2,500 |
| Trace Elements | — | 100 | — | — | — | 100 |
| Total | 6,010 | 4,390 | 1,120 | 1,120 | 560 | 13,200 |

*See discussion under pertinent compound in "Compounds Included in the 1987 Residue Plan."

Table XII
ESTIMATED IMPORT SAMPLES
PER COUNTRY FOR ANALYSIS—1987

| Country | Beef | Pork | Veal | Mutton/Lamb | Poultry * | Totals |
|----------------|--------------|--------------|--------------|--------------|------------|---------------|
| Argentina | 340 | — | 303 | — | — | 340 |
| Australia | 1,158 | 153 | — | 355 | — | 1,969 |
| Belize | 102 | — | — | — | — | 102 |
| Belgium | — | 145 | — | — | — | 145 |
| Brazil | 268 | — | — | — | — | 268 |
| Canada | 1,062 | 1,231 | 294 | — | 268 | 2,988 |
| Costa Rica | 389 | — | — | 133 | — | 389 |
| Czechoslovakia | — | 146 | — | — | — | 146 |
| Denmark | 165 | 987 | 156 | — | — | 1,308 |
| Dominican Rep. | 243 | — | — | — | — | 243 |
| EI Salvador | 165 | — | — | — | — | 165 |
| Finland | — | 237 | — | — | — | 237 |
| France | — | — | 36 | — | 65 | 65 |
| Germany | — | — | — | — | — | 36 |
| Guatemala | 283 | — | — | — | — | 283 |
| Honduras | 202 | — | — | — | — | 202 |
| Hong Kong | — | — | — | — | — | — |
| Hungary | — | — | 221 | — | — | 221 |
| Iceland | — | — | — | — | — | — |
| Ireland | 175 | — | — | — | — | 175 |
| Israel | — | — | — | — | 142 | 142 |
| Netherlands | — | — | — | — | — | 201 |
| New Zealand | 897 | 201 | 367 | — | — | 1,885 |
| Nicaragua | 207 | 67 | — | — | — | 207 |
| Panama | 102 | — | — | — | — | 102 |
| Poland | — | 355 | — | — | — | 355 |
| Romania | — | 130 | — | — | — | 130 |
| Sweden | 173 | 108 | 16 | — | — | 281 |
| Switzerland | — | 133 | — | — | — | 16 |
| Taiwan | — | — | — | — | — | 133 |
| Uruguay | 79 | 224 | — | — | — | 79 |
| Yugoslavia | — | — | — | — | — | 224 |
| TOTAL | 6,010 | 4,390 | 1,120 | 1,120 | 560 | 13,200 |

* Includes chickens, turkeys, ducks, and geese.

Table XIII

**SAMPLING RATES FOR IMPORTED PRODUCTS
(INDIVIDUAL COUNTRY BASIS)**

Monitoring Program Sampling

| <i>Pounds Exported/Yr.</i> | <i>Total Samples/Yr.</i> |
|-------------------------------|---|
| 1-100,000 lbs. | 8 samples |
| 100,000-1,000,000 lbs. | 8 plus 2 for each 100,000 lbs. |
| 1,000,000-25,000,000 lbs. | 35 plus 2 for each 1,000,000 lbs. |
| 25,000,000-1,000,000,000 lbs. | 85 plus 1 for each 1,000,000 lbs. |
| > 1,000,000,000 lbs. | 200 plus 10 for each 100,000,000 lbs. Not to exceed 300 samples. |

The above criteria are used as the starting point for import product sampling. The actual numbers arrived at are modified according to a compound's evaluation and ranking and FSIS laboratory capabilities.

Table XIV**ESTIMATED SAMPLE COLLECTION
FOR IMPORTED BEEF**

| Country | Estimated Annual Imports (lbs) | Fresh Product (lbs) | Processed Product (lbs) |
|--------------------|--------------------------------|---------------------|-------------------------|
| Argentina | 100,598,970 | — | 100,598,970 |
| Australia | 581,423,937 | 580,367,683 | 1,056,254 |
| Belize | 146,901 | 146,901 | — |
| Brazil | 76,092,980 | — | 76,092,980 |
| Canada | 193,896,401 | 193,816,461 | 79,940 |
| Costa Rica | 51,834,911 | 51,834,911 | — |
| Denmark | 4,774,085 | 4,682,285 | 91,800 |
| Dominican Republic | 18,181,466 | 18,181,466 | — |
| El Salvador | 2,050,322 | 2,050,322 | — |
| Guatemala | 28,016,071 | 28,016,071 | — |
| Honduras | 13,653,563 | 13,653,563 | — |
| Ireland | 5,327,676 | 5,183,149 | 144,527 |
| New Zealand | 370,732,706 | 369,749,532 | 983,174 |
| Nicaragua | 9,485,146 | 9,485,146 | — |
| Panama | 117,802 | 117,802 | — |
| Sweden | 3,798,513 | 3,798,513 | — |
| Uruguay | 3,620,569 | — | 3,620,569 |

Table XV
IMPORTED BEEF MONITORING AND EXPLORATORY
SAMPLE UNIT ANALYSES FOR FRESH (F)
AND PROCESSED (P) PRODUCTS FOR 1987

| Country | Albenazole * | Antibiotics | Benzimidazoles | Chloramphenicol | Chlorinated Hydrocarbons | Cyromazine | Clorsulon | Decoquinate | DES/Zeranol | Melengestrol Acetate | Organophosphates | Sulfonamides | Total Est. Samples |
|--------------------|--------------|-------------|----------------|-----------------|--------------------------|------------|------------|-------------|-------------|----------------------|------------------|--------------|--------------------|
| | F | F | F | F | F | F | F | F | F | F | F | F | F/P |
| Argentina | — | — | — | — | 250 | — | — | — | — | — | — | 90 | 340 |
| Australia | 94 | 183 | 52 | 94 | 300 | 30 | 94 | 94 | 30 | — | 94 | 93 | 1,150 |
| Belize | 8 | 8 | 8 | 8 | 30 | 8 | 8 | 8 | — | — | 8 | 8 | 102 |
| Brazil | — | — | — | — | 200 | — | — | — | — | — | — | 68 | 268 |
| Canada | 50 | 180 | 28 | 50 | 300 | 16 | 50 | 50 | — | 190 | 50 | 98 | 1,062 |
| Costa Rica | 16 | 110 | 10 | 16 | 125 | 8 | 16 | 16 | — | — | 16 | 56 | 389 |
| Denmark | 9 | 39 | 8 | 9 | 45 | 8 | 9 | 9 | — | — | 9 | 20 | 165 |
| Dominican Republic | 10 | 51 | 8 | 10 | 100 | 8 | 10 | 10 | — | — | 10 | 26 | 243 |
| El Salvador | 8 | 36 | 8 | 8 | 55 | 8 | 8 | 8 | — | — | 8 | 18 | 165 |
| Guatemala | 12 | 37 | 9 | 12 | 150 | 8 | 12 | 12 | — | — | 12 | 19 | 283 |
| Honduras | 9 | 47 | 8 | 9 | 70 | 8 | 9 | 9 | — | — | 9 | 24 | 202 |
| Ireland | 9 | 39 | 8 | 9 | 45 | 8 | 9 | 9 | — | 10 | 9 | 20 | 175 |
| New Zealand | 50 | 180 | 29 | 50 | 300 | 16 | 50 | 50 | 30 | — | 50 | 92 | 897 |
| Nicaragua | 9 | 44 | 8 | 9 | 80 | 8 | 9 | 9 | — | — | 9 | 22 | 207 |
| Panama | 8 | 38 | 8 | 8 | 30 | 8 | 8 | 8 | — | — | 8 | 8 | 102 |
| Sweden | 8 | — | — | — | 60 | — | — | — | — | — | 8 | 19 | 173 |
| Uruguay | — | — | — | — | — | — | — | — | — | — | — | 19 | 79 |
| Total | 300 | 1000 | 200 | 300 | 2200 | 150 | 300 | 300 | 60 | 200 | 300 | 700 | 6010 |

*See discussion under pertinent compound in "Compounds Included in the 1987 Residue Plan."

Table XVI**ESTIMATED SAMPLE COLLECTION
FOR IMPORTED PORK**

| Country | Estimated Annual Imports (lbs) | Fresh Product (lbs) | Processed Product (lbs) |
|----------------|--------------------------------|---------------------|-------------------------|
| Australia | 538,783 | 470,000 | 68,783 |
| Belgium | 1,930,259 | — | 1,930,259 |
| Canada | 417,194,049 | 414,305,340 | 2,888,709 |
| Czechoslovakia | 2,514,888 | — | 2,514,888 |
| Denmark | 335,971,451 | 133,792,691 | 202,178,760 |
| Finland | 3,382,356 | 3,382,356 | — |
| Germany | 407,981 | — | 407,981 |
| Hungary | 38,489,554 | — | 38,489,554 |
| Netherlands | 22,324,879 | — | 22,324,879 |
| New Zealand | 16,901 | 16,901 | — |
| Poland | 72,183,282 | — | 72,183,282 |
| Romania | 4,063,357 | — | 4,063,357 |
| Sweden | 652,087 | — | 652,087 |
| Switzerland | 107,118 | — | 107,118 |
| Taiwan | 1,359,428 | — | 1,359,428 |
| Yugoslavia | 19,933,193 | — | 19,933,193 |

Table XVII
IMPORTED PORK MONITORING AND EXPLORATORY
SAMPLE UNIT ANALYSES FOR FRESH (F)
AND/OR PROCESSED (P) PRODUCTS FOR 1987

| Country | Antibiotics | Arsenic | Benzimidazoles* | Carbadox | Chloramphenicol | Chlorinated Hydrocarbons | Ipronidazole | Sulfonamides | Trace Elements | Total Est. Samples |
|------------------|-------------|------------|-----------------|------------|-----------------|--------------------------|--------------|--------------|----------------|--------------------|
| | F | F/P | F | F | F/P | F | F | F/P | F/P | |
| Australia | 20 | 8 | 16 | 8 | 16 | 16 | 45 | 16 | 8 | 153 |
| Belgium | — | 8 | 16 | — | 16 | 37 | — | 60 | 8 | 145 |
| Canada | 300 | 30 | 20 | 149 | 52 | 200 | 240 | 230 | 10 | 1231 |
| Czechoslovakia | — | 8 | 16 | — | 16 | 38 | — | 60 | 8 | 146 |
| Denmark | 220 | 25 | 20 | 110 | 42 | 180 | 180 | 200 | 10 | 987 |
| Finland | 50 | 8 | — | 25 | 16 | 39 | 60 | 39 | — | 237 |
| Germany | — | — | — | — | 8 | 14 | — | 14 | — | 36 |
| Hungary | — | 9 | 16 | — | 18 | 80 | — | 90 | 8 | 221 |
| Netherlands | — | 8 | 16 | — | 16 | 77 | — | 76 | 8 | 201 |
| New Zealand | 10 | — | — | 8 | 8 | 10 | 15 | 16 | — | 67 |
| Poland | — | 13 | 16 | — | 26 | 132 | — | 160 | 8 | 355 |
| Romania | — | 8 | 16 | — | 16 | 41 | — | 41 | 8 | 130 |
| Sweden | — | 8 | 16 | — | 16 | 20 | — | 40 | 8 | 108 |
| Switzerland | — | — | — | — | — | 8 | — | 8 | — | 16 |
| Taiwan | — | 8 | 16 | — | 16 | 35 | — | 50 | 8 | 133 |
| Yugoslavia | — | 9 | 16 | — | 18 | 73 | — | 100 | 8 | 224 |
| Total | 600 | 150 | 200 | 300 | 300 | 1000 | 540 | 1200 | 100 | 4390 |

* See discussion under pertinent compound in "Compounds Included in the 1987 Residue Plan."

Table XVIII
**IMPORTED VEAL ESTIMATED SAMPLE UNIT ANALYSES
FOR FRESH AND PROCESSED PRODUCT 1987**

| Country | Estimated Annual Imports (lbs) | Antibiotics | Chloramphenicol | Chlorinated Hydrocarbons | DESizeranol | Sulfonamides | Total Est. Samples |
|-------------|--------------------------------|-------------|-----------------|--------------------------|-------------|--------------|--------------------|
| | F | F/P | F/P | F | F/P | F | |
| Australia | 4,934,602 | 80 | 80 | 43 | 20 | 80 | 303 |
| Canada | 2,942,296 | 80 | 80 | 39 | 15 | 80 | 294 |
| Denmark | 909,720 | 40 | 40 | 21 | 15 | 40 | 156 |
| New Zealand | 11,428,102 | 100 | 100 | 47 | 20 | 100 | 367 |
| Total | | 300 | 300 | 150 | 70 | 300 | 1,120 |

Table XIX
**IMPORTED MUTTON AND LAMB SAMPLE UNIT ANALYSES
FOR FRESH AND PROCESSED PRODUCT 1987**

| Country | Estimated Annual Imports (lbs) | Albendazole * | Antibiotics | Benzimidazoles * | Chloramphenicol | Chlorinated Hydrocarbons | DESizeranol | Organophosphates | Sulfonamides | Total Est. Samples |
|-------------|--------------------------------|---------------|-------------|------------------|-----------------|--------------------------|-------------|------------------|--------------|--------------------|
| | F | F | F | F | F/P | F | F | F | F | |
| Australia | 8,731,362 | 30 | 30 | 60 | 30 | 60 | 25 | 60 | 30 | 355 |
| Canada | 225,742 | 12 | 12 | 25 | 12 | 15 | 8 | 25 | 12 | 133 |
| Iceland | 79,140 | 8 | 8 | 15 | 8 | — | 8 | 15 | 8 | 78 |
| New Zealand | 28,887,250 | 50 | 50 | 100 | 50 | 75 | 29 | 100 | 50 | 554 |
| Total | | 100 | 100 | 200 | 100 | 100 | 150 | 70 | 200 | 1,120 |

*See discussion under pertinent compound in "Compounds Included in the 1987 Residue Plan."

Table XX
**IMPORTED DUCK/GEESE SAMPLE UNIT ANALYSES
 FOR FRESH AND PROCESSED PRODUCT 1987**

| Country | Estimated Annual Imports (lbs) | Chlorinated Hydrocarbons | | Sulfonamides | | Total Est. Samples |
|---------|--------------------------------|--------------------------|-----|--------------|----|--------------------|
| | | F/P | F/P | F/P | F | |
| Canada | 1,179,349 | | 16 | | 16 | 32 |
| Total | | | 16 | | 16 | 32 |

Table XXI
**IMPORTED TURKEY SAMPLE UNIT ANALYSES
 FOR FRESH AND PROCESSED PRODUCT 1987**

| Country | Estimated Annual Imports (lbs) | Arsenic | Chlorinated Hydrocarbons | | Ipronidazole | | Total Est. Samples |
|---------|--------------------------------|---------|--------------------------|-----|--------------|----|--------------------|
| | | | F/P | F/P | F/P | F | |
| Canada | 495,236 | 9 | 9 | 9 | 9 | 60 | 87 |
| Total | | 9 | 9 | 9 | 9 | 60 | 87 |

Table XII

**IMPORTED POULTRY (CHICKEN) SAMPLE UNIT ANALYSES
FOR FRESH AND PROCESSED PRODUCT 1987**

| Country | Estimated Annual Imports (lbs) | Arsenic | | Chlorinated Hydrocarbons | | Sulfonamides | | Total Est. Analyses |
|-----------|--------------------------------|---------|-----|--------------------------|-----|--------------|-----|---------------------|
| | | F/P | F/P | F/P | F/P | F/P | F/P | |
| Canada | 3,282,867 | 47 | | 42 | | 60 | | 149 |
| France | 575,559 | 18 | | 18 | | 29 | | 65 |
| Hong Kong | 691,022 | 30 | | 25 | | 30 | | 85 |
| Israel | 1,780,529 | 46 | | 40 | | 56 | | 142 |
| Total | | 141 | | 125 | | 175 | | 441 |

GUIDE

INTRODUCTION

COMPOUNDS CONSIDERED AND CRITERIA FOR EVALUATION

RESIDUE LIMITS

FSIS RESIDUE ANALYTICAL CAPABILITY

COMPOUNDS INCLUDED IN THE NATIONAL RESIDUE PROGRAM (HISTORICAL CHART)

NATIONAL RESIDUE PROGRAM ANNUAL PLAN